var title_f34_52_35648="Iliotibial band anatomy PI";
var content_f34_52_35648=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F86674&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F86674&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Iliotibial band",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 258px; height: 554px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This drawing shows a side view of the leg. The iliotibial band is a strong band of tissue that runs down the outside of the thigh, from the hip bone to the top of the shinbone.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Moore KL, Dalley AR. Clinically Oriented Anatomy, 5th ed, Lippincott Williams &amp; Wilkins, Philadelphia 2006. Copyright &copy; 2006 Lippincott Williams &amp; Wilkins.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_52_35648=[""].join("\n");
var outline_f34_52_35648=null;
var title_f34_52_35649="Tree-in-bud CT";
var content_f34_52_35649=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F52831&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F52831&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Tree-in-bud",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 280px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Chest CT with arrow A pointing to extensive tree-in-bud and arrow B of dilated and thickened airways.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_52_35649=[""].join("\n");
var outline_f34_52_35649=null;
var title_f34_52_35650="Preterm labor";
var content_f34_52_35650=[" <h1 id=\"patTopicTitle\">",
"  Patient information: Preterm labor (Beyond the Basics)",
" </h1>",
" <div id=\"patTopicContributors\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <table>",
"    <tr>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"mobipreview.htm?34/52/35650/contributors\">",
"       Author",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/52/35650/contributors\" id=\"au4908\">",
"       Edmund F Funai, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"mobipreview.htm?34/52/35650/contributors\">",
"       Section Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/52/35650/contributors\" id=\"se4723\">",
"       Charles J Lockwood, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"mobipreview.htm?34/52/35650/contributors\">",
"       Deputy Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/52/35650/contributors\" id=\"de4555\">",
"       Vanessa A Barss, MD",
"      </a>",
"     </td>",
"    </tr>",
"   </table>",
"  </div>",
"  <div class=\"rcBottom\">",
"   <div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"patTopicTool\" id=\"patTopicToolTop\">",
"  <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"   Find",
"  </a>",
"  <a class=\"toolbutton printicon\" href=\"mobipreview.htm?34/52/35650?view=print\" title=\"Print This Topic\">",
"   Print",
"  </a>",
"  <script src=\"file://w.sharethis.com/button/sharethis.js#publisher=357881b8-c7e3-4c31-b7d2-242aeb1528e1&amp;type=website&amp;post_services=care2%2Cfacebook%2Ctwitter%2Cmyspace%2Cdigg%2Cdelicious%2Cfaves%2Creddit%2Cxanga%2Cstumbleupon%2Cblinklist%2Csimpy%2Cyigg%2Ctechnorati%2Cmeneame%2Corkut%2Cmixx%2Cfunp%2Cfresqui%2Cmister_wong%2Cfriendster%2Cfriendfeed%2Clinkedin%2Coknotizie%2Cgoogle_bmarks%2Cyahoo_bmarks%2Cfark%2Cnewsvine%2Clivejournal%2Ctypepad%2Cbus_exchange%2Cpropeller%2Cwordpress%2Cblogger%2Cblogmarks%2Cwindows_live%2Cfurl%2Cybuzz%2Cdiigo\" type=\"text/javascript\">",
"  </script>",
" </div>",
" <div id=\"patTopicMiddle\">",
"  <div id=\"topicContent\">",
"   <div id=\"topicText\">",
"    <p class=\"headingAnchor\" id=\"H1\">",
"     <span class=\"h1\">",
"      INTRODUCTION",
"     </span>",
"    </p>",
"    <p>",
"     A normal pregnancy lasts 37 to 42 weeks, counting from the first day of the last menstrual period. A pregnancy that continues beyond 37 weeks is called a \"term\" pregnancy. Preterm labor is defined as labor that begins before 37 weeks of pregnancy.",
"    </p>",
"    <p>",
"     Approximately 12 percent of babies in the United States are born preterm; 80 percent of these are due to preterm labor that occurs on its own or after preterm premature rupture of the fetal membranes (or \"broken bag of waters\"). The remaining 20 percent are planned early deliveries that are done for maternal or fetal problems that prevent the woman from being able to safely continue with her pregnancy.",
"    </p>",
"    <p>",
"     Not all women who have preterm labor will deliver their baby early; estimates are that between 30 and 50 percent of women who develop preterm labor will go on to deliver their infant at term. If preterm labor leads to an early delivery, the premature newborn is at risk for problems related to incomplete development of its organ systems. These problems include difficulty with breathing, staying warm, feeding, as well as injury to the eyes, intestines, and nervous system.",
"    </p>",
"    <p>",
"     Preterm birth is a major cause of newborn complications and death. Regular prenatal care can help to identify some, but not all, women at risk for preterm labor. Should preterm labor occur, measures can be taken to delay delivery and decrease the risk of newborn complications.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H2\">",
"     <span class=\"h1\">",
"      PRETERM LABOR RISK FACTORS",
"     </span>",
"    </p>",
"    <p>",
"     It is difficult to predict who will develop preterm labor. Certain obstetrical conditions and other factors are known to increase a woman's risk. However, most preterm births occur in women who have no known risk factors.",
"    </p>",
"    <p>",
"     The strongest risk factor for preterm birth is a previous preterm birth, although most women who have had a preterm birth will have a term pregnancy in the future. As an example, one study found that only 22 percent of women with a previous preterm delivery had a preterm delivery with their next pregnancy [",
"     <a class=\"abstract\" href=\"mobipreview.htm?34/52/35650/abstract/1\">",
"      1",
"     </a>",
"     ].",
"    </p>",
"    <p>",
"     Other factors that may increase a woman's risk include:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       Being pregnant with twins, triplets, or more",
"      </li>",
"      <li>",
"       A history of cervical surgery (eg, conization or cone biopsy) for abnormal Pap smears, if the amount of the cervix removed is large",
"      </li>",
"      <li>",
"       Abnormalities of the uterus",
"      </li>",
"      <li>",
"       Uterine bleeding, especially in the second or third trimester",
"      </li>",
"      <li>",
"       Use of certain illicit drugs, such as cocaine",
"      </li>",
"      <li>",
"       Cigarette smoking",
"      </li>",
"      <li>",
"       Some infections",
"      </li>",
"      <li>",
"       Low prepregnancy weight and low weight gain during pregnancy",
"      </li>",
"      <li>",
"       Excessive amniotic fluid",
"      </li>",
"      <li>",
"       Moderate to severe anemia early in the pregnancy",
"      </li>",
"      <li>",
"       A short interval (less than 12 to 18 months) between pregnancies (deliveries)",
"      </li>",
"      <li>",
"       Abdominal surgery during pregnancy",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     Black women appear to have double the incidence of preterm labor and delivery when compared to white women. The risk of preterm delivery is also higher in women under 18 to 20 years of age. Older maternal age alone (over 35 to 40) is not associated with an increased risk of preterm labor. However, older women are more likely to have other conditions (such as hypertension and diabetes) that can cause complications requiring preterm delivery.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H3\">",
"     <span class=\"h1\">",
"      PRETERM LABOR CAUSES",
"     </span>",
"    </p>",
"    <p>",
"     It is usually difficult to identify the cause of preterm labor. Four general categories causes include:",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H4\">",
"     <span class=\"h2\">",
"      Uterine bleeding",
"     </span>",
"     &nbsp;&mdash;&nbsp;Conditions like placenta previa (when the placenta partially or completely covers the cervix) and placental abruption (when the placenta separates from the uterus before delivery) can cause the fetal membranes to rupture prematurely and can trigger preterm labor.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H5\">",
"     <span class=\"h2\">",
"      Stretching of the uterus",
"     </span>",
"     &nbsp;&mdash;&nbsp;Having twins, triplets, or more, or having polyhydramnios (an excessive amount of amniotic fluid around the baby) causes stretching of the uterus, which can lead to uterine contractions and preterm labor.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H6\">",
"     <span class=\"h2\">",
"      Bacteria or inflammation",
"     </span>",
"     &nbsp;&mdash;&nbsp;Bacteria or inflammation caused by an infection in the uterus can stimulate the production of substances that trigger uterine contractions.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H7\">",
"     <span class=\"h2\">",
"      Physical or psychological stress",
"     </span>",
"     &nbsp;&mdash;&nbsp;Severe stress can lead to the release of hormones that cause uterine contractions and preterm labor.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H8\">",
"     <span class=\"h1\">",
"      PREDICTING PRETERM DELIVERY",
"     </span>",
"    </p>",
"    <p>",
"     Research is ongoing to identify a chemical or physical marker that predicts whether and when premature delivery will occur. Two tests have been identified that may be helpful in some settings.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H9\">",
"     <span class=\"h2\">",
"      Fetal fibronectin",
"     </span>",
"     &nbsp;&mdash;&nbsp;A substance called fetal fibronectin is released when the fetal membranes begin to change prior to labor. Studies have shown that if this substance is",
"     <strong>",
"      not",
"     </strong>",
"     present in vaginal discharge in high concentrations, premature delivery is unlikely. If there are high amounts of fetal fibronectin, it does not always mean that the woman will deliver prematurely.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H10\">",
"     <span class=\"h2\">",
"      Cervical length",
"     </span>",
"     &nbsp;&mdash;&nbsp;Ultrasound measurement of the cervix can help to predict the risk of preterm delivery; the risk increases as cervical length decreases.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H11\">",
"     <span class=\"h1\">",
"      PRETERM LABOR SIGNS AND SYMPTOMS",
"     </span>",
"    </p>",
"    <p>",
"     The signs of preterm labor are similar to the signs of labor at the end of pregnancy:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       Change in type or amount of vaginal discharge (watery, mucus, or bloody)",
"      </li>",
"      <li>",
"       Pelvic or lower abdominal pressure or pain",
"      </li>",
"      <li>",
"       Constant, low, dull backache",
"      </li>",
"      <li>",
"       Mild or menstrual-like abdominal cramps, with or without diarrhea",
"      </li>",
"      <li>",
"       Regular or frequent contractions or uterine tightening that may be painless",
"      </li>",
"      <li>",
"       Ruptured membranes (broken water)",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     Braxton Hicks contractions (also called false labor contractions) are uterine contractions (tightening of the uterus) that occur less than eight times in an hour or four times every twenty minutes; these contractions are not accompanied by bleeding or vaginal discharge and are relieved by resting. These are normal and do not increase the risk of preterm birth. However, it is often difficult to tell the difference between preterm labor and false labor without having a pelvic examination.",
"    </p>",
"    <p>",
"     In the early stages of labor, a woman may experience cramping that is relatively mild and occurs irregularly. At this stage the discomfort may be similar to menstrual cramping and may cause low back pain. As uterine contractions strengthen they usually become more painful and occur at regular and shorter intervals.",
"    </p>",
"    <p>",
"     In addition, a woman may notice excessive mucus discharge from the vagina. Light bleeding or spotting is also common. The fetal membranes can rupture (known as \"water breaking\") before or during preterm labor. If this happens, a trickle to a sudden gush of fluid will drain from the vagina.",
"    </p>",
"    <p>",
"     A woman should contact her hospital or healthcare provider immediately if she is concerned she could be in preterm labor or has other concerning symptoms. In particular, a woman should call if she has more than six contractions in an hour that continue despite lying down, if she has leakage of amniotic fluid, or has any vaginal bleeding.",
"    </p>",
"    <p>",
"     The healthcare provider will perform a pelvic examination to determine if the membranes have ruptured and if the cervix is effacing (thinning) or dilating (beginning to open), and may also perform an ultrasound examination. He or she may also place a monitor on the uterus that electronically records uterine contractions and the fetal heart rate.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H12\">",
"     <span class=\"h1\">",
"      HOME MONITORING",
"     </span>",
"    </p>",
"    <p>",
"     A healthcare provider may ask a woman to monitor herself for contractions. This is best accomplished by lying down and gently feeling the uterus with the fingertips. Normally, the uterus should be relaxed, soft, and easily indented by pushing on it with the fingers. During a contraction, the uterus becomes firm and difficult to indent. The time between the start of one contraction and the start of the next indicates how often contractions are occurring.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H13\">",
"     <span class=\"h1\">",
"      PRETERM LABOR TREATMENT",
"     </span>",
"    </p>",
"    <p>",
"     Treatment can be given in an attempt to slow or stop preterm labor. The primary goal of treatment is to delay delivery long enough that steroids, which promote development of the baby's lungs, can be given. Delaying preterm delivery also allows the woman to be transferred, if necessary, to a facility that can provide specialized care to a premature infant.",
"    </p>",
"    <p>",
"     Treatment to delay delivery is typically recommended if the woman is less than 34 weeks pregnant because infants born before 34 weeks are at particularly high risk for complications of premature birth. However, if the mother or infant's health are at risk, labor may be allowed to proceed. Labor may also be allowed to proceed if the mother is more than 34 weeks pregnant or if tests show that the baby's lungs are fully developed.",
"    </p>",
"    <p>",
"     A woman in preterm labor will be admitted to the hospital for close monitoring while medications to stop labor are administered. An intravenous line will be inserted to give medications and fluids, and a fetal monitor will be used to measure uterine contractions and the baby's heart rate.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H14\">",
"     <span class=\"h2\">",
"      Treatments to stop labor",
"     </span>",
"     &nbsp;&mdash;&nbsp;If the mother and baby are healthy, medications are often used to try to relax the uterine muscle and stop contractions. Medications used to stop or slow labor are called \"tocolytic\" agents. They include terbutaline, magnesium sulfate, nifedipine, and indomethacin. Some of these drugs are given intravenously or by injection while others can be taken orally.",
"    </p>",
"    <p>",
"     Tocolytics are usually given along with a steroid (glucocorticoid) injection (see below). Tocolytic medications are intended to delay delivery for several hours and optimally for 48 hours.",
"    </p>",
"    <p>",
"     While tocolytics are used, the mother is monitored for medication side effects. If labor stops, the woman is usually kept in the hospital for a period of time to monitor for more uterine contractions. Depending upon a number of factors, the woman may be discharged home or asked to stay in the hospital. While at home, the woman may be asked to limit her activities, and she should contact her hospital or healthcare provider immediately if signs of labor return.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H15\">",
"     <span class=\"h2\">",
"      Treatments to help the infant",
"     </span>",
"     &nbsp;&mdash;&nbsp;Steroids (glucocorticoids) can speed the development of a preterm infant's lungs, and are often administered during preterm labor. Steroids help the lungs mature and may promote the production of surfactant, a substance that prevents the collapse of alveoli (small sacs in the lungs where air is exchanged). Steroids also decrease the infant's risk for intraventricular hemorrhage (bleeding into the brain) and other complications affecting the bowels and circulatory system.",
"    </p>",
"    <p>",
"     Steroids are usually administered if the mother is between about 23 and 34 weeks of gestation. Before about 23 weeks of gestation, the fetus is too immature to benefit from steroids. After 34 weeks, the infant's lungs are usually sufficiently developed, although steroids may be given if fetal lung tests suggest that the lungs are not mature. The most commonly used steroid is betamethasone.",
"    </p>",
"    <p>",
"     The timing of the dose of steroids is important. Steroids must be given to the mother as an injection several hours before the infant is delivered. A second dose is usually given 24 hours after the first dose. There is probably some benefit from steroids, even if the woman delivers before the second dose is given. The greatest benefit is seen when the steroid is given at least 48 hours before the infant is delivered. It is not usually necessary to repeat the steroid treatment later in pregnancy if preterm labor recurs.",
"    </p>",
"    <p>",
"     If the mother delivers early, a number of treatments can be given to support the premature infant. Over the past decade, significant advances have been made in the care of premature newborns. However, not all hospitals are equipped to care for them. For this reason, it is important that a woman who is at high risk for premature delivery be treated in a hospital with a neonatal intensive care unit.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H16\">",
"     <span class=\"h1\">",
"      PRETERM LABOR PREVENTION",
"     </span>",
"    </p>",
"    <p>",
"     One of the most important things a pregnant woman can do to prevent preterm labor is to stop habits that can be harmful, such as smoking and use of illegal drugs.",
"    </p>",
"    <p>",
"     Women with a history of a previous preterm birth at less than 37 weeks of pregnancy (due to spontaneous labor or premature rupture of membranes) may be offered a progesterone supplement, either as an injection or a vaginal gel, to prevent recurrent preterm labor. Progesterone supplementation is begun between 16 and 26 weeks of pregnancy and continued until 36 weeks. There is no evidence that this drug is effective in women with no previous history of preterm labor. In addition, it has not been effective in women with multiple gestations (eg, twins).",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H17\">",
"     <span class=\"h1\">",
"      WHERE TO GET MORE INFORMATION",
"     </span>",
"    </p>",
"    <p>",
"     Your healthcare provider is the best source of information for questions and concerns related to your medical problem.",
"    </p>",
"    <p>",
"     This article will be updated as needed on our web site (",
"     <a class=\"external\" href=\"file://www.uptodate.com/patients\">",
"      www.uptodate.com/patients",
"     </a>",
"     ). Related topics for patients, as well as selected articles written for healthcare professionals, are also available. Some of the most relevant are listed below.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H15454160\">",
"     <span class=\"h2\">",
"      Patient level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H15454168\">",
"     <span class=\"h3\">",
"      The Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;The Basics patient education pieces answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?27/20/27970?source=see_link\">",
"      Patient information: Preterm labor (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?38/21/39249?source=see_link\">",
"      Patient information: Preterm premature rupture of membranes (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?8/15/8434?source=see_link\">",
"      Patient information: Activity during pregnancy (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?1/44/1732?source=see_link\">",
"      Patient information: Having twins (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?12/58/13219?source=see_link\">",
"      Patient information: Hyperthyroidism (overactive thyroid) and pregnancy (The Basics)",
"     </a>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H15454176\">",
"     <span class=\"h3\">",
"      Beyond the Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are best for patients who want in-depth information and are comfortable with some medical jargon.",
"    </p>",
"    <p>",
"     This topic currently has no corresponding Beyond the Basics content.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H18\">",
"     <span class=\"h2\">",
"      Professional level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;Professional level articles are designed to keep doctors and other health professionals up-to-date on the latest medical findings. These articles are thorough, long, and complex, and they contain multiple references to the research on which they are based. Professional level articles are best for people who are comfortable with a lot of medical terminology and who want to read the same materials their doctors are reading.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/55/31610?source=see_link\">",
"      Antenatal corticosteroid therapy for reduction of neonatal morbidity and mortality from preterm delivery",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/22/4457?source=see_link\">",
"      Cervical insufficiency",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/53/35674?source=see_link\">",
"      Inhibition of acute preterm labor",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/36/24135?source=see_link\">",
"      Management of pregnant women after inhibition of acute preterm labor",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/30/5608?source=see_link\">",
"      Overview of preterm labor and birth",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/40/32393?source=see_link\">",
"      Pathogenesis of spontaneous preterm birth",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/45/11994?source=see_link\">",
"      Prevention of spontaneous preterm birth",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/3/35898?source=see_link\">",
"      Risk factors for preterm labor and delivery",
"     </a>",
"    </p>",
"    <p>",
"     <br/>",
"     The following organizations also provide reliable health information.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Library of Medicine",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.nlm.nih.gov/medlineplus/healthtopics.html\">",
"      www.nlm.nih.gov/medlineplus/healthtopics.html",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Institute of Child Health and Human Development",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.nichd.nih.gov/womenshealth\">",
"      www.nichd.nih.gov/womenshealth",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       The March of Dimes",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.marchofdimes.com/\">",
"      www.marchofdimes.com",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       The Mayo Clinic",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.mayoclinic.com/\">",
"      www.mayoclinic.com",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     [",
"     <a class=\"abstract\" href=\"mobipreview.htm?34/52/35650/abstract/1-5\">",
"      1-5",
"     </a>",
"     ]",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 14, 2012.",
"  </div>",
"  <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"   <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"    Find",
"   </a>",
"   <a class=\"toolbutton printicon\" href=\"mobipreview.htm?34/52/35650?view=print\" title=\"Print This Topic\">",
"    Print",
"   </a>",
"  </div>",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <div id=\"patTopicRefHeader\">",
"    <div id=\"patTopicRefHeaderHeader\">",
"     References",
"    </div>",
"    <div id=\"patTopicRefHeaderTop\">",
"     <a href=\"#top\">",
"      <img alt=\"\" src=\"./../images/top_arrow.myextg\">",
"       Top",
"      </img>",
"     </a>",
"    </div>",
"   </div>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/52/35650/abstract/1\">",
"      Crowther CA, Han S. Hospitalisation and bed rest for multiple pregnancy. Cochrane Database Syst Rev 2010; :CD000110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/52/35650/abstract/2\">",
"      Yost NP, Bloom SL, McIntire DD, Leveno KJ. Hospitalization for women with arrested preterm labor: a randomized trial. Obstet Gynecol 2005; 106:14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/52/35650/abstract/3\">",
"      Crowther CA, Hiller JE, Doyle LW. Magnesium sulphate for preventing preterm birth in threatened preterm labour. Cochrane Database Syst Rev 2002; :CD001060.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/52/35650/abstract/4\">",
"      King J, Flenady V, Cole S, Thornton S. Cyclo-oxygenase (COX) inhibitors for treating preterm labour. Cochrane Database Syst Rev 2005; :CD001992.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/52/35650/abstract/5\">",
"      Marret S, Marpeau L, Zupan-Simunek V, et al. Magnesium sulphate given before very-preterm birth to protect infant brain: the randomised controlled PREMAG trial*. BJOG 2007; 114:310.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
" </div>",
" <!-- patTopicMiddle -->",
"</div>"].join("\n");
var script_f34_52_35650=[""].join("\n");
var outline_f34_52_35650=[" <div class=\"patTopicFancyTop\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <p>",
"    Contents of this article",
"   </p>",
"  </div>",
" </div>",
" <div class=\"patTopicFancySpacer\">",
" </div>",
" <div class=\"patTopicOutline\">",
"  <div class=\"rcbBottom\">",
"   <div class=\"rcbLeft\">",
"    <div class=\"rcbRight\">",
"     <div class=\"rcbBottomLeft\">",
"      <div class=\"rcbBottomRight rcbBottomRightBottomOnly\">",
"       <div id=\"outline\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          <a href=\"#H1\">",
"           INTRODUCTION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H2\">",
"           PRETERM LABOR RISK FACTORS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H3\">",
"           PRETERM LABOR CAUSES",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H8\">",
"           PREDICTING PRETERM DELIVERY",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H11\">",
"           PRETERM LABOR SIGNS AND SYMPTOMS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H12\">",
"           HOME MONITORING",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H13\">",
"           PRETERM LABOR TREATMENT",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H16\">",
"           PRETERM LABOR PREVENTION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H17\">",
"           WHERE TO GET MORE INFORMATION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#references\">",
"           REFERENCES",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"  </div>",
" </div>"].join("\n");
var title_f34_52_35651="Kienbock disease stages";
var content_f34_52_35651=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F82436&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F82436&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Schematic representation of the stages of Kienbock disease",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 400px; height: 524px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Kienbock's disease is a progressive collapse of the lunate. There are four radiographic stages: 1) Normal radiograph. 2) Increased density, but the shape of the lunate remains intact. 3) Collapse of the lunate with proximal displacement of the capitate, rotation of the scaphoid, and negative ulnar variance. 4) Severe collapse, sclerosis, and osteophyte formation in the remaining wrist.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_52_35651=[""].join("\n");
var outline_f34_52_35651=null;
var title_f34_52_35652="Barretts esophagus with high grade dysplasia CPC Light";
var content_f34_52_35652=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F80215&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F80215&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Barrett's esophagus with high grade dysplasia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 269px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Medium power of a biopsy specimen with high grade glandular dysplasia. Compared to low grade dysplasia, the cells here have higher nuclear-cytoplasmic ratios, are more hyperchromatic, and demonstrate a lack of maturation at the mucosal surface.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Donald Antonioli, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_52_35652=[""].join("\n");
var outline_f34_52_35652=null;
var title_f34_52_35653="Endobronchial Kaposi sarcoma";
var content_f34_52_35653=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F78341&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F78341&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Endobronchial Kaposi sarcoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 402px; height: 266px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    High power light micrograph of endobronchial Kaposi sarcoma showing spindle cells surrounding thin vascular channels.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Steven E Weinberger, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_52_35653=[""].join("\n");
var outline_f34_52_35653=null;
var title_f34_52_35654="Chlorambucil: Drug information";
var content_f34_52_35654=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Chlorambucil: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?25/16/25861?source=see_link\">",
"    see \"Chlorambucil: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?35/9/35989?source=see_link\">",
"    see \"Chlorambucil: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5708649\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F149339\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Leukeran&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F149340\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Leukeran&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F149382\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antineoplastic Agent, Alkylating Agent",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F149343\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     With bone marrow lymphocytic infiltration involvement (in CLL, Hodgkin lymphoma, or NHL), the maximum dose is 0.1 mg/kg/day. While short treatment courses are preferred, if maintenance therapy is required, the maximum dose is 0.1 mg/kg/day.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Chronic lymphocytic leukemia (CLL):",
"     </b>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      U.S. labeling:",
"     </i>",
"     0.1 mg/kg/day for 3-6 weeks",
"     <b>",
"      or",
"     </b>",
"     0.4 mg/kg pulsed doses administered intermittently, biweekly, or monthly (increased by 0.1 mg/kg/dose until response/toxicity observed)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Canadian labeling:",
"     </i>",
"     Initial: 0.15 mg/kg/day until WBC is 10,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     ; interrupt treatment for 4 weeks, then may resume at 0.1 mg/kg/day until response (generally ~2 years)/toxicity observed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Unlabeled dosing:",
"     </i>",
"     30 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     day 1 every 2 weeks (in combination with prednisone) (Raphael, 1991)",
"     <b>",
"      or",
"     </b>",
"     0.4 mg/kg day 1 every 2 weeks; if tolerated may increase by 0.1 mg/kg with each treatment course to a maximum dose of 0.8 mg/kg and maximum of 24 cycles (Eichhorst, 2009)",
"     <b>",
"      or",
"     </b>",
"     40 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     day 1 every 4 weeks until disease progression or complete remission or response plateau for up to a maximum of 12 cycles (Rai, 2000)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Hodgkin lymphoma:",
"     </b>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      U.S. labeling:",
"     </i>",
"     0.2 mg/kg/day for 3-6 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Canadian labeling:",
"     </i>",
"     0.2 mg/kg/day for 4-8 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Non-Hodgkin&rsquo;s lymphomas (NHL):",
"     </b>",
"     Oral",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      U.S. labeling:",
"     </i>",
"     0.1 mg/kg/day for 3-6 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Canadian labeling:",
"     </i>",
"     Initial: 0.1-0.2 mg/kg/day for 4-8 weeks; for maintenance treatment, reduce dose or administer intermittently",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Waldenstr&ouml;m's macroglobulinemia (U.S. unlabeled use):",
"     </b>",
"     Oral: 0.1 mg/kg/day (continuously) for at least 6 months",
"     <b>",
"      or",
"     </b>",
"     0.3 mg/kg/day for 7 days every 6 weeks for at least 6 months (Kyle, 2000)",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F149362\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?35/9/35989?source=see_link\">",
"      see \"Chlorambucil: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     <b>",
"      Nephrotic syndrome, steroid sensitive (unlabeled use):",
"     </b>",
"     Oral: 0.2 mg/kg once daily  for ~8 weeks (Hodson, 2010)",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F149344\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;display:inline\">",
"     Refer to adult dosing. Begin at the lower end of dosing range(s)",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F5526979\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling; however, renal elimination of unchanged chlorambucil and active metabolite (phenylacetic acid mustard) is minimal and renal impairment is not likely to affect elimination. The following adjustments have been recommended: Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Aronoff, 2007:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &gt;50 mL/minute: No adjustment necessary.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     10-50 mL/minute: Administer 75% of dose.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;10 mL/minute: Administer 50% of dose.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Peritoneal dialysis (PD): Administer 50% of dose.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Kintzel, 1995: Based on the pharmacokinetics, dosage adjustment is not indicated",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F5527179\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Chlorambucil undergoes extensive hepatic metabolism. Although dosage reduction should be considered in patients with hepatic impairment, no dosage adjustment is provided in the manufacturer&rsquo;s labeling (data is insufficient).",
"    </p>",
"   </div>",
"   <div class=\"block dot drugH1Div\" id=\"F4412251\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adjustment for Toxicity",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Skin reactions: Discontinue treatment",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Hematologic:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     WBC or platelets below normal: Reduce dose.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Severely depressed WBC or platelet counts: Discontinue.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Persistently low neutrophil or platelet counts or peripheral lymphocytosis: May be suggestive of bone marrow infiltration; if infiltration confirmed, do not exceed 0.1 mg/kg/day.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Concurrent or within 4 weeks (before or after) of chemotherapy/radiotherapy: Initiate treatment cautiously; reduce dose; monitor closely.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F149314\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Leukeran&reg;: 2 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F149299\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F149318\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Usually administered as a single dose; preferably on an empty stomach.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Hazardous agent; use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F149317\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;display:inline\">",
"     Management of chronic lymphocytic leukemia (CLL), Hodgkin lymphoma, non-Hodgkin's lymphomas (NHL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">",
"     Canadian labeling: Additional uses (not in U.S. labeling): Management of Waldenstr&ouml;m's macroglobulinemia",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F4412249\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of nephrotic syndrome (steroid sensitive) in children; treatment of Waldenstr&ouml;m's macroglobulinemia (unlabeled in U.S.)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F149390\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Chlorambucil may be confused with Chloromycetin&reg;",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Leukeran&reg; may be confused with Alkeran&reg;, leucovorin, Leukine&reg;, Myleran&reg;",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F149380\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Frequency not always defined.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Central nervous system: Agitation (rare), ataxia (rare), confusion (rare), drug fever, fever, focal/generalized seizure (rare), hallucinations (rare)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Dermatologic: Angioneurotic edema, erythema multiforme (rare), rash, skin hypersensitivity, Stevens-Johnson syndrome (rare), toxic epidermal necrolysis (rare), urticaria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Amenorrhea, infertility, SIADH (rare)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Gastrointestinal: Diarrhea (infrequent), nausea (infrequent), oral ulceration (infrequent), vomiting (infrequent)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Genitourinary: Azoospermia, cystitis (sterile)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Hematologic: Neutropenia (onset: 3 weeks; recovery: 10 days after last dose), bone marrow failure (irreversible), bone marrow suppression, anemia, leukemia (secondary), leukopenia, lymphopenia, pancytopenia, thrombocytopenia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Hepatic: Hepatotoxicity, jaundice",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Flaccid paresis (rare), muscular twitching (rare), myoclonia (rare), peripheral neuropathy, tremor (rare)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Respiratory: Interstitial pneumonia, pulmonary fibrosis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Miscellaneous: Allergic reactions, malignancies (secondary)",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F149322\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to chlorambucil or any component of the formulation; hypersensitivity to other alkylating agents (may have cross-hypersensitivity); prior (demonstrated) resistance to chlorambucil",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Canadian labeling: Additional contraindications (not in U.S. labeling): Use within 4 weeks of a full course of radiation or chemotherapy",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F149303\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Bone marrow suppression:",
"     <b>",
"      [U.S. Boxed Warning]: May cause severe bone marrow suppression;",
"     </b>",
"     neutropenia may be severe. Reduce initial dosage if patient has received myelosuppressive or radiation therapy within the previous 4 weeks, or has a depressed baseline leukocyte or platelet count. Irreversible bone marrow damage may occur with total doses approaching 6.5 mg/kg. Progressive lymphopenia may develop (recovery is generally rapid after discontinuation).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Fertility effects:",
"     <b>",
"      [U.S. Boxed Warning]: Affects human fertility;  probably mutagenic and teratogenic as well;",
"     </b>",
"     chromosomal damage has been documented. Reversible and irreversible sterility (when administered to prepubertal and pubertal males), azoospermia (in adult males) and amenorrhea (in females) have been observed.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Secondary malignancy:",
"     <b>",
"      [U.S. Boxed Warning]: Carcinogenic;",
"     </b>",
"     acute myelocytic leukemia and secondary malignancies may be associated with chronic therapy. Duration of treatment and higher cumulative doses are associated with a higher risk for development of leukemia.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Seizures: Have been observed with use; patients with a history of nephrotic syndrome and high pulse doses are at higher risk of seizures. Use with caution in patients with a history of seizure disorder or head trauma.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Skin reactions: Rare instances of severe skin reactions (eg, erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis) have been reported; discontinue promptly if skin reaction occurs.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Chlorambucil is primarily metabolized in the liver.  Dosage reductions should be considered in patients with hepatic impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special handling:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hazardous agent: Use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Vaccines: Avoid administration of live vaccines to immunocompromised patients.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299014\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F149308\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BCG: Immunosuppressants may diminish the therapeutic effect of BCG.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CloZAPine: Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically, the risk for agranulocytosis may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Coccidioidin Skin Test: Immunosuppressants may diminish the diagnostic effect of Coccidioidin Skin Test.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Denosumab: May enhance the adverse/toxic effect of Immunosuppressants. Specifically, the risk for serious infections may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Echinacea: May diminish the therapeutic effect of Immunosuppressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Leflunomide: Immunosuppressants may enhance the adverse/toxic effect of Leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased.  Management: Consider not using a leflunomide loading dose in patients receiving other immunosuppressants.  Patients receiving both leflunomide and another immunosuppressant should be monitored for bone marrow suppression at least monthly.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Natalizumab: Immunosuppressants may enhance the adverse/toxic effect of Natalizumab. Specifically, the risk of concurrent infection may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimecrolimus: May enhance the adverse/toxic effect of Immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Roflumilast: May enhance the immunosuppressive effect of Immunosuppressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sipuleucel-T: Immunosuppressants may diminish the therapeutic effect of Sipuleucel-T.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tacrolimus (Topical): May enhance the adverse/toxic effect of Immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tofacitinib: Immunosuppressants may enhance the immunosuppressive effect of Tofacitinib.  Management: Concurrent use with antirheumatic doses of methotrexate or other non-disease modifying antirheumatic drugs (non-DMARDs) is permitted, and this warning seems to particularly focused on more potent immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trastuzumab: May enhance the neutropenic effect of Immunosuppressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaccines (Inactivated): Immunosuppressants may diminish the therapeutic effect of Vaccines (Inactivated).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaccines (Live): Immunosuppressants may enhance the adverse/toxic effect of Vaccines (Live). Vaccinial infections may develop. Immunosuppressants may diminish the therapeutic effect of Vaccines (Live).  Management: Avoid use of live organism vaccines with immunosuppressants; live-attenuated vaccines should not be given for at least 3 months after immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F13645942\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Food: Absorption is decreased when administered with food.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F149310\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     D (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F149325\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal reproduction studies have demonstrated teratogenicity. Chlorambucil crosses the human placenta. Following exposure during the first trimester, case reports have noted adverse renal effects (unilateral agenesis). Women of childbearing potential should avoid becoming pregnant while receiving treatment.",
"     <b>",
"      [U.S. Boxed Warning]: Affects human fertility; probably mutagenic and teratogenic as well",
"     </b>",
"     ; chromosomal damage has been documented. Reversible and irreversible sterility (when administered to prepubertal and pubertal males), azoospermia (in adult males) and amenorrhea (in females) have been observed. Fibrosis, vasculitis and depletion of primordial follicles have been noted on autopsy of the ovaries.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F149351\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F4412250\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     According to the manufacturer, due to the potential for serious adverse reactions in the nursing infant, the decision to discontinue chlorambucil or to discontinue breast-feeding during treatment should take into account the benefits of treatment to the mother.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F149324\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Leukeran Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2 mg (50): $278.40",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F149312\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Liver function tests, CBC with differential (weekly, with WBC monitored twice weekly during the first 3-6 weeks of treatment)",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F149326\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Chloraminophene (FR);",
"     </li>",
"     <li>",
"      Leukeran (AE, AR, AT, AU, BB, BD, BE, BF, BG, BH, BJ, BM, BR, BS, BZ, CH, CI, CL, CN, CY, CZ, DE, DK, EE, EG, ES, ET, FI, FR, GB, GH, GM, GN, GR, GY, HK, HN, HR, HU, ID, IE, IL, IN, IQ, IR, IT, JM, JO, JP, KE, KP, KW, LB, LR, LU, LY, MA, ML, MR, MT, MU, MW, MX, MY, NE, NG, NL, NO, NZ, OM, PE, PH, PK, PL, PT, QA, RU, SA, SC, SD, SE, SG, SK, SL, SN, SR, SY, TH, TN, TR, TT, TW, TZ, UG, UY, YE, ZA, ZM, ZW)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F149302\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Alkylating agent; interferes with DNA replication and RNA transcription by alkylation and cross-linking the strands of DNA",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F149321\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Rapid and complete (&gt;70%); reduced with food",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : ~0.3 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: ~99%; primarily to albumin",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatic (extensively); primarily to active metabolite, phenylacetic acid mustard",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: ~1.5 hours; Phenylacetic acid mustard: ~1.8 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak, plasma: Within 1 hour; Phenylacetic acid mustard: 1.2-2.6 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (~20% to 60%, primarily as inactive metabolites, &lt;1% as unchanged drug or phenylacetic acid mustard)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Aronoff GR, Bennett WM, Berns JS, et al,",
"      <i>",
"       Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children",
"      </i>",
"      , 5th ed. Philadelphia, PA: American College of Physicians; 2007, p 98.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Eichhorst BF, Busch R, Stilgenbauer S, et al, &ldquo;First-Line Therapy With Fludarabine Compared With Chlorambucil Does Not Result in a Major Benefit for Elderly Patients With Advanced Chronic Lymphocytic Leukemia,&rdquo;",
"      <i>",
"       Blood",
"      </i>",
"      , 2009, 114(16):3382-91.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/52/35654/abstract-text/19605849/pubmed\" id=\"19605849\" target=\"_blank\">",
"        19605849",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hodson EM, Willis NS, and Craig JC, &ldquo;Non-Corticosteroid Treatment for Nephrotic Syndrome in Children (Review),&rdquo;",
"      <i>",
"       Cochrane Database Syst Rev",
"      </i>",
"      , 2010, (4):CD002290.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kintzel PE and Dorr RT, &ldquo;Anticancer Drug Renal Toxicity and Elimination: Dosing Guidelines for Altered Renal Function,&rdquo;",
"      <i>",
"       Cancer Treat Rev",
"      </i>",
"      , 1995, 21(1):33-64.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/52/35654/abstract-text/7859226/pubmed\" id=\"7859226\" target=\"_blank\">",
"        7859226",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kyle RA, Greipp PR, Gertz MA, et al, &ldquo;Waldenstr&ouml;m's Macroglobulinemia: A Prospective Study Comparing Daily With Intermittent Oral Chlorambucil,&rdquo;",
"      <i>",
"       Br J Haematol",
"      </i>",
"      , 2000, 108(4):737-42.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/52/35654/abstract-text/10792277/pubmed\" id=\"10792277\" target=\"_blank\">",
"        10792277",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Institute for Occupational Safety and Health (NIOSH), \"NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2012.\" Available at",
"      <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"       file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf",
"      </a>",
"      . Accessed January 21, 2013.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rai KR, Peterson BL, Appelbaum FR, et al, &ldquo;Fludarabine Compared With Chlorambucil as Primary Therapy for Chronic Lymphocytic Leukemia,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2000, 343(24):1750-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/52/35654/abstract-text/11114313/pubmed\" id=\"11114313\" target=\"_blank\">",
"        11114313",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Raphael B, Andersen JW, Silber R, et al, &ldquo;Comparison of Chlorambucil and Prednisone Versus Cyclophosphamide, Vincristine, and Prednisone as Initial Treatment for Chronic Lymphocytic Leukemia: Long-Term Follow-Up of an Eastern Cooperative Oncology Group Randomized Clinical Trial,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 1991, 9(5):770-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/52/35654/abstract-text/2016618/pubmed\" id=\"2016618\" target=\"_blank\">",
"        2016618",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Robinson RF, Nahata MC, Mahan JD, &ldquo;Management of Nephrotic Syndrome in Children,&rdquo;",
"      <i>",
"       Pharmacotherapy",
"      </i>",
"      , 2003, 23(8):1021-36.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/52/35654/abstract-text/12921248/pubmed\" id=\"12921248\" target=\"_blank\">",
"        12921248",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Selby P, Patel P, Milan S, et al, &ldquo;ChIVPP Combination Chemotherapy for Hodgkin's Disease: Long-Term Results,&rdquo;",
"      <i>",
"       Br J Cancer",
"      </i>",
"      , 1990, 62(2):279-85.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/52/35654/abstract-text/2386744 /pubmed\" id=\"2386744 \" target=\"_blank\">",
"        2386744",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      The International ChIVPP Treatment Group, &ldquo;ChIVPP Therapy for Hodgkin&rsquo;s Disease: Experience of 960 Patients,&rdquo;",
"      <i>",
"       Ann Oncol",
"      </i>",
"      , 1995, 6(2):167-72.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/52/35654/abstract-text/7786824/pubmed\" id=\"7786824\" target=\"_blank\">",
"        7786824",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Vose JM, Bierman PJ, Anderson JR, et al, &ldquo;CHLVPP Chemotherapy With Involved-Field Irradiation for Hodgkin&rsquo;s Disease: Favorable Results With Acceptable Toxicity,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 1991, 9(8):1421-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/52/35654/abstract-text/2072145/pubmed\" id=\"2072145\" target=\"_blank\">",
"        2072145",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wagner AM, Brunet S, Puig J, et al, &ldquo; Chlorambucil-Induced Inappropriate Antidiuresis in Man With Chronic Lymphocytic Leukemia,&rdquo;",
"      <i>",
"       Ann Hemat",
"      </i>",
"      , 1999, 78(1):37-8.",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9240 Version 46.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-79.123.134.1-8BED796ECD-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_52_35654=[""].join("\n");
var outline_f34_52_35654=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5708649\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F149339\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F149340\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F149382\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F149343\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F149362\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F149344\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5526979\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5527179\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4412251\">",
"      Dosing: Adjustment for Toxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F149314\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F149299\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F149318\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F149317\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4412249\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F149390\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F149380\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F149322\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F149303\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299014\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F149308\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13645942\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F149310\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F149325\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F149351\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4412250\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F149324\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F149312\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F149326\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F149302\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F149321\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9240\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9240|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?25/16/25861?source=related_link\">",
"      Chlorambucil: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?35/9/35989?source=related_link\">",
"      Chlorambucil: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f34_52_35655="Antidromic AVRT";
var content_f34_52_35655=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F50433&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F50433&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1046px;\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Antidromic atrioventricular reentrant tachycardia (AVRT) in the setting of an accessory AV pathway",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 450px; height: 288px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The rhythm strip shows a sinus (S) beat that has a short PR interval and a wide QRS complex as a result of a delta wave (d). Panel A shows the activation sequence with an atrial premature beat (APB,*). The impulse reaches the atrioventricular node (N) before it has repolarized and hence is blocked in this structure. However, the accessory pathway (AP), which has a short refractory period, is able to conduct the impulse antegradely, resulting in an APB with a widened QRS morphology similar to the sinus beat. As seen in panel B, following myocardial activation, the impulse is conducted retrogradely along the His Purkinje system and AV node, resulting in retrograde atrial activation, seen on the rhythm strip as an inverted P wave. If this activation sequence repeats itself (panel C), a wide QRS complex antidromic atrioventricular reentrant (or reciprocating) tachycardia (AVRT) is established.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
"  <div class=\"figure\" style=\"width: 456px\">",
"   <div class=\"ttl\">",
"    Sinus rhythm",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 456px; height: 103px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The normal P wave in sinus rhythm is slightly notched since activation of the right atrium precedes that of the left atrium. The P wave is upright in a positive direction in leads I and II. A P wave with a uniform morphology precedes each QRS complex. The rate is between 60 and 100 beats per minute and the cycle length is uniform between sequential P waves and QRS complexes. In addition, the P wave morphology and PR intervals are identical from beat to beat.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_52_35655=[""].join("\n");
var outline_f34_52_35655=null;
var title_f34_52_35656="Clinical manifestations and diagnosis of patent ductus arteriosus";
var content_f34_52_35656=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Clinical manifestations and diagnosis of patent ductus arteriosus",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/52/35656/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/52/35656/contributors\">",
"     Thomas Doyle, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/52/35656/contributors\">",
"     Ann Kavanaugh-McHugh, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/52/35656/contributors\">",
"     Thomas P Graham, Jr, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/52/35656/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/52/35656/contributors\">",
"     Heidi M Connolly, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/52/35656/contributors\">",
"     John K Triedman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/52/35656/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/52/35656/contributors\">",
"     Melanie S Kim, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?34/52/35656/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 25, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The ductus arteriosus (DA) is a fetal vascular connection between the main pulmonary artery and the aorta (",
"    <a class=\"graphic graphic_figure graphicRef65828 \" href=\"mobipreview.htm?10/31/10739\">",
"     figure 1",
"    </a>",
"    ) that diverts blood away from the pulmonary bed. After birth, the DA undergoes active constriction and eventual obliteration. A patent ductus arteriosus (PDA) occurs when the DA fails to completely close postnatally. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/19/8502?source=see_link\">",
"     \"Physiologic transition from intrauterine to extrauterine life\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The clinical manifestations and diagnosis of PDA in full term infants, older children, and adults will be reviewed here. PDA in the premature infant and the management of PDA are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/50/15145?source=see_link\">",
"     \"Pathophysiology, clinical manifestations, and diagnosis of patent ductus arteriosus in premature infants\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/42/33448?source=see_link\">",
"     \"Management of patent ductus arteriosus\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DUCTAL EMBRYOLOGY AND ANATOMY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The DA is thought to derive from the embryonic left sixth aortic arch (",
"    <a class=\"graphic graphic_figure graphicRef55186 \" href=\"mobipreview.htm?32/31/33265\">",
"     figure 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef61946 \" href=\"mobipreview.htm?29/1/29712\">",
"     image 1",
"    </a>",
"    ). In the typical left aortic arch, the aortic end of the DA arises distal to the left subclavian artery and the pulmonary end inserts at the junction of the main and left pulmonary arteries.",
"   </p>",
"   <p>",
"    The anatomy is more varied in the presence of a right aortic arch. Most commonly, the DA arises from the left innominate artery and inserts into the region of the proximal left pulmonary artery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/52/35656/abstract/1\">",
"     1",
"    </a>",
"    ]. Less frequently, the DA arises distal to the right subclavian artery and inserts near the proximal right pulmonary artery. In rare instances, there is a bilateral DA, usually in the presence of other complex congenital cardiovascular anomalies.",
"   </p>",
"   <p>",
"    Regardless of the aortic arch orientation, the vascular structures remain anterior to the trachea and esophagus, and there is no vascular ring. One exception to this general rule occurs when there is a right aortic arch with an aberrant left subclavian artery (called RALL). In this setting, the DA typically arises from the aberrant subclavian artery and inserts into the proximal left pulmonary artery. This creates a vascular ring with the aorta anterior to and rightward of the trachea and esophagus; the aberrant subclavian artery is posterior, and the DA is along the left side, connecting the subclavian to the pulmonary artery. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/5/27735?source=see_link&amp;anchor=H7#H7\">",
"     \"Vascular rings\", section on 'R aortic arch with aberrant L subclavian artery and L ductus arteriosus/ligamentum'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Histologically, ductal tissue differs from that of the adjacent aorta and pulmonary artery. The intima of the ductus is thicker, and the media contains more smooth muscle fibers arranged in a characteristic spiral fashion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/52/35656/abstract/2\">",
"     2",
"    </a>",
"    ]. The DA may take a variety of shapes and forms. The Krichenko classification describes the angiographic appearance of the patent ductus, including several subtypes broadly defined as [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/52/35656/abstract/3\">",
"     3",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Type A: Conical with the narrowest portion at the PA side",
"     </li>",
"     <li>",
"      Type B: Short with narrowing at the aortic insertion",
"     </li>",
"     <li>",
"      Type C: Tubular without constriction",
"     </li>",
"     <li>",
"      Type D: Tubular with multiple constrictions",
"     </li>",
"     <li>",
"      Type E: Bizarre, with an elongated, conical appearance and multiple constrictions",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    This classification scheme does not include the reverse-oriented ductus, which is commonly associated with congenital heart disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     FETAL AND TRANSITIONAL DUCTAL CIRCULATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the fetus, the right ventricle accommodates approximately 60 percent of the total cardiac output [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/52/35656/abstract/4\">",
"     4",
"    </a>",
"    ]. The pulmonary vasculature is constricted, resulting in a high vascular resistance within the pulmonary bed. In contrast, the placenta creates a very low resistance bed arising from the aorta, and systemic vascular resistance is low. As a result, the majority of blood exiting from the right ventricle passes right-to-left across the DA into the descending aorta and on to the placenta. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/19/8502?source=see_link&amp;anchor=H2#H2\">",
"     \"Physiologic transition from intrauterine to extrauterine life\", section on 'Fetus'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In the fetus, the DA is large, with a diameter approximating that of the descending aorta. With the onset of respiration after delivery, the lungs expand and the systemic oxygen saturation rises, resulting in pulmonary vasodilatation and a drop in pulmonary vascular resistance. At the same time, systemic resistance rises with placental removal after cutting the umbilical cord. These factors lead to a sudden reversal of blood flow in the DA from right-to-left to left-to-right. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/19/8502?source=see_link&amp;anchor=H5#H5\">",
"     \"Physiologic transition from intrauterine to extrauterine life\", section on 'Transition at delivery'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Patency of the ductus",
"    </span>",
"    &nbsp;&mdash;&nbsp;The fetal DA is kept patent by low arterial oxygen content and circulating prostaglandin E2 (PGE2), which is produced in part by the placenta [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/52/35656/abstract/5\">",
"     5",
"    </a>",
"    ]. PGE2 appears to be mediated by its COX-2 isoform, since constriction of the fetal DA in mice is induced by selective COX-2 inhibitors but not selective COX-1 inhibitors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/52/35656/abstract/6\">",
"     6",
"    </a>",
"    ]. The rationale for the administration of nonsteroidal anti-inflammatory drugs in the treatment of PDA in preterm infants is based upon the role of PGE2 in maintaining DA patency. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/62/1002?source=see_link&amp;anchor=H1214592#H1214592\">",
"     \"Management of patent ductus arteriosus in premature infants\", section on 'Indomethacin'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Ductal constriction",
"    </span>",
"    &nbsp;&mdash;&nbsp;At birth, the rise in systemic arterial oxygen tension and a decrease in circulating PGE2 levels trigger ductal constriction.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Although the mechanism that causes active ductal constriction is not known, gene transfer studies suggest that an oxygen-sensitive potassium channel mediates DA constriction [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/52/35656/abstract/7\">",
"       7",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      After delivery, circulating PGE2 levels fall because of reduced production following removal of the placenta, and increased PGE2 clearance due to increase in circulating levels of prostaglandin dehydrogenase [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/52/35656/abstract/6,8\">",
"       6,8",
"      </a>",
"      ]. Removal of the strong vasodilatory effect of PGE2 is sensed by the PGE2 receptor (EP4) and promotes further constriction of the ductus [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/52/35656/abstract/9,10\">",
"       9,10",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Constriction of the DA usually results in functional hemodynamic closure within 10 to 15 hours after delivery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/52/35656/abstract/11\">",
"     11",
"    </a>",
"    ]. Closure begins at the pulmonary end of the DA and proceeds toward the aortic end [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/52/35656/abstract/12\">",
"     12",
"    </a>",
"    ], and is usually completed by two to three weeks of age. Following initial constriction, a series of histologic changes result in obliteration of the ductus and conversion into the ligamentum arteriosum [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/52/35656/abstract/12\">",
"     12",
"    </a>",
"    ]. It appears that these changes do not occur in a PDA, suggesting distinct anatomic differences in the DA tissue [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/52/35656/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     INCIDENCE OF PDA",
"    </span>",
"    &nbsp;&mdash;&nbsp;The incidence of PDA has increased dramatically over the last two decades. This is due to the improved survival rate of premature infants, because the incidence of PDA significantly increases in infants born before 30 weeks gestation. The effect of prematurity on the incidence of PDA is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/50/15145?source=see_link\">",
"     \"Pathophysiology, clinical manifestations, and diagnosis of patent ductus arteriosus in premature infants\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The reported incidence of an isolated PDA among term infants ranges from 0.03 to 0.08 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/52/35656/abstract/13\">",
"     13",
"    </a>",
"    ]. In a population-based study of 400,000 term infants born in Atlanta from 1998 to 2005, the reported incidence of PDA was 2.9 per 10,000 live births [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/52/35656/abstract/14\">",
"     14",
"    </a>",
"    ]. In this study, the diagnosis was defined as a PDA persisting up to or beyond six weeks after delivery in infants with a gestational age at or greater than 36 weeks, and excluded patients with obligatory shunt lesions due to complex congenital heart disease (CHD) or those who received prostaglandin therapy.",
"   </p>",
"   <p>",
"    There is a female predominance for PDA with a 2:1 female to male ratio in most case series of term infants [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/52/35656/abstract/14,15\">",
"     14,15",
"    </a>",
"    ]. The incidence of PDA is also greater in infants born at high altitude compared to those born at sea level [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/52/35656/abstract/8\">",
"     8",
"    </a>",
"    ], and in infants with congenital rubella. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/49/10010?source=see_link&amp;anchor=H8#H8\">",
"     \"Congenital rubella syndrome: Clinical features and diagnosis\", section on 'Clinical features'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    PDA may present with other congenital heart lesions, especially those associated with hypoxemia. PDA should be considered when the clinical features of left-to-right shunt seem out of proportion to the particular lesion being considered.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Genetic factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is likely that genetic factors contribute to some cases of PDA. Siblings of patients with PDA have an increased frequency of this abnormality (2 to 4 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/52/35656/abstract/16\">",
"     16",
"    </a>",
"    ]. PDA occasionally occurs in many members of multiple generations of a family, making simple autosomal dominant inheritance likely in these families [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/52/35656/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In Char syndrome, for example, family members have PDA, unusual facial features, and an abnormal fifth digit of the hand [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/52/35656/abstract/18\">",
"     18",
"    </a>",
"    ]. A gene for this syndrome has been mapped to chromosome 6p12-p21 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/52/35656/abstract/19\">",
"     19",
"    </a>",
"    ] and is caused by defects in TFAP2B proteins, encoding a neural crest-related transcription factor [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/52/35656/abstract/20\">",
"     20",
"    </a>",
"    ]",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical manifestations of a PDA are determined by the degree of left-to-right shunting, which is dependent upon the size and length of the PDA, and the difference between pulmonary and systemic vascular resistances.",
"   </p>",
"   <p>",
"    The hemodynamic consequences of the PDAs can be categorized by the degree of left-to-right shunting based upon the pulmonary to systemic flow ratio (Qp:Qs) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/52/35656/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Small &mdash; Qp:Qs &lt;1.5 to 1",
"     </li>",
"     <li>",
"      Moderate &mdash; Qp:Qs between 1.5 and 2.2 to 1",
"     </li>",
"     <li>",
"      Large &mdash; Qp:Qs &gt;2.2 to 1",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The clinical findings for the full term infant, older children, and adults based upon the size of PDA are discussed in the next sections. The clinical manifestations of PDA in preterm infants are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/50/15145?source=see_link\">",
"     \"Pathophysiology, clinical manifestations, and diagnosis of patent ductus arteriosus in premature infants\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Small PDA",
"    </span>",
"    &nbsp;&mdash;&nbsp;A small PDA (Qp:Qs &lt;1.5 to 1) that restricts excessive blood flow into the lungs may go undetected, and the patient will have no identifiable symptoms. These patients are commonly identified incidentally by the detection of the characteristic continuous flow murmur noted during a routine primary care visit or by a finding of a PDA on a diagnostic study (eg, computed tomography or echocardiography) performed for other medical conditions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/52/35656/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In patients with a small PDA, the physical examination reveals normal precordial activity, and normal first and second heart sounds. Pulses are normal or only mildly accentuated. The respiratory examination also is unremarkable, and there is no evidence of cyanosis.",
"   </p>",
"   <p>",
"    A murmur is commonly present, and its characteristics vary between the neonate and older patients because of changes in the relative differences between pulmonary and systemic vascular resistances.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the newborn, aortic systolic pressure is greater than pulmonary systolic pressure, but this gradient may not be present during diastole. As a result, the murmur may be confined to systole.",
"     </li>",
"     <li>",
"      Pulmonary artery pressure falls after the newborn period. As a result, aortic pressure is higher than pulmonary artery pressure during both systole and diastole, producing continuous flow through the ductus and a characteristic continuous murmur (Gibson's murmur or machinery murmur). The murmur is grade",
"      <span class=\"nowrap\">",
"       3/6",
"      </span>",
"      or less and is heard best in the left infraclavicular region. The intensity of the murmur is maximal immediately before and after the second heart sound (S2) and is not affected by position (",
"      <a class=\"graphic graphic_figure graphicRef54292 \" href=\"mobipreview.htm?18/5/18526\">",
"       figure 3",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?25/37/26202?source=see_link&amp;anchor=H53#H53\">",
"       \"Auscultation of cardiac murmurs\", section on 'Patent ductus arteriosus'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Infective endarteritis is an uncommon presentation and complication of small PDAs. It appears to occur more frequently in patients in developing countries. In one case series of 14 Pakistani patients, fever was the presenting symptom and the presence of a heart murmur was detected upon physical examination in all patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/52/35656/abstract/23\">",
"     23",
"    </a>",
"    ]. The diagnosis of PDA was confirmed by echocardiography and vegetations were detected in 12 of the 14 patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Moderate PDA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with moderate size PDAs (Qp:Qs between 1.5 and 2.2 to 1) may present with exercise intolerance. In these patients, the moderate left-to-right shunt increases the volume load on the left atrium and ventricle, which results in left ventricular dilation and dysfunction.",
"   </p>",
"   <p>",
"    The characteristic continuous murmur (usually grade 2 or 3, occasionally grade 4) in the left infraclavicular area, which is louder than that associated with a small PDA, is typically accompanied by a wide systemic pulse pressure and signs of left ventricular overload, such as a displaced left ventricular apex.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Large PDA",
"    </span>",
"    &nbsp;&mdash;&nbsp;A large PDA (Qp:Qs &gt;2.2 to 1) initially causes left ventricular overload. Over time, there may be a progressive rise in pulmonary artery pressures, which in the uncorrected patient, may lead to irreversible pulmonary vascular changes. With sufficiently increased pulmonary vascular resistance, flow reverses to a right-to-left shunt and over time, these patients develop cyanotic heart disease (ie, Eisenmenger syndrome). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/55/6007?source=see_link\">",
"     \"Evaluation and prognosis of Eisenmenger syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In the infant, a large PDA may present with signs of heart failure, including failure to thrive, poor feeding, and respiratory distress. The older child may present with shortness of breath or easy fatigability.",
"   </p>",
"   <p>",
"    In the uncorrected adult, a large PDA may present with a short systolic ejection murmur, and features of Eisenmenger syndrome including cyanosis and clubbing. Patients with PDA and Eisenmenger syndrome typically have cyanosis and clubbing that is more pronounced in the lower extremities (ie, differential cyanosis) because the ductus typically delivers unoxygenated blood distal to the left subclavian artery.",
"   </p>",
"   <p>",
"    In the patient with a left-to-right shunt, precordial palpation reveals a dynamic left ventricular impulse and a thrill, and the pulses are bounding with a wide pulse pressure due to runoff into the pulmonary bed. On auscultation, S1 is normal, S2 may be split with an accentuated pulmonary component, and eddy sounds may be heard in late systole and early diastole. A grade",
"    <span class=\"nowrap\">",
"     4/6",
"    </span>",
"    continuous murmur is heard in the left infraclavicular region. An apical diastolic rumble induced by increased flow across the mitral valve may be present, preceded by a third heart sound.",
"   </p>",
"   <p>",
"    As mentioned above, adult patients with PDA may have a short systolic ejection murmur because the diastolic run-off into the pulmonary circulation is decreased due to increasing pulmonary vascular resistance. With increasing pulmonary vascular resistance, patients may develop pulmonary hypertension. (See",
"    <a class=\"local\" href=\"#H25\">",
"     'Pulmonary hypertension'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of PDA is usually based upon its characteristic clinical findings and typically confirmed by echocardiography. The chest x-ray and the electrocardiogram may be helpful but are less sensitive and specific than echocardiography. Cardiac catheterization and angiography are generally only necessary when percutaneous therapy is being considered or in the context of more complex congenital heart disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Echocardiography",
"    </span>",
"    &nbsp;&mdash;&nbsp;A complete echocardiographic evaluation of a PDA includes anatomic confirmation by two-dimensional imaging, and Doppler echocardiography hemodynamic assessment including the degree of shunting and pulmonary artery pressure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/52/35656/abstract/24,25\">",
"     24,25",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Two-dimensional echocardiography",
"    </span>",
"    &nbsp;&mdash;&nbsp;The PDA can be imaged in many views using two-dimensional imaging and superimposed Doppler color flow mapping [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/52/35656/abstract/24,25\">",
"     24,25",
"    </a>",
"    ]. Most commonly, the ductus is imaged in the parasternal and suprasternal notch views.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Parasternal view &mdash; In the high parasternal short axis view, with the transducer oriented leftward toward the pulmonary artery bifurcation, the ductus can be imaged coursing between the pulmonary artery and the descending aorta (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef53283 graphicRef66016 \" href=\"mobipreview.htm?2/44/2760\">",
"       image 2A-B",
"      </a>",
"      ). In this view, the ductus can be seen arising from the anterior aspect of the descending aorta, which is viewed in cross section. The patent ductus enters the pulmonary artery near the origin of the left pulmonary artery.",
"     </li>",
"     <li>",
"      Suprasternal view &mdash; In the suprasternal notch window, the ductus arises from the descending aorta at the level of the left subclavian artery, and courses anteriorly to join the pulmonary artery (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef76785 \" href=\"mobipreview.htm?6/56/7041\">",
"       image 3",
"      </a>",
"      ). Moving the transducer just laterally and inferiorly to an infraclavicular position, and rotating clockwise, permits further imaging of the ductus and its relationship to the branch pulmonary arteries and descending aorta (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef54940 \" href=\"mobipreview.htm?38/37/39506\">",
"       image 4",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In patients with a right aortic arch, the ductus usually arises from the left brachiocephalic vessels instead of the descending aorta and can be followed caudally to its insertion on the pulmonary artery in the suprasternal view.",
"   </p>",
"   <p>",
"    The presence of a PDA may mask an aortic coarctation, since the ductus augments the left aortic arch at its origin. The presence of a bicuspid aortic valve, hypoplasia of the aortic isthmus, or a posterior shelf should alert the echocardiographer to the possible presence of a coexistent coarctation. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/12/21706?source=see_link\">",
"     \"Clinical features and evaluation of aortic stenosis in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Two-dimensional imaging may give important qualitative information regarding the hemodynamic significance of a PDA. Left atrial and ventricular dilation are seen in the presence of a large left-to-right shunt.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Doppler color flow",
"    </span>",
"    &nbsp;&mdash;&nbsp;Doppler color flow mapping can supplement imaging of the PDA, which is most commonly seen as a retrograde color flow jet in the pulmonary artery (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef53283 graphicRef66016 \" href=\"mobipreview.htm?2/44/2760\">",
"     image 2A-B",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef76785 \" href=\"mobipreview.htm?6/56/7041\">",
"     image 3",
"    </a>",
"    ). This jet usually occurs along the leftward aspect of the pulmonary artery but may be directed into the center or more rightward (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef65214 \" href=\"mobipreview.htm?2/49/2834\">",
"     image 5",
"    </a>",
"    ). In patients with normal pulmonary artery pressure, the high velocity turbulent flow is easily seen in both systole and diastole. In patients with high pulmonary vascular resistance, the retrograde jet may be visible only in diastole.",
"   </p>",
"   <p>",
"    Color flow mapping is particularly helpful in the setting of a small PDA that may be difficult to identify by two-dimensional imaging, especially in adults in whom resolution is more limited than in infants and small children. Determination of the origin of the retrograde flow into the pulmonary artery using two-dimensional imaging as well as color flow mapping is crucial to avoid confusion of the patent ductus with other aortopulmonary shunts, such as collateral vessels, coronary artery fistulae, or an aortopulmonary window. (See",
"    <a class=\"local\" href=\"#H21\">",
"     'Differential diagnosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Doppler echocardiography",
"    </span>",
"    &nbsp;&mdash;&nbsp;Doppler echocardiography can estimate the degree of left-to right shunt and assess the pulmonary artery pressure. In the setting of a large left-to-right shunt at the DA, continuous runoff can be seen in the branch pulmonary arteries and in the aorta proximal to the PDA by pulsed Doppler (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef56853 \" href=\"mobipreview.htm?42/43/43696\">",
"     image 6",
"    </a>",
"    ). Distal to the origin of the PDA, diastolic retrograde flow can be demonstrated corresponding to the runoff into the pulmonary artery (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef63458 graphicRef74912 \" href=\"mobipreview.htm?40/26/41381\">",
"     image 7A-B",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/52/35656/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Pulmonary to systemic flow ratio (Qp:Qs) can be estimated echocardiographically using the area of the left and right ventricular outflow tracts, and Doppler-derived velocity and flow data. Paradoxically, in the setting of the patent ductus arteriosus, the systemic blood flow is calculated by using the area of the right ventricular and pulmonary outflow tracts and velocity time integrals, and the pulmonary blood flow is calculated utilizing the aortic outflow tract area and velocity time integral. However, the ductal jet frequently distorts the antegrade pulmonary flow signal; as a result, this measurement is not usually helpful [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/52/35656/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Doppler information derived directly from the ductus is helpful in assessing pulmonary artery pressure. When the pulmonary artery pressure is lower than systemic arterial pressure, there is continuous left-to-right shunting demonstrated by both color flow mapping and pulsed Doppler interrogation. The velocity of flow across the ductus, measured by either pulsed or continuous wave Doppler, can be translated into the gradient between the aorta and the pulmonary artery using the modified Bernoulli equation (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef79806 \" href=\"mobipreview.htm?6/36/6723\">",
"     image 8",
"    </a>",
"    ). This Doppler-derived gradient correlates with gradients measured at catheterization and can be subtracted from the cuff pressure to estimate pulmonary artery pressure.",
"   </p>",
"   <p>",
"    Information regarding right ventricular and pulmonary artery pressure may also be derived by determination of tricuspid regurgitation velocity and, qualitatively, by ventricular septal configuration.",
"   </p>",
"   <p>",
"    As with any Doppler-derived measurement, care must be taken to minimize the angle between the Doppler interrogation and the direction of flow in the ductus. The length and shape of the ductus may influence the accuracy of gradient estimates using the Bernoulli equation; longer and more \"tunnel\" like structures are less reliably evaluated using this equation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/52/35656/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    When the pulmonary artery pressure is equal to systemic pressure, pulsed Doppler within the ductus demonstrates systolic right-to-left shunting, with diastolic left-to-right flow within the vessel (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef61439 \" href=\"mobipreview.htm?13/58/14241\">",
"     image 9",
"    </a>",
"    ). The finding of systolic right-to-left flow within the ductus may be confused with normal antegrade systolic flow in the left pulmonary artery if the sample volume is not placed within the ductus. In rare cases of arch abnormalities and pulmonary hypertension, right-to-left shunting may be seen throughout the cardiac cycle [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/52/35656/abstract/27,28\">",
"     27,28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Transesophageal echocardiography can be used for identification of a PDA, but the PDA may be difficult to visualize using this technique.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     M-mode echocardiography",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although M-mode echocardiography may reveal findings suggesting a left-to-right shunt, it is not diagnostic for a PDA. A ratio of left atrial-to-aortic diameter greater than 1.5:1 is usually associated with significant left-to-right shunting.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Other diagnostic tests",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Chest radiograph",
"    </span>",
"    &nbsp;&mdash;&nbsp;The findings on chest radiography vary with the size of the ductus and the degree of left-to-right shunting. In patients with a small PDA (ie, restrictive), the chest radiograph is normal.",
"   </p>",
"   <p>",
"    The earliest radiographic finding usually is a prominent main pulmonary artery segment blending with a prominent aortic knob along the upper left heart border. In patients with moderate size PDAs, the heart is slightly enlarged and the pulmonary vascular markings are increased. In patients with a large PDA, these features become more pronounced with enlargement of the left ventricle and atrium, and increased pulmonary vascular markings.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Electrocardiogram",
"    </span>",
"    &nbsp;&mdash;&nbsp;The electrocardiogram (ECG) is often normal in patients with a small PDA. In contrast, a large PDA with a large left-to-right shunt typically produces ECG findings of biventricular hypertrophy and a left atrial abnormality. With longstanding pulmonary hypertension, the ductus shunt is reversed and signs of right ventricular hypertrophy predominate. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/36/27204?source=see_link\">",
"     \"ECG tutorial: Chamber enlargement and hypertrophy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A PDA can usually be distinguished from other causes of continuous murmurs by the physical examination [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/52/35656/abstract/29\">",
"     29",
"    </a>",
"    ] and be completely differentiated by echocardiography.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A venous hum is more often located on the right side, and changes with position and local compression.",
"     </li>",
"     <li>",
"      Murmurs of systemic arteriovenous fistulas are in extracardiac locations.",
"     </li>",
"     <li>",
"      Murmurs of coronary artery fistulas are most often located over the lower precordium.",
"     </li>",
"     <li>",
"      Aortopulmonary window often has only a systolic murmur.",
"     </li>",
"     <li>",
"      Aortic stenosis or ventricular septal defect with aortic regurgitation is characterized by systolic and diastolic murmurs rather than continuous murmurs.",
"     </li>",
"     <li>",
"      The murmur of a ruptured sinus of Valsalva aneurysm is typically a new murmur loudest at the second left interspace.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Individuals with PDA have increased morbidity and mortality, primarily due to heart failure and rarely infective endocarditis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/52/35656/abstract/30\">",
"     30",
"    </a>",
"    ]. Pulmonary vascular disease is an uncommon problem.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Heart failure",
"    </span>",
"    &nbsp;&mdash;&nbsp;If untreated, a large PDA can cause significant cardiac volume overload resulting in heart failure. This most commonly occurs in the young infant and in elderly patients, whose left atrial and ventricular function have been impaired due to the effects of chronic volume workload. In the elderly, heart failure is often associated with atrial fibrillation.",
"   </p>",
"   <p>",
"    Infants with heart failure will present with failure to thrive, poor feeding, and respiratory distress. Initial management includes",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/27/29113?source=see_link\">",
"     digoxin",
"    </a>",
"    and diuretic therapy, until they are candidates for device or surgical closure. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/42/33448?source=see_link\">",
"     \"Management of patent ductus arteriosus\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Infective endocarditis",
"    </span>",
"    &nbsp;&mdash;&nbsp;A PDA carries a moderate risk of infective endocarditis (IE). When IE does occur, the vegetations usually accumulate at the pulmonary end of the PDA and shower the lungs with septic emboli. IE is an indication for PDA closure based upon the American College of",
"    <span class=\"nowrap\">",
"     Cardiology/American",
"    </span>",
"    Heart Association 2008 guidelines for the management of adults with congenital heart disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/52/35656/abstract/31\">",
"     31",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/31/14840?source=see_link\">",
"     \"Epidemiology, risk factors and microbiology of infective endocarditis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Antibiotic prophylaxis is not recommended in patients with unrepaired PDA, unless it is complicated by pulmonary",
"    <span class=\"nowrap\">",
"     hypertension/Eisenmenger",
"    </span>",
"    syndrome resulting in cyanosis, then antibiotic prophylaxis is indicated. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/36/585?source=see_link\">",
"     \"Antimicrobial prophylaxis for bacterial endocarditis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Antibiotic prophylaxis is recommended during the first six months after repair with prosthetic material or device. Prophylaxis is recommend if there is a residual defect adjacent to the site of repair",
"   </p>",
"   <p>",
"    As a result of surgical repair, IE is now a rare complication of PDA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/52/35656/abstract/32-34\">",
"     32-34",
"    </a>",
"    ]. In a population-based registry in Oregon, for example, no child with a surgically corrected PDA developed IE at up to 25-year follow-up [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/52/35656/abstract/33\">",
"     33",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/36/585?source=see_link\">",
"     \"Antimicrobial prophylaxis for bacterial endocarditis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Pulmonary hypertension",
"    </span>",
"    &nbsp;&mdash;&nbsp;An isolated large PDA, as with any large left-to-right shunt, is a risk factor for irreversible pulmonary vascular disease. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/47/19193?source=see_link\">",
"     \"Overview of pulmonary hypertension in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/8/7304?source=see_link\">",
"     \"Pathogenesis of pulmonary hypertension\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In such patients, the classic physical findings of a patent ductus are no longer present, and are replaced by signs of pulmonary hypertension. The continuous murmur vanishes, precordial palpation reveals a right ventricular impulse, and auscultation reveals a pulmonary ejection sound, a loud single second heart sound, and, in some cases, a Graham Steel murmur. The Graham-Steel murmur of pulmonic regurgitation and hypertension is high-pitched and \"blowing.\" It begins with an accentuated P2 of S2 and can be of variable duration. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/37/26202?source=see_link&amp;anchor=H38#H38\">",
"     \"Auscultation of cardiac murmurs\", section on 'Pulmonic regurgitation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Pulmonary vascular disease may lead to right-to left shunting. This will deliver unoxygenated blood into the descending aorta distal to the left subclavian artery, leading to cyanosis and clubbing in the lower extremities (ie, Eisenmenger syndrome). &nbsp;(See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/55/6007?source=see_link\">",
"     \"Evaluation and prognosis of Eisenmenger syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A PDA appears to be a relatively common cause of pulmonary artery hypertension of unknown cause in adolescents and adults. In one series of 24 such patients, 16 had a left-to-right shunt (atrial septal defect in eight, PDA in six, and ventricular septal defect in two) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/52/35656/abstract/35\">",
"     35",
"    </a>",
"    ]. In this series, these lesions were best detected by transesophageal echocardiography.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The ductus arteriosus (DA) is a fetal vascular connection between the main pulmonary artery and the aorta that normally closes soon after birth (",
"    <a class=\"graphic graphic_figure graphicRef65828 \" href=\"mobipreview.htm?10/31/10739\">",
"     figure 1",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Ductal embryology and anatomy'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H3\">",
"     'Fetal and transitional ductal circulation'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The incidence of patent ductus arteriosus (PDA), failure of the DA to completely close postnatally, has risen over the last two decades due to the improved survival rate of premature infants below 30 weeks gestation who are at increased risk for PDA. In term infants, the reported incidence of an isolated PDA ranges from 0.03 to 0.08 percent. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Incidence of PDA'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The clinical manifestations of a PDA are determined by the degree of left-to-right shunting, which is dependent upon the size and length of the PDA, and the difference between pulmonary and systemic vascular resistances. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Patients with a small PDA are generally asymptomatic and are detected incidentally during routine primary care visits or testing for other conditions.",
"     </li>",
"     <li>",
"      Symptoms vary in patients with moderate and large PDAs depending upon the size of the shunt. Symptoms may range from exertional dyspnea to heart failure.",
"     </li>",
"     <li>",
"      Adults with uncorrected large PDAs may develop pulmonary vascular disease, which may result in a right-to-left shunt and cyanosis (ie, Eisenmenger syndrome).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The diagnosis of PDA is usually based upon its characteristic clinical findings and typically confirmed by echocardiography. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Complications of PDA include heart failure, infective endocarditis, and pulmonary hypertension. Antibiotic prophylaxis is not recommended in patients with unrepaired PDA unless they have developed Eisenmenger syndrome. (See",
"      <a class=\"local\" href=\"#H22\">",
"       'Complications'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/52/35656/abstract/1\">",
"      Knight L, Edwards JE. Right aortic arch. Types and associated cardiac anomalies. Circulation 1974; 50:1047.",
"     </a>",
"    </li>",
"    <li>",
"     Allen HD, Driscoll DJ, Shaddy RE, Feltes T. T Moss and Adams' heart disease in infants, children, and adolescents: including the fetus and young adult, 7th, Lippincott Williams and Wilkins, Philadelphia 2007.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/52/35656/abstract/3\">",
"      Krichenko A, Benson LN, Burrows P, et al. Angiographic classification of the isolated, persistently patent ductus arteriosus and implications for percutaneous catheter occlusion. Am J Cardiol 1989; 63:877.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/52/35656/abstract/4\">",
"      Rudolph AM. The changes in the circulation after birth. Their importance in congenital heart disease. Circulation 1970; 41:343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/52/35656/abstract/5\">",
"      Smith GC. The pharmacology of the ductus arteriosus. Pharmacol Rev 1998; 50:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/52/35656/abstract/6\">",
"      Loftin CD, Trivedi DB, Langenbach R. Cyclooxygenase-1-selective inhibition prolongs gestation in mice without adverse effects on the ductus arteriosus. J Clin Invest 2002; 110:549.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/52/35656/abstract/7\">",
"      Th&eacute;baud B, Michelakis ED, Wu XC, et al. Oxygen-sensitive Kv channel gene transfer confers oxygen responsiveness to preterm rabbit and remodeled human ductus arteriosus: implications for infants with patent ductus arteriosus. Circulation 2004; 110:1372.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/52/35656/abstract/8\">",
"      Coggins KG, Latour A, Nguyen MS, et al. Metabolism of PGE2 by prostaglandin dehydrogenase is essential for remodeling the ductus arteriosus. Nat Med 2002; 8:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/52/35656/abstract/9\">",
"      Nguyen M, Camenisch T, Snouwaert JN, et al. The prostaglandin receptor EP4 triggers remodelling of the cardiovascular system at birth. Nature 1997; 390:78.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/52/35656/abstract/10\">",
"      Segi E, Sugimoto Y, Yamasaki A, et al. Patent ductus arteriosus and neonatal death in prostaglandin receptor EP4-deficient mice. Biochem Biophys Res Commun 1998; 246:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/52/35656/abstract/11\">",
"      Heymann MA, Rudolph AM. Control of the ductus arteriosus. Physiol Rev 1975; 55:62.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/52/35656/abstract/12\">",
"      Gittenberger-de Groot AC, Strengers JL, Mentink M, et al. Histologic studies on normal and persistent ductus arteriosus in the dog. J Am Coll Cardiol 1985; 6:394.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/52/35656/abstract/13\">",
"      Hoffman JI, Kaplan S. The incidence of congenital heart disease. J Am Coll Cardiol 2002; 39:1890.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/52/35656/abstract/14\">",
"      Reller MD, Strickland MJ, Riehle-Colarusso T, et al. Prevalence of congenital heart defects in metropolitan Atlanta, 1998-2005. J Pediatr 2008; 153:807.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/52/35656/abstract/15\">",
"      RECORD RG, McKEOWN T. Observations relating to the aetiology of patent ductus arteriosus. Br Heart J 1953; 15:376.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/52/35656/abstract/16\">",
"      Nora JJ. Multifactorial inheritance hypothesis for the etiology of congenital heart diseases. The genetic-environmental interaction. Circulation 1968; 38:604.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/52/35656/abstract/17\">",
"      Davidson HR. A large family with patent ductus arteriosus and unusual face. J Med Genet 1993; 30:503.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/52/35656/abstract/18\">",
"      Char F. Peculiar facies with short philtrum, duck-bill lips, ptosis and low-set ears--a new syndrome? Birth Defects Orig Artic Ser 1978; 14:303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/52/35656/abstract/19\">",
"      Satoda M, Pierpont ME, Diaz GA, et al. Char syndrome, an inherited disorder with patent ductus arteriosus, maps to chromosome 6p12-p21. Circulation 1999; 99:3036.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/52/35656/abstract/20\">",
"      Satoda M, Zhao F, Diaz GA, et al. Mutations in TFAP2B cause Char syndrome, a familial form of patent ductus arteriosus. Nat Genet 2000; 25:42.",
"     </a>",
"    </li>",
"    <li>",
"     Webb, GD, Smallhorn, FJ, Terrien, J, Redington, AN. Congenital heart disease. In: Braunwalds' Heart Disease, 8th ed, Libby P, Bonow, RO, Mann, DL, Zipes, DP (eds), Philadelphia, 2008. p. 1561.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/52/35656/abstract/22\">",
"      Goitein O, Fuhrman CR, Lacomis JM. Incidental finding on MDCT of patent ductus arteriosus: use of CT and MRI to assess clinical importance. AJR Am J Roentgenol 2005; 184:1924.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/52/35656/abstract/23\">",
"      Sadiq M, Latif F, Ur-Rehman A. Analysis of infective endarteritis in patent ductus arteriosus. Am J Cardiol 2004; 93:513.",
"     </a>",
"    </li>",
"    <li>",
"     Silverman, NH. Pediatric Echocardiography. Williams &amp; Wilkins, Baltimore 1993. p.173.",
"    </li>",
"    <li>",
"     Snider, AR, Serwer, GA, Ritter, SB. Echocardiography in Pediatric Heart Disease. Mosby-Year Book, St. Louis 1977. p.455.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/52/35656/abstract/26\">",
"      Serwer GA, Armstrong BE, Anderson PA. Nonivasive detection of retrograde descending aortic flow in infants using continuous wave doppler ultrasonography. Implications for diagnosis of aortic run-off lesions. J Pediatr 1980; 97:394.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/52/35656/abstract/27\">",
"      Cloez JL, Isaaz K, Pernot C. Pulsed Doppler flow characteristics of ductus arteriosus in infants with associated congenital anomalies of the heart or great arteries. Am J Cardiol 1986; 57:845.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/52/35656/abstract/28\">",
"      Hiraishi S, Horiguchi Y, Misawa H, et al. Noninvasive Doppler echocardiographic evaluation of shunt flow dynamics of the ductus arteriosus. Circulation 1987; 75:1146.",
"     </a>",
"    </li>",
"    <li>",
"     Mullins, CE. Patent ductus arteriosus. In: The Science and Practice of Pediatric Cardiology, Garson, A, Bricker, JT, McNamara, DG (Eds), Lea &amp; Febiger, Philadelphia 1990. p.1055.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/52/35656/abstract/30\">",
"      Campbell M. Natural history of persistent ductus arteriosus. Br Heart J 1968; 30:4.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/52/35656/abstract/31\">",
"      Warnes CA, Williams RG, Bashore TM, et al. ACC/AHA 2008 Guidelines for the Management of Adults with Congenital Heart Disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (writing committee to develop guidelines on the management of adults with congenital heart disease). Circulation 2008; 118:e714.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/52/35656/abstract/32\">",
"      Thil&eacute;n U, Astr&ouml;m-Olsson K. Does the risk of infective endarteritis justify routine patent ductus arteriosus closure? Eur Heart J 1997; 18:503.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/52/35656/abstract/33\">",
"      Morris CD, Reller MD, Menashe VD. Thirty-year incidence of infective endocarditis after surgery for congenital heart defect. JAMA 1998; 279:599.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/52/35656/abstract/34\">",
"      Lankipalli RS, Lax K, Keane MG, et al. Images in cardiovascular medicine. Infected patent ductus arteriosus. Circulation 2005; 112:e364.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/52/35656/abstract/35\">",
"      Chen WJ, Chen JJ, Lin SC, et al. Detection of cardiovascular shunts by transesophageal echocardiography in patients with pulmonary hypertension of unexplained cause. Chest 1995; 107:8.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1421 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-122.72.76.133-425BDFC11D-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_52_35656=[""].join("\n");
var outline_f34_52_35656=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H26\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DUCTAL EMBRYOLOGY AND ANATOMY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      FETAL AND TRANSITIONAL DUCTAL CIRCULATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Patency of the ductus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Ductal constriction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      INCIDENCE OF PDA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Genetic factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Small PDA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Moderate PDA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Large PDA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Echocardiography",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Two-dimensional echocardiography",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Doppler color flow",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Doppler echocardiography",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - M-mode echocardiography",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Other diagnostic tests",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Chest radiograph",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Electrocardiogram",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Heart failure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Infective endocarditis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Pulmonary hypertension",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/1421\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/1421|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?29/1/29712\" title=\"diagnostic image 1\">",
"      PDA arteriogram III",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?38/47/39666\" title=\"diagnostic image 2A\">",
"      PDA color Doppler echo I",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?41/34/42530\" title=\"diagnostic image 2B\">",
"      PDA color Doppler echo II",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?6/56/7041\" title=\"diagnostic image 3\">",
"      PDA color Doppler echo III",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?38/37/39506\" title=\"diagnostic image 4\">",
"      PDA two D echocardiogram",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?2/49/2834\" title=\"diagnostic image 5\">",
"      Color flow Doppler PDA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?42/43/43696\" title=\"diagnostic image 6\">",
"      PDA pulsed Doppler echo I",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?32/6/32864\" title=\"diagnostic image 7A\">",
"      PDA pulsed Doppler echo II",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?33/47/34544\" title=\"diagnostic image 7B\">",
"      PDA pulsed Doppler echo III",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?6/36/6723\" title=\"diagnostic image 8\">",
"      PA pressure PDA Doppler echo-I",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?13/58/14241\" title=\"diagnostic image 9\">",
"      PA pressure PDA Doppler echo II",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/1421|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?10/31/10739\" title=\"figure 1\">",
"      Pathophysiology PDA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?32/31/33265\" title=\"figure 2\">",
"      Derivation great vessels",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?18/5/18526\" title=\"figure 3\">",
"      Schematic continuous murmurs",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/36/585?source=related_link\">",
"      Antimicrobial prophylaxis for bacterial endocarditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/37/26202?source=related_link\">",
"      Auscultation of cardiac murmurs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/12/21706?source=related_link\">",
"      Clinical features and evaluation of aortic stenosis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/49/10010?source=related_link\">",
"      Congenital rubella syndrome: Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/36/27204?source=related_link\">",
"      ECG tutorial: Chamber enlargement and hypertrophy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/31/14840?source=related_link\">",
"      Epidemiology, risk factors and microbiology of infective endocarditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/55/6007?source=related_link\">",
"      Evaluation and prognosis of Eisenmenger syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/42/33448?source=related_link\">",
"      Management of patent ductus arteriosus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/62/1002?source=related_link\">",
"      Management of patent ductus arteriosus in premature infants",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/47/19193?source=related_link\">",
"      Overview of pulmonary hypertension in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/8/7304?source=related_link\">",
"      Pathogenesis of pulmonary hypertension",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/50/15145?source=related_link\">",
"      Pathophysiology, clinical manifestations, and diagnosis of patent ductus arteriosus in premature infants",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/19/8502?source=related_link\">",
"      Physiologic transition from intrauterine to extrauterine life",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/5/27735?source=related_link\">",
"      Vascular rings",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f34_52_35657="Schistocytes on peripheral smear";
var content_f34_52_35657=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F70851%7EHEME%2F50715&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F70851%7EHEME%2F50715&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1040px;\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Peripheral smear in microangiopathic hemolytic anemia showing presence of schistocytes",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 370px; height: 249px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Peripheral blood smear from a patient with a microangiopathic hemolytic anemia with marked red cell fragmentation. The smear shows multiple helmet cells (small black arrows), other fragmented red cells (large black arrow); microspherocytes are also seen (blue arrows). The platelet number is reduced; the large platelet in the center (red arrow) suggests that the thrombocytopenia is due to enhanced destruction.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Carola von Kapff, SH (ASCP).",
"    </div>",
"   </div>",
"  </div>",
"  <div class=\"figure\" style=\"width: 450px\">",
"   <div class=\"ttl\">",
"    Normal peripheral blood smear",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 393px; height: 257px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    High power view of a normal peripheral blood smear. Several platelets (black arrows) and a normal lymphocyte (blue arrow) can also be seen. The red cells are of relatively uniform size and shape. The diameter of the normal red cell should approximate that of the nucleus of the small lymphocyte; central pallor (red arrow) should equal one-third of its diameter.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Carola von Kapff, SH (ASCP).",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 481px\">",
"   <div class=\"ttl\">",
"    Helmet cells in microangiopathic hemolytic anemia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 461px; height: 287px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Peripheral smears from two patients with microangiopathic hemolytic anemia, showing a number of red cell fragments (i.e., schistocytes), some of which take the form of combat (red arrow), bicycle (thick black arrow), or football (blue arrow) \"helmets.\" Microspherocytes are also seen (thin black arrows), along with a nucleated red cell (green arrow).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Carola von Kapff, SH (ASCP).",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_52_35657=[""].join("\n");
var outline_f34_52_35657=null;
var title_f34_52_35658="Risk stratification for cardiac events after acute ST elevation myocardial infarction";
var content_f34_52_35658=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Risk stratification for cardiac events after acute ST elevation myocardial infarction",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/52/35658/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/52/35658/contributors\">",
"     Joseph S Alpert, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/52/35658/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/52/35658/contributors\">",
"     Christopher P Cannon, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/52/35658/contributors\">",
"     Allan S Jaffe, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/52/35658/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/52/35658/contributors\">",
"     Gordon M Saperia, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?34/52/35658/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 29, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The process of risk stratification in a patient who has had an acute ST-myocardial infarction (STEMI) has two components:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Early in-hospital identification of patients at increased risk for recurrent ischemic events.",
"     </li>",
"     <li>",
"      Identification of patients after an MI who are at increased risk for arrhythmic or nonarrhythmic death.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patients at high risk for recurrent ischemic events are usually considered to require an aggressive management strategy in addition to standard medical management. Direct transport or, less optimally, prompt interhospital transfer to a facility with revascularization capabilities is recommended for such patients. For patients at low risk, a more conservative management strategy may be appropriate. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/46/16106?source=see_link\">",
"     \"Primary percutaneous coronary intervention in acute ST elevation myocardial infarction: Determinants of outcome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/43/1721?source=see_link\">",
"     \"Fibrinolytic therapy in acute ST elevation myocardial infarction: Initiation of therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    An overview of in-hospital risk stratification after an acute ST elevation MI will be presented here. Risk stratification for arrhythmic or nonarrhythmic death during the months after an MI and in the subset of patients with non-ST elevation (non-Q) wave MI are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/24/20874?source=see_link\">",
"     \"Incidence of and risk stratification for sudden cardiac death after acute myocardial infarction\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/43/2746?source=see_link\">",
"     \"Risk stratification after unstable angina or non-ST elevation myocardial infarction\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     RISK SCORES",
"    </span>",
"    &nbsp;&mdash;&nbsp;A report published in 1998 from the National Registry of Myocardial Infarction (NRMI) evaluated data on 170,143 patients admitted with an acute MI (with or without ST segment elevation) in an attempt to identify patients at high risk [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/52/35658/abstract/1\">",
"     1",
"    </a>",
"    ]. Significant risk factors included age over 70 years, prior MI, Killip class at admission (",
"    <a class=\"graphic graphic_table graphicRef65592 \" href=\"mobipreview.htm?3/59/4027\">",
"     table 1",
"    </a>",
"    ), anterior MI, and the combination of hypotension and tachycardia.",
"   </p>",
"   <p>",
"    Similar data were reported by the GUSTO trial of 41,021 patients, which found that predictors of one-year mortality among those who survived to 30 days after their MI included [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/52/35658/abstract/2\">",
"     2",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Demographics, including older age (&gt;55), lower weight (&le;80 kg), previous MI, and previous bypass surgery. In another population-based study of 2541 patients, severe obesity (BMI &gt;30",
"      <span class=\"nowrap\">",
"       kg/m",
"       <sup>",
"        2",
"       </sup>",
"       )",
"      </span>",
"      also increased the risk of a cardiac event [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/52/35658/abstract/3\">",
"       3",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?29/35/30266?source=see_link&amp;anchor=H14#H14\">",
"       \"Health hazards associated with obesity in adults\", section on 'Heart disease'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Larger MIs, as determined by higher Killip class, anterior wall MI, lower blood pressure, faster heart rate (&gt;115 bpm), longer QRS duration (&gt;125 ms), lower LVEF, HF and pulmonary edema, and cardiogenic shock",
"     </li>",
"     <li>",
"      Presence of cardiac risk factors, including smoking, hypertension, and prior cerebrovascular disease",
"     </li>",
"     <li>",
"      Other findings such as in-hospital stroke, ventricular or supraventricular arrhythmias, black race, and absence of revascularization",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Based upon these findings and analyses from other large clinical trials and registries, a number of different risk scores have been developed to assess short and long-term outcomes after STEMI [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/52/35658/abstract/4-10\">",
"     4-10",
"    </a>",
"    ]. Only two specifically addressed patients treated with primary percutaneous coronary intervention, which is the current modality of choice [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/52/35658/abstract/5,7\">",
"     5,7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The following discussion will review the TIMI risk score, TIMI risk index, the GRACE risk model, the Zwolle primary PCI risk index, and the CADILLAC risk score. The GISSI risk index has not been prospectively validated (",
"    <a class=\"graphic graphic_table graphicRef59209 graphicRef82205 \" href=\"mobipreview.htm?20/53/21342\">",
"     table 2A-B",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/52/35658/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     TIMI risk score",
"    </span>",
"    &nbsp;&mdash;&nbsp;The TIMI risk score, based upon data from 15,000 patients with an STEMI eligible for fibrinolytic therapy, is an arithmetic sum of eight independent predictors of mortality [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/52/35658/abstract/4\">",
"     4",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Age &ge;75 years &mdash; 3 points",
"     </li>",
"     <li>",
"      Age 65 to 74 years &mdash; 2 points",
"     </li>",
"     <li>",
"      History of diabetes, hypertension, or angina &mdash; 1 point",
"     </li>",
"     <li>",
"      Systolic blood pressure &lt;100 mmHg &mdash; 3 points",
"     </li>",
"     <li>",
"      Heart rate",
"      <span class=\"nowrap\">",
"       &gt;100/min",
"      </span>",
"      &mdash; 2 points",
"     </li>",
"     <li>",
"      Killip class II to IV (",
"      <a class=\"graphic graphic_table graphicRef65592 \" href=\"mobipreview.htm?3/59/4027\">",
"       table 1",
"      </a>",
"      ) and (see",
"      <a class=\"local\" href=\"#H12\">",
"       'Killip class'",
"      </a>",
"      below) &mdash; 2 points",
"     </li>",
"     <li>",
"      Weight &lt;76 kg &mdash; 1 point",
"     </li>",
"     <li>",
"      Anterior ST elevation or left bundle branch block &mdash; 1 point",
"     </li>",
"     <li>",
"      Time to reperfusion therapy &gt;4 hours &mdash; 1 point",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    There is a continuous relationship between mortality and score; a score of 0 to &gt;8 was associated with a 30 day mortality of 0.8 to 36 percent, while the one year mortality among those surviving the first 30 days ranges from 1 to 17 percent (",
"    <a class=\"calc calc_professional\" href=\"mobipreview.htm?27/53/28497?source=see_link\">",
"     calculator 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The usefulness of the TIMI risk score to predict in-hospital mortality was validated in a community-based population of 84,029 patients; the predictive accuracy of the TIMI risk score was the same in those treated with fibrinolysis or percutaneous coronary intervention, but underestimated mortality in those not undergoing reperfusion therapy (",
"    <a class=\"calc calc_professional\" href=\"mobipreview.htm?27/53/28497?source=see_link\">",
"     calculator 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/52/35658/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     TIMI risk index",
"    </span>",
"    &nbsp;&mdash;&nbsp;The TIMI risk index (TRI) is a simpler model derived from the InTIME-II trial of fibrinolytic therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/52/35658/abstract/8\">",
"     8",
"    </a>",
"    ] and then validated in other populations to predict in-hospital mortality [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/52/35658/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]. It can be used simultaneously with the TIMI risk score",
"   </p>",
"   <p>",
"    The TRI is calculated from the following equation, using data obtained at presentation (",
"    <a class=\"graphic graphic_table graphicRef52542 \" href=\"mobipreview.htm?40/14/41195\">",
"     table 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/52/35658/abstract/8\">",
"     8",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    &nbsp;TRI &nbsp;= &nbsp;(Heart rate &nbsp;x &nbsp;",
"    <span class=\"nowrap\">",
"     [age/10]",
"    </span>",
"    squared) &nbsp;&divide; &nbsp;systolic pressure",
"   </p>",
"   <p>",
"    The TRI was applied to over 153,000 patients with STEMI in the National Registry of Myocardial Infarction (NRMI) in the United States [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/52/35658/abstract/12\">",
"     12",
"    </a>",
"    ]. There was a graded relationship to in-hospital mortality, ranging from 0.6 to 60 percent from the lowest (0 to &lt;10) to the highest scores (&ge;80) in patients who received reperfusion therapy and from 1.9 to 52.2 percent in patients who did not receive reperfusion therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/52/35658/abstract/12\">",
"     12",
"    </a>",
"    ]. Patients with a TRI &lt;30 were at low risk. The percent of patients at high risk (TRI &gt;60) was 14.1 percent in those who were not reperfused compared to 2.1 percent in those who were reperfused [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/52/35658/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     GRACE risk model",
"    </span>",
"    &nbsp;&mdash;&nbsp;The TIMI risk score was derived from clinical trial databases, although it has been validated in a community-based populations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/52/35658/abstract/11,12\">",
"     11,12",
"    </a>",
"    ]. The GRACE registry, a global registry of ACS patients from 94 hospitals in 14 countries, developed two models to estimate the risk of both in-hospital and six-month mortality among all patients with an ACS.",
"   </p>",
"   <p>",
"    The in-hospital model was based upon data from 11,389 patients with either an STEMI or a non-ST elevation ACS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/52/35658/abstract/5\">",
"     5",
"    </a>",
"    ]. This model was then validated based upon data from an additional 3972 patients from GRACE and 12,142 patients from the GUSTO IIb trial. Eight independent risk factors were found to account for almost 90 percent of the prognostic information:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Age",
"     </li>",
"     <li>",
"      Killip class (",
"      <a class=\"graphic graphic_table graphicRef65592 \" href=\"mobipreview.htm?3/59/4027\">",
"       table 1",
"      </a>",
"      ) and (see",
"      <a class=\"local\" href=\"#H12\">",
"       'Killip class'",
"      </a>",
"      below)",
"     </li>",
"     <li>",
"      Systolic blood pressure",
"     </li>",
"     <li>",
"      Presence of ST segment deviation",
"     </li>",
"     <li>",
"      Cardiac arrest during presentation",
"     </li>",
"     <li>",
"      Serum creatinine concentration",
"     </li>",
"     <li>",
"      Presence of elevated serum cardiac biomarkers",
"     </li>",
"     <li>",
"      Heart rate",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Point scores were assigned for each predictive factor and are added together to arrive at an estimate of the risk of in-hospital mortality. A nomogram was published with the GRACE risk model to allow calculation of the risk score [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/52/35658/abstract/5,15\">",
"     5,15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The six-month model was based upon data from 15,007 patients and validated in a cohort of 7638 patients, all in the GRACE registry [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/52/35658/abstract/15\">",
"     15",
"    </a>",
"    ]. The variables incorporated into this model include age, prior history of heart failure, prior history of myocardial infarction, resting heart rate, systolic blood pressure, ST-segment depression, initial serum creatinine concentration, elevated serum cardiac biomarkers, and performance of in-hospital PCI. The six-month mortality risk based upon this model can be calculated using the internet website",
"    <a class=\"external\" href=\"file://www.outcomes-umassmed.org/grace\">",
"     www.outcomes-umassmed.org/grace",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H183452799\">",
"    <span class=\"h2\">",
"     CHADS2 score",
"    </span>",
"    &nbsp;&mdash;&nbsp;While the GRACE prediction model is well validated and its use is recommended by multiple guideline organizations, its complexity makes it somewhat difficult to use in some clinical settings. The value of the CHADS2 score, which is a well validated tool for predicting the risk of stroke in patients with atrial fibrillation, was evaluated in a study of more than 2300 patients with ACS (37 percent with STEMI; 19 percent with AF) cared for between 1995 and 2001 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/52/35658/abstract/16\">",
"     16",
"    </a>",
"    ]. All-cause mortality at 10 years was strongly associated with the CHADS2 score in patients with and without AF. As expected, the more complex GRACE score provided a better prediction for short- and long-term mortality. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/23/27001?source=see_link&amp;anchor=H7#H7\">",
"     \"Risk of embolization in atrial fibrillation\", section on 'CHADS2 score'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Primary PCI scores",
"    </span>",
"    &nbsp;&mdash;&nbsp;The risk models described above were developed using study populations treated primarily with fibrinolytic therapy. They therefore may not be applicable to patients who undergo primary PCI, which is the preferred approach to the management of STEMI if PCI can be performed in a timely fashion. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/46/16106?source=see_link\">",
"     \"Primary percutaneous coronary intervention in acute ST elevation myocardial infarction: Determinants of outcome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Two multivariable models have been devised and validated for patients undergoing primary PCI: the Zwolle primary PCI risk index and the CADILLAC risk score.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Zwolle primary PCI index",
"    </span>",
"    &nbsp;&mdash;&nbsp;A risk index based upon a primary PCI population was developed in Zwolle, the Netherlands from data on 1791 patients undergoing primary PCI between 1994 and 2001 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/52/35658/abstract/6\">",
"     6",
"    </a>",
"    ]. All patients received",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    . Fifty percent received a stent and either",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    (prior to 1996) or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/27/35255?source=see_link\">",
"     ticlopidine",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    (after 1996). At 30 days, the mortality rate was 3.6 percent. Significant independent risk factors for 30-day mortality were incorporated into the Zwolle index, including Killip class (",
"    <a class=\"graphic graphic_table graphicRef65592 \" href=\"mobipreview.htm?3/59/4027\">",
"     table 1",
"    </a>",
"    ) and (see",
"    <a class=\"local\" href=\"#H12\">",
"     'Killip class'",
"    </a>",
"    below) post-PCI TIMI flow grade (",
"    <a class=\"graphic graphic_table graphicRef51941 \" href=\"mobipreview.htm?1/49/1819\">",
"     table 4",
"    </a>",
"    ), age, number of diseased vessels, location of infarction, and time to reperfusion. The risk index was validated in an additional group of 747 patients with similar characteristics treated with primary PCI between 2001 and 2003.",
"   </p>",
"   <p>",
"    Based upon the Zwolle risk index, more than two-thirds of patients undergoing primary PCI were classified as low risk (risk score &le;3) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/52/35658/abstract/6\">",
"     6",
"    </a>",
"    ]. For these patients, the mortality rate was 0.1 percent at two days and 0.2 percent between two and 10 days post-MI. It was suggested that such low-risk patients could safely be discharged early (48 hours after PCI).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     CADILLAC risk score",
"    </span>",
"    &nbsp;&mdash;&nbsp;A second primary PCI risk model was derived from the 2082 patients in the CADILLAC trial of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/15/6392?source=see_link\">",
"     abciximab",
"    </a>",
"    or placebo and stenting or angioplasty in primary PCI and then validated using data from the 900 patients in the Stent-PAMI trial [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/52/35658/abstract/7\">",
"     7",
"    </a>",
"    ]. Seven variables, which are readily available at the time of intervention, were weighted according to their odds ratio for one-year mortality (",
"    <a class=\"graphic graphic_table graphicRef70537 \" href=\"mobipreview.htm?2/61/3036\">",
"     table 5",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      LVEF &lt;40 percent &mdash; 4 points",
"     </li>",
"     <li>",
"      Killip class",
"      <span class=\"nowrap\">",
"       2/3",
"      </span>",
"      &mdash; 3 points (see",
"      <a class=\"local\" href=\"#H12\">",
"       'Killip class'",
"      </a>",
"      below)",
"     </li>",
"     <li>",
"      Renal insufficiency (estimated creatinine clearance &lt;60",
"      <span class=\"nowrap\">",
"       mL/min)",
"      </span>",
"      &mdash; 3 points",
"     </li>",
"     <li>",
"      TIMI flow grade after PCI 0 to 2 &mdash; 2 points",
"     </li>",
"     <li>",
"      Age &gt;65 years &mdash; 2 points",
"     </li>",
"     <li>",
"      Anemia (hematocrit &lt;39 percent in men and &lt;36 percent in women) &mdash; 2 points",
"     </li>",
"     <li>",
"      Triple-vessel disease &mdash; 2 points",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In both the derivation and validation models, patients could be stratified into three risk groups that predicted 30-day and one-year mortality:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Low risk (score 0-2) &mdash; 0.1 to 0.2 percent at 30 days and 0.8 to 0.9 percent at one year",
"     </li>",
"     <li>",
"      Intermediate risk (score 3 to 5) &mdash; 1.3 to 1.9 percent at 30 days and 4.0 to 4.5 percent at one year",
"     </li>",
"     <li>",
"      High risk (score &ge;6) &mdash; 6.6 to 8.1 percent at 30 days and 12.4 to 13.2 percent at one year",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The percentage of patients in these three groups was 56, 24, and 20 percent, respectively. The results compared favorably with the TIMI risk score, which was based upon patients undergoing fibrinolysis, and Zwolle primary PCI index.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Comparison of risk scores",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prognostic value of the TIMI, CADILLAC, and GRACE risk scores were directly compared in 855 registry patients with STEMI, but without cardiogenic shock, who underwent primary PCI [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/52/35658/abstract/17\">",
"     17",
"    </a>",
"    ]. The TIMI and CADILLAC scores had relatively high and similar predictive accuracies for 30-day and one-year mortality; the GRACE model performed less well.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     RISK PREDICTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A long list of individual markers of risk have been evaluated for their predictive value after STEMI. These include many of the variables identified in the multifactorial risk scores cited above, as well as other factors. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8885815\">",
"    <span class=\"h2\">",
"     Number of CHD risk factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;The four modifiable coronary heart disease (CHD) risk factors (hypertension, smoking, dyslipidemia, and diabetes), as well as a family history of premature CHD, predict the development of atherosclerosis and its clinical consequences (including STEMI) in a high percentage of patients. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/59/39866?source=see_link&amp;anchor=H2#H2\">",
"     \"Overview of the risk equivalents and established risk factors for cardiovascular disease\", section on 'Established risk factors for atherosclerotic CVD'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The relationship between the number of these risk factors and in-hospital mortality was evaluated in a study of 542,008 patients with first myocardial infarction (MI) and without prior cardiovascular disease from the National (United States) Registry of Myocardial Infarction (NRMI) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/52/35658/abstract/18\">",
"     18",
"    </a>",
"    ]. Over 85 percent of patients had at least one CHD risk factor. After adjustment for age and other clinical risk factors, there was a significant inverse increase in risk between the number of CHD risk factors and in-hospital mortality (odds ratios of 1.54, 1.39, 1.30, 1.10, 1.09, and 1.00 with 0, 1, 2, 3, 4, and 5 risk factors, respectively). The explanation for this surprising finding is unknown.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Heart failure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Evidence of heart failure (HF) on physical examination or chest x-ray indicates extensive LV systolic",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    diastolic dysfunction and is associated with a worse prognosis compared to those with no pulmonary congestion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/52/35658/abstract/1\">",
"     1",
"    </a>",
"    ]. Right ventricular MI or biventricular HF is associated with an elevation in jugular venous pressure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Killip class",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Killip classification, published in 1967, categorizes patients with an acute MI based upon the presence or absence of simple physical examination findings that suggest LV dysfunction (",
"    <a class=\"graphic graphic_table graphicRef65592 \" href=\"mobipreview.htm?3/59/4027\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/52/35658/abstract/19\">",
"     19",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Class I - no evidence of HF",
"     </li>",
"     <li>",
"      Class II - findings consistent with mild to moderate HF (S3, lung rales less than one-half way up the posterior lung fields, or jugular venous distension)",
"     </li>",
"     <li>",
"      Class III - overt pulmonary edema",
"     </li>",
"     <li>",
"      Class IV - cardiogenic shock",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patients presenting with Killip class II or III HF complicating an acute MI tend to be older and are more often female; they also have higher rates of comorbidities, including hypertension and diabetes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/52/35658/abstract/20,21\">",
"     20,21",
"    </a>",
"    ]. Patients with HF are also less likely to receive therapies of known efficacy in acute MI, including",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    , beta blockers, statins, fibrinolytic agents, and angioplasty, despite evidence that these therapies are beneficial in this patient subset [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/52/35658/abstract/20,21\">",
"     20,21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The higher the Killip class on presentation, the greater the subsequent mortality [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/52/35658/abstract/1,2,4,6,7,19-23\">",
"     1,2,4,6,7,19-23",
"    </a>",
"    ]. A study from the Second National Registry of Myocardial Infarction (NRMI-2) included 190,518 patients with acute MI, of whom 36,303 (19 percent) had Killip class II or III HF on admission [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/52/35658/abstract/20\">",
"     20",
"    </a>",
"    ]. These patients had a significantly higher in-hospital mortality than those without HF (21.4 versus 7.2 percent). Similar findings were noted in an analysis of international data on 4830 patients with STEMI from the GRACE registry [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/52/35658/abstract/21\">",
"     21",
"    </a>",
"    ]. Sixteen percent had Killip class II or III HF on admission; patients with HF had increased mortality in-hospital (17 versus 4 percent) as well as from discharge to six months (20 versus 3 percent). In this report, HF developing after admission was associated with an even higher in-hospital mortality (18 percent).",
"   </p>",
"   <p>",
"    The Killip class is prognostically important in patients who undergo fibrinolysis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/52/35658/abstract/1,2,4\">",
"     1,2,4",
"    </a>",
"    ] or primary PCI (angioplasty with or without stenting) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/52/35658/abstract/6,7,22,23\">",
"     6,7,22,23",
"    </a>",
"    ]. In one series of 1548 patients undergoing primary angioplasty, increasing Killip class was associated with increasing mortality at one year, an association that appears to have been due to a higher incidence of suboptimal myocardial perfusion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/52/35658/abstract/23\">",
"     23",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/48/9994?source=see_link\">",
"     \"Suboptimal reperfusion after primary percutaneous coronary intervention in acute ST elevation myocardial infarction\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Hypotension",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypotension (systolic pressure &lt;100 mmHg) or frank shock are associated with a poor prognosis. This is especially true in the patient with an anterior MI in whom hypotension is the result of extensive myocardial damage and markedly reduced LV ejection fraction (LVEF) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/52/35658/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/60/16329?source=see_link\">",
"     \"Clinical manifestations and diagnosis of cardiogenic shock in acute myocardial infarction\"",
"    </a>",
"    .) In comparison, hypotension in the presence of an inferior MI may be the result of increased vagal activity, the so-called Bezold-Jarisch reflex. This tends to be a transient phenomenon which is often reversed with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/23/11640?source=see_link\">",
"     atropine",
"    </a>",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    intravenous volume administration. The prognosis for these patients is usually good.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Tachycardia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although heart rate may be elevated soon after the patient arrives in the CCU, heart rate usually declines thereafter to a level which reflects the degree of activation of the sympathetic nervous system. Patients with sustained heart rates &gt;90",
"    <span class=\"nowrap\">",
"     beats/min",
"    </span>",
"    usually have larger and more often anterior infarcts, marked impairment of left ventricular (LV) function, and therefore a poor prognosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/52/35658/abstract/1,24\">",
"     1,24",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/25/14742?source=see_link&amp;anchor=H9#H9\">",
"     \"Sinus tachycardia\", section on 'Acute myocardial infarction'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Electrocardiogram",
"    </span>",
"    &nbsp;&mdash;&nbsp;The outcome after an acute MI is directly proportional to the extent of myocardial injury, and is therefore worse in a number of settings that can be detected on the ECG. These include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Anterior compared to inferior infarcts",
"     </li>",
"     <li>",
"      The presence of Q waves",
"     </li>",
"     <li>",
"      A greater number of leads showing ST elevation",
"     </li>",
"     <li>",
"      Lack of ST elevation resolution at 90 to 180 minutes after fibrinolysis or of ST depression in leads without ST elevation",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The prognostic role of the ECG is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/26/4521?source=see_link\">",
"     \"Electrocardiogram in the prognosis of myocardial infarction or unstable angina\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Atrial fibrillation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Atrial fibrillation (AF) is the most common supraventricular arrhythmia after an MI and its development at any time is associated with increased mortality. The reported incidence of new onset (no prior history) AF within 48 hours of MI is 6.7-7.8 percent in large series [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/52/35658/abstract/25\">",
"     25",
"    </a>",
"    ]. The discussion of AF developing shortly after MI is found elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/14/16615?source=see_link&amp;anchor=H5#H5\">",
"     \"Supraventricular arrhythmias after myocardial infarction\", section on 'Atrial fibrillation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The best available information on the relationship between AF and long-term mortality after MI comes from a community based study of 3220 patients with first MI cared for between 1983 and 2007 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/52/35658/abstract/26\">",
"     26",
"    </a>",
"    ]. AF developed in 729 (218 within 2 days, 119 between days 3 and 30, and 392 after 30 days) with a cumulative incidence of 19 percent at 5 years (incidence rate of 42 per 1000 person-years). During a mean follow-up of 6.6 years, the development of AF was independently associated with an increased risk of death (hazard ratio [HR] 3.77, 95% CI 3.37-4.21).The magnitude of this risk was associated with the time of development of AF (HR 1.63 for AF within 2 days, 1.81 for AF between 3 and 30 days, and 2.58 for AF &gt;30 days). An increased risk of long-term mortality was also noted in a study of more than 2300 patients with ACS (37 percent with STEMI; 19 percent with AF) cared for between 1995 and 2001 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/52/35658/abstract/16\">",
"     16",
"    </a>",
"    ]. The risk of all-cause mortality was increased significantly at 10 years.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H105894234\">",
"    <span class=\"h2\">",
"     Ventricular arrhythmias",
"    </span>",
"    &nbsp;&mdash;&nbsp;The occurrence of VT in the peri-MI period (ie, within the first 48 hours after the MI) is presumably due to transient ischemia. The prognosis after either early VT or VF is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/10/30890?source=see_link&amp;anchor=H19#H19\">",
"     \"Clinical features and treatment of ventricular arrhythmias during acute myocardial infarction\", section on 'Prognosis after early VT'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/10/30890?source=see_link&amp;anchor=H27#H27\">",
"     \"Clinical features and treatment of ventricular arrhythmias during acute myocardial infarction\", section on 'Prognosis after early VF'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Recurrent ischemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Recurrent ischemia, either symptomatic (ie, angina at rest or with minimal exertion) or silent, markedly worsens the prognosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/52/35658/abstract/27-31\">",
"     27-31",
"    </a>",
"    ]. The following observations from GUSTO-I and GUSTO-IIb illustrate the range of findings.",
"   </p>",
"   <p>",
"    The GUSTO-I trial evaluated 40,484 patients with an STEMI who were treated with fibrinolysis. Recurrent ischemia occurred in 8131 patients (20 percent), including 4488 who had angina only, 3021 with angina and ST segment changes, 337 with angina and hemodynamic abnormalities, and 285 patients with angina, ST segment changes and hemodynamic abnormalities [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/52/35658/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with recurrent ischemia were more often female, had more cardiovascular risk factors, less often received intravenous",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      , and had more extensive and severe coronary disease.",
"     </li>",
"     <li>",
"      The 30-day reinfarction rate was higher in patients with recurrent ischemia, particularly when associated with ST segment changes or hemodynamic abnormalities (",
"      <a class=\"graphic graphic_figure graphicRef51228 \" href=\"mobipreview.htm?0/62/1007\">",
"       figure 1",
"      </a>",
"      ). In comparison, 30 day mortality was higher only in those patients who had hemodynamic abnormalities (",
"      <a class=\"graphic graphic_figure graphicRef73231 \" href=\"mobipreview.htm?29/36/30287\">",
"       figure 2",
"      </a>",
"      ). This pattern was maintained at one year.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Similar findings were noted in the GUSTO-IIb trial, which included 4125 patients with an STEMI: 23 percent had recurrent ischemia, which responded to medical therapy in 78 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/52/35658/abstract/28\">",
"     28",
"    </a>",
"    ]. Compared to those without ischemia, those with responsive or refractory ischemia had a higher rate of reinfarction at 30 days (2.7 versus 11 and 28 percent, respectively) and at six months (4.6 versus 13 and 30 percent, respectively). The patients without ischemia had a lower mortality at 30 days and at one year (9 versus 10.7 and 16.4 percent, respectively).",
"   </p>",
"   <p>",
"    A report from the GISSI-3 trial, in which 14 percent of patients had recurrent angina after fibrinolytic therapy, also evaluated the setting and timing of ischemia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/52/35658/abstract/29\">",
"     29",
"    </a>",
"    ]. Angina occurred at rest in 94 percent of patients; one-third of episodes occurred within 72 hours of the MI and between 6 and 10 AM.",
"   </p>",
"   <p>",
"    The clinical features and management of recurrent angina after STEMI are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/59/7098?source=see_link&amp;anchor=H13#H13\">",
"     \"Overview of the non-acute management of ST elevation myocardial infarction\", section on 'Recurrent chest pain'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/27/8634?source=see_link\">",
"     \"Management of failed fibrinolysis (thrombolysis) or threatened reocclusion in acute ST elevation myocardial infarction\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with silent ischemia after STEMI are at less risk than symptomatic patients. Nevertheless, silent ischemia post-MI is associated with a two to four-fold increase in cardiac event rates during follow-up compared to those without evidence of ischemia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/52/35658/abstract/30,31\">",
"     30,31",
"    </a>",
"    ]. The management of silent ischemia post STEMI is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/35/4665?source=see_link&amp;anchor=H16#H16\">",
"     \"Silent myocardial ischemia: Prognosis and therapy\", section on 'Post-MI ischemia'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Serum biomarkers",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of serum biomarkers have been correlated with risk in patients with STEMI. The two most commonly used are serum troponins and CK-MB.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Serum CK",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is a direct relationship between infarct size, as reflected by total CK",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    CK-MB, and prognosis. As an example, the GUSTO IIb trial of 11,725 patients with an ST segment or non-ST segment MI found a continuous relationship between maximum CK (or CK-MB) ratio (maximum CK",
"    <span class=\"nowrap\">",
"     level/upper",
"    </span>",
"    limit of normal) and death and death and reinfarction at six months; the correlation was similar for those with or without ST elevation, although for all CK levels the event rate was higher in patients without ST elevation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/52/35658/abstract/32\">",
"     32",
"    </a>",
"    ]. The peak serum CK also has prognostic value in patients with an ST elevation MI who undergo primary PCI [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/52/35658/abstract/33\">",
"     33",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/38/39530?source=see_link&amp;anchor=H28#H28\">",
"     \"Troponins and creatine kinase as biomarkers of cardiac injury\", section on 'Prognosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Serum troponins",
"    </span>",
"    &nbsp;&mdash;&nbsp;Troponin I (cTnI) and T (cTnT) are regulatory proteins found in cardiac myocytes; they are sensitive and specific markers of myocardial necrosis and elevated levels have prognostic importance. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/38/39530?source=see_link\">",
"     \"Troponins and creatine kinase as biomarkers of cardiac injury\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The potent prognostic value of elevated plasma troponins, obtained within 24 hours of admission or even three of four days after the MI, has been demonstrated in patients with both ST elevation and non-ST elevation MIs, even when a percutaneous coronary intervention is performed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/52/35658/abstract/34-37\">",
"     34-37",
"    </a>",
"    ]. As an example, in the GUSTO-III trial of 12,666 patients with an MI associated with ST-segment elevation, the 8.9 percent of patients with a positive cTnT (&ge;0.2",
"    <span class=\"nowrap\">",
"     &micro;g/L)",
"    </span>",
"    at admission had a significantly higher 30 day mortality (15.7 versus 6.2 percent for a negative cTnT) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/52/35658/abstract/37\">",
"     37",
"    </a>",
"    ]. In a multivariate regression analysis, a positive cTnT was an independent predictor of mortality at 30 days. The GUSTO IIa study also demonstrated the importance of early minor elevations in troponins in patients with acute ischemic syndromes characterized by chest pain and electrocardiographic changes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/52/35658/abstract/38\">",
"     38",
"    </a>",
"    ]. Among 801 patients presenting with an acute MI, 289 had elevated cTnT levels (&gt;0.1",
"    <span class=\"nowrap\">",
"     &micro;g/L).",
"    </span>",
"    Mortality at 30 days was significantly higher in these patients when compared to those with lower levels of cTnT (11.8 versus 3.9 percent, p&lt;0.001). Furthermore, the relation between the serum cTnT level and mortality was linear (",
"    <a class=\"graphic graphic_figure graphicRef79900 \" href=\"mobipreview.htm?23/35/24125\">",
"     figure 3",
"    </a>",
"    ). The cTnT level provided additional prognostic information to the ECG and CK-MB levels.",
"   </p>",
"   <p>",
"    A pooled analysis of 21 studies involving 18,982 patients with an acute coronary syndrome found that an elevated level of troponin I or T was associated with an increased risk of cardiac death or reinfarction at 30 days (14.4 versus 8 percent, odds ratio 3.44); subgroup analysis found that elevated troponins were predictive of 30 day and long-term outcome (5 months to 3 years) in those with an MI associated with ST-segment elevation (odds ratio 2.86 and 3.11, respectively) or a non-Q wave (no ST-elevation) MI (odds ratio 4.93 and 2.79, respectively) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/52/35658/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Serum cTnT levels are also predictive of long term outcome, as found in a study of 240 patients with an acute MI [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/52/35658/abstract/39\">",
"     39",
"    </a>",
"    ]. Among those with ST segment elevations, the three year rates of cardiac death (28 versus 7.5 percent) and death or nonfatal reinfarction (37 versus 12.5 percent) were higher in patients with initial cTnT levels &ge;0.2",
"    <span class=\"nowrap\">",
"     &micro;g/L",
"    </span>",
"    compared to those with lower levels.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Brain natriuretic peptide",
"    </span>",
"    &nbsp;&mdash;&nbsp;Plasma concentrations of brain natriuretic peptide (BNP) and N-terminal-pro-BNP (NT pro-BNP) are useful in the diagnosis and prognosis of heart failure. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/22/19818?source=see_link\">",
"     \"Natriuretic peptide measurement in heart failure\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Plasma BNP and NT pro-BNP also appear to have predictive value in ST elevation and non-ST elevation MI [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/52/35658/abstract/40-46\">",
"     40-46",
"    </a>",
"    ]. Elevated values are associated with increased mortality, even in patients without clinical heart failure and after adjustment for age and left ventricular ejection fraction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/52/35658/abstract/41-45\">",
"     41-45",
"    </a>",
"    ]. It has been suggested that plasma NT pro-BNP drawn within 24 hours of the onset of chest pain is more accurate than the TIMI risk score in predicting mortality at nine months [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/52/35658/abstract/46\">",
"     46",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'TIMI risk score'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The clinical role of plasma BNP and NT pro-BNP in risk stratification in patients with ST elevation MI remains to be determined.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Plasma aldosterone",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although the plasma aldosterone concentration is not routinely measured in patients with acute MI, there is evidence that it is a predictor of patient outcomes. The relationship between the plasma aldosterone concentration at the time of presentation of STEMI and subsequent cardiovascular morbidity and mortality was evaluated in an observational study of 356 patients treated with primary PCI [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/52/35658/abstract/47\">",
"     47",
"    </a>",
"    ]. Patients were divided into four quartiles of plasma aldosterone and evaluated for in hospital events and six month mortality. There was a stepwise significant increase in the risk of in-hospital death, heart failure, ventricular fibrillation or resuscitated cardiac arrest and, after adjusting for age, Killip class (",
"    <a class=\"graphic graphic_table graphicRef65592 \" href=\"mobipreview.htm?3/59/4027\">",
"     table 1",
"    </a>",
"    ), and reperfusion status, compared with patients in the first aldosterone quartile, patients in the highest quartile were at a significantly higher risk of death at six months.",
"   </p>",
"   <p>",
"    The adverse outcomes associated with hyperaldosteronism may be explained by at least two mechanisms: hyperaldosteronism is a secondary event, being a marker of reduced peripheral perfusion;",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    high levels of aldosterone have direct cardiovascular toxicity. Support for the latter hypothesis comes from studies of patients with primary hyperaldosteronism and from the survival benefit associated with aldosterone antagonists in selected patients with heart failure and myocardial infarction. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/1/37911?source=see_link&amp;anchor=H12#H12\">",
"     \"Clinical features of primary aldosteronism\", section on 'Cardiovascular risk'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/54/28521?source=see_link&amp;anchor=H2#H2\">",
"     \"Use of aldosterone antagonists in heart failure\", section on 'Efficacy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/59/7098?source=see_link&amp;anchor=H27#H27\">",
"     \"Overview of the non-acute management of ST elevation myocardial infarction\", section on 'Discharge medications'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H458465082\">",
"    <span class=\"h2\">",
"     Serum potassium",
"    </span>",
"    &nbsp;&mdash;&nbsp;Studies performed before the routine use of beta blockers, statins, and aggressive antithrombotic therapy, in addition to urgent reperfusion in many patients, demonstrated a relationship between low serum potassium levels and the risk of ventricular arrhythmias. These early studies led to specific recommendations for the serum potassium level in patients with acute MI. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/10/30890?source=see_link&amp;anchor=H26#H26\">",
"     \"Clinical features and treatment of ventricular arrhythmias during acute myocardial infarction\", section on 'VF Predictors'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The relationship between serum potassium level and in-hospital mortality in patients with biomarker confirmed acute MI and managed with more recent recommended therapies was evaluated in a study of nearly 40,000 patients enrolled in a United States database between 2000 and 2008 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/52/35658/abstract/48\">",
"     48",
"    </a>",
"    ]. After multivariate analysis, a U-shaped relationship between mean postadmission serum potassium level and in-hospital mortality was found. Using a mean postadmission serum potassium level of 3.5 to &lt;4.0",
"    <span class=\"nowrap\">",
"     mEq/L",
"    </span>",
"    as the reference, the adjusted significant odds ratio for mortality for those with serum potassium levels of &lt;3.0, 3.0 to &lt;3.5, 4.0 to &lt;4.5, 4.5 to &lt;5.0, 5.0 to &lt;5.5, and &ge;5.5",
"    <span class=\"nowrap\">",
"     mEq/L",
"    </span>",
"    were 8.11, 1.45, 1.25, 1.96, 3.27, and 6.44, respectively. It is important to note that patients with a serum potassium between 4.5 and 5.0",
"    <span class=\"nowrap\">",
"     mEq/L,",
"    </span>",
"    a range that has previously considered &ldquo;within normal limits&rdquo;, had a nearly twofold greater risk of death compared to those with levels between 3.5 to &lt;4.0",
"    <span class=\"nowrap\">",
"     mEq/L.",
"    </span>",
"    The findings of this study pertaining to the secondary composite outcome of ventricular fibrillation or cardiac arrest are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/10/30890?source=see_link&amp;anchor=H26#H26\">",
"     \"Clinical features and treatment of ventricular arrhythmias during acute myocardial infarction\", section on 'VF Predictors'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Glycemic control",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is increasing evidence that suboptimal glycemic control in diabetic patients and stress hyperglycemia in nondiabetic patients are associated with worse in-hospital outcomes after acute MI and that strict glycemic control may be beneficial. The management of hyperglycemia in patients with acute myocardial infarction is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/33/44567?source=see_link&amp;anchor=H21#H21\">",
"     \"Glycemic control for acute myocardial infarction in patients with and without diabetes mellitus\", section on 'Summary and recommendations'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with diabetes have a worse long-term outcome after an acute MI than those without diabetes (",
"    <a class=\"graphic graphic_figure graphicRef80251 \" href=\"mobipreview.htm?34/1/34845\">",
"     figure 4",
"    </a>",
"    ), and strict glycemic control should be maintained after discharge. The data supporting these conclusions are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/33/44567?source=see_link\">",
"     \"Glycemic control for acute myocardial infarction in patients with and without diabetes mellitus\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/35/43577?source=see_link&amp;anchor=H3#H3\">",
"     \"Initial management of blood glucose in type 2 diabetes mellitus\", section on 'Degree of glycemic control'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Claudication",
"    </span>",
"    &nbsp;&mdash;&nbsp;The presence of intermittent claudication appears to predict worse outcomes in patients with an STEMI. This was illustrated in a study of 1045 patients (52 percent with a known STEMI) evaluated two months after an acute MI in which 78 (7 percent) had intermittent claudication [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/52/35658/abstract/49\">",
"     49",
"    </a>",
"    ]. At 26 months of follow-up, those with claudication were five times more likely to have a fatal cardiac event than those without claudication (19.2 versus 3.6 percent). The patients with claudication were older and more likely to have a history of diabetes, a prior MI, a stroke, or diminished left ventricular function. Even when these comorbidities were taken into account, patients with claudication had a significantly higher incidence of cardiac death (hazard ratio 6.57).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Decreased renal function",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with chronic renal failure as well as those with end-stage renal disease have a higher risk for and a worse outcome after myocardial infarction. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/31/34298?source=see_link\">",
"     \"Chronic kidney disease and coronary heart disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/0/29703?source=see_link\">",
"     \"Risk factors and epidemiology of coronary artery disease in end-stage renal disease (dialysis)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The magnitude of this effect has been examined in several studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/52/35658/abstract/50-53\">",
"     50-53",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a review of over 130,000 elderly patients hospitalized with an acute MI, the one-year mortality was 24, 46, and 66 percent in patients with a serum creatinine of &lt;1.5, 1.5 to 2.4, and 2.5 to 3.9",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (&lt;132, 132 to 212, and 221 to 345",
"      <span class=\"nowrap\">",
"       &micro;mol/L),",
"      </span>",
"      respectively [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/52/35658/abstract/50\">",
"       50",
"      </a>",
"      ]. After adjustment for patient and treatment characteristics, the hazard ratios for mild and moderate renal insufficiency were greatest at one month and gradually declined, no longer being significant at one year. The relative risk was similar in patients with different severities of myocardial dysfunction (Killip class I, II, and III).",
"     </li>",
"     <li>",
"      Similar observations were made in an analysis from the VALIANT trial of 14,527 patients with an acute MI (two-thirds with an STEMI) complicated by heart failure, left ventricular dysfunction, or both [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/52/35658/abstract/51\">",
"       51",
"      </a>",
"      ]. At three years, the mortality rates for patients with an estimated GFR of &ge;75, 60 to 74.9, 45 to 59.9, and &lt;45",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"      per 1.73 m2 were 14.1, 20.5, 28.9, and 45.5 percent. After adjustment for other risk factors, the risk of death or nonfatal cardiovascular complications increased significantly with declining GFR (hazard ratio 1.10 for each 10-unit decrease in GFR below 81.0",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"      per 1.73 m2).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A potential limitation of these studies is that only baseline serum creatine values were used. This can be a source of error because the formulas used for calculation of the creatinine clearance and the estimated GFR require stable values over time, which might not be present in patients with an acute coronary syndrome. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/45/36570?source=see_link\">",
"     \"Assessment of kidney function\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition to renal dysfunction, the blood urea nitrogen (BUN) may be an independent risk factor for mortality [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/52/35658/abstract/54\">",
"     54",
"    </a>",
"    ]. A possible mechanism is that an elevated BUN reflects renal hypoperfusion due to a low cardiac output. Renal hypoperfusion leads to enhanced tubular sodium and urea reabsorption, raising the BUN out of proportion to any reduction in GFR. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/45/36570?source=see_link\">",
"     \"Assessment of kidney function\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     White blood cell count",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with a higher baseline white blood cell (WBC) count, which is a marker of inflammation, have an increased risk for an adverse event, in-hospital mortality, and short- and long-term mortality after an acute ST elevation or non-ST elevation MI [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/52/35658/abstract/55-60\">",
"     55-60",
"    </a>",
"    ]. In a report from the Cooperative Cardiovascular Project of over 150,000 patients &ge;65 years of age with an acute MI (40 percent with ST elevation or left bundle branch block), patients in the highest quintile of WBC were significantly more likely to die at 30 days than those in the lowest quintile (10.3 versus 30.2 percent, adjusted odds ratio 2.37) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/52/35658/abstract/58\">",
"     58",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Similar findings were noted in the TIMI 10A and B trials in which the mortality at 30 days was higher in patients with a WBC count",
"    <span class=\"nowrap\">",
"     &gt;15,000/&micro;L",
"    </span>",
"    (10.4 versus 0 to 4.9 for a count &lt;15,000",
"    <span class=\"nowrap\">",
"     /&micro;L)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/52/35658/abstract/56\">",
"     56",
"    </a>",
"    ]. In addition, patients with a closed artery at 60 and 90 minutes, those with evidence of thrombus, and those with poorer TIMI myocardial perfusion grades had a significantly higher WBC count than those without these findings [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/52/35658/abstract/56\">",
"     56",
"    </a>",
"    ]. The increase in mortality associated with an elevated baseline WBC persists for as long as 10 months [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/52/35658/abstract/57\">",
"     57",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An elevated WBC is also of prognostic significance in stable patients with a past MI. This was illustrated in a study of 1294 patients who had a WBC count obtained six months after an ST elevation or non-ST elevation MI. An increased WBC count",
"    <span class=\"nowrap\">",
"     (&ge;8,700/&micro;L)",
"    </span>",
"    was associated with a significantly higher incidence of reinfarction or death at 25 months (16.7 versus 8.7 percent for WBC count",
"    <span class=\"nowrap\">",
"     &le;6,100/&micro;L)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/52/35658/abstract/61\">",
"     61",
"    </a>",
"    ]. The hazard ratio for each increase in WBC count of approximately",
"    <span class=\"nowrap\">",
"     1000/&micro;L",
"    </span>",
"    was 1.26.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Anemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;The presence of anemia appears to be an adverse predictor of prognosis in patients with an STEMI. In a review of clinical trials that included over 25,000 patients with STEMI, there was an adjusted odds ratio (OR) for cardiovascular mortality at 30 days of 1.21 for each 1",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    decline in hemoglobin below 14",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/52/35658/abstract/62\">",
"     62",
"    </a>",
"    ]. The risk was also significantly increased (adjusted OR 1.79) in patients with hemoglobin values above 17",
"    <span class=\"nowrap\">",
"     g/dL.",
"    </span>",
"   </p>",
"   <p>",
"    There",
"    also may be a graded increase in late (up to 24 months) mortality in patients with anemia on admission or at discharge [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/52/35658/abstract/63\">",
"     63",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The value of blood transfusion in anemic patients for the sole purpose of raising the hemoglobin concentration with a non-ST elevation ACS is unproven in the absence of a clear indication for such therapy. This issue has been primarily studied in patients with a non-ST elevation ACS; the available data are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/33/44569?source=see_link&amp;anchor=H2#H2\">",
"     \"Overview of the non-acute management of unstable angina and non-ST elevation myocardial infarction\", section on 'Further medical therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Bleeding",
"    </span>",
"    &nbsp;&mdash;&nbsp;The relationship between in hospital major bleeding and subsequent outcomes, such as death or myocardial infarction, has not been well studied in patients with STEMI.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Abnormal myocardial perfusion",
"    </span>",
"    &nbsp;&mdash;&nbsp;Angiographic (myocardial blush or perfusion grade and TIMI frame count) and electrocardiographic (persistent ST elevation) signs of abnormal myocardial perfusion predict a worse outcome after both fibrinolysis and primary PCI. The definition of the angiographic variables and their predictive value are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/38/7786?source=see_link\">",
"     \"Fibrinolytic (thrombolytic) agents in acute ST elevation myocardial infarction: Markers of efficacy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/16/29961?source=see_link\">",
"     \"Primary percutaneous coronary intervention versus fibrinolysis in acute ST elevation myocardial infarction: Clinical trials\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h2\">",
"     Age of aspirated thrombus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Thrombus aspiration is performed in many patients who undergo primary percutaneous coronary intervention for STEMI. The short-term outcomes of thrombus aspiration and the possible prognostic importance of thrombus age are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/48/9994?source=see_link&amp;anchor=H9#H9\">",
"     \"Suboptimal reperfusion after primary percutaneous coronary intervention in acute ST elevation myocardial infarction\", section on 'Thrombectomy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h1\">",
"     LATE RISK STRATIFICATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Late risk stratification is performed before or sometimes after discharge. The main components are measurement of the left ventricular ejection fraction and, in most patients, stress testing to detect possible residual ischemia. Methods used for risk stratification for arrhythmic death are discussed separately. These include ventricular arrhythmias and late potentials on signal-averaged ECG. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/24/20874?source=see_link\">",
"     \"Incidence of and risk stratification for sudden cardiac death after acute myocardial infarction\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Risk stratification does",
"    <strong>",
"     not",
"    </strong>",
"    identify every patient who will experience a cardiac event during follow-up. Rather, the tests described below yield a \"predictive density gradient\" for future cardiac events, thereby enabling the cardiologist to employ more aggressive therapy in those patients who are at greatest risk for future events.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h2\">",
"     Left ventricular ejection fraction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Assessment of resting left ventricular function is an important part of risk stratification in patients with acute MI and was recommended by the 2013 American College of Cardiology",
"    <span class=\"nowrap\">",
"     Foundation/American",
"    </span>",
"    Heart Association and 2012 European Society of Cardiology STEMI guideline [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/52/35658/abstract/64-66\">",
"     64-66",
"    </a>",
"    ]. Echocardiography is preferred to magnetic resonance imaging in the European guideline, while the United States guideline makes no preference for the type of imaging modality. Patients with left ventricular systolic dysfunction have increased mortality at six months and one year (",
"    <a class=\"graphic graphic_figure graphicRef75743 \" href=\"mobipreview.htm?29/2/29741\">",
"     figure 5",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef68071 \" href=\"mobipreview.htm?37/50/38701\">",
"     figure 6",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/52/35658/abstract/67-69\">",
"     67-69",
"    </a>",
"    ]. The increase in mortality is most pronounced in the minority of patients with an LVEF &le;30 percent.",
"   </p>",
"   <p>",
"    Left ventricular ejection fraction (LVEF) is usually measured before discharge in the absence of a specific indication (eg, heart failure or suspected mechanical complication) for which echocardiography may be indicated early in the hospitalization. However, measurements during hospitalization may be misleading, since improvement in LVEF, beginning within three days and largely complete by 14 days, is common in patients who are reperfused.",
"   </p>",
"   <p>",
"    Two separate studies have shown that approximately 58 percent of patients significantly improve LVEF after reperfusion in acute STEMI [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/52/35658/abstract/70,71\">",
"     70,71",
"    </a>",
"    ]. This may reflect, at least in part, recovery from myocardial stunning [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/52/35658/abstract/70,72\">",
"     70,72",
"    </a>",
"    ] since it is associated with a reduction in the size of the myocardial perfusion defect [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/52/35658/abstract/71\">",
"     71",
"    </a>",
"    ]. Patients with improved LVEF may have significantly lower mortality than those who show no improvement (1.2 versus 5.6 percent at three years in one study) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/52/35658/abstract/71\">",
"     71",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/35/8759?source=see_link&amp;anchor=H5#H5\">",
"     \"Clinical syndromes of stunned or hibernating myocardium\", section on 'Acute myocardial infarction'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Multiple imaging techniques for assessing left ventricular function are available and each has equivalent prognostic value in the post-MI patient. In general, echocardiography should be used for routine assessment of LVEF after acute MI. It has the added advantage of detecting other factors that can be associated with a worse prognosis such as diastolic dysfunction, concurrent right ventricular dysfunction, left atrial enlargement, mitral regurgitation, and a high wall motion score index, which reflects a more severe impairment in overall left ventricular systolic function [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/52/35658/abstract/73-79\">",
"     73-79",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/6/11369?source=see_link&amp;anchor=H22#H22\">",
"     \"Role of echocardiography in acute myocardial infarction\", section on 'Left ventricular systolic function'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/6/11369?source=see_link&amp;anchor=H23#H23\">",
"     \"Role of echocardiography in acute myocardial infarction\", section on 'Left ventricular diastolic function'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/55/18297?source=see_link\">",
"     \"Ischemic mitral regurgitation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Among patients with an STEMI who have an interpretable ECG (ie, no left bundle branch block, paced rhythm, or left ventricular hypertrophy with strain pattern), the absence of an anterior infarction, a previous Q wave MI, or a history of HF predicts an LVEF of at least 40 percent (positive predictive value of 91 to 98 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/52/35658/abstract/80,81\">",
"     80,81",
"    </a>",
"    ]. The LVEF is variable among patients who do not fit the prediction rule.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h2\">",
"     Right ventricular ejection fraction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Long term impairment of right ventricular systolic function after MI is associated with a worse prognosis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/57/922?source=see_link&amp;anchor=H20#H20\">",
"     \"Right ventricular myocardial infarction\", section on 'Long-term prognosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h2\">",
"     Stress testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;A noninvasive stress test, usually with exercise, is often performed after STEMI to detect residual ischemia. Thus, it is reasonable in patients who did not undergo coronary angiography",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    in those for whom there is question about the severity of another coronary artery lesion. Stress testing also permits assessment of the exercise capacity needed for the cardiac rehabilitation exercise prescription and can, in some patients, identify arrhythmias. It may be required by some cardiac rehabilitation programs.",
"   </p>",
"   <p>",
"    While the prognostic value of stress testing has declined in the reperfusion era (see",
"    <a class=\"local\" href=\"#H38\">",
"     'Predictive value'",
"    </a>",
"    below), the 2013",
"    <span class=\"nowrap\">",
"     ACCF/AHA",
"    </span>",
"    guideline strongly recommended stress testing for patients who did not under coronary angiography and weakly recommended it for those in whom the functional significance of a noninfarct artery stenosis identified at angiography was of concern [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/52/35658/abstract/64,65\">",
"     64,65",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/6/35945?source=see_link\">",
"     \"Performance of exercise ECG testing\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36\">",
"    <span class=\"h3\">",
"     Candidates for testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Predischarge stress testing to detect residual ischemia is generally not performed in patients who have undergone PCI or CABG and have been fully revascularized (eg, single vessel disease and successful PCI). Such patients often undergo exercise testing a few weeks or more after discharge as part of a cardiac rehabilitation program or for activity counseling.",
"   </p>",
"   <p>",
"    Patients who have undergone partial revascularization or no revascularization, in contrast, are candidates for predischarge testing. Candidates for post MI stress testing should be properly screened. Low level exercise testing appears to be safe if:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      The patient has undergone in-hospital cardiac rehabilitation",
"     </li>",
"     <li>",
"      There have not been symptoms of heart failure or recurrent angina",
"     </li>",
"     <li>",
"      The electrocardiogram has been stable for 48 to 72 hours prior to the exercise test",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Stress testing should",
"    <strong>",
"     not",
"    </strong>",
"    be performed in patients with unstable postinfarction angina, decompensated heart failure, or life-threatening cardiac arrhythmias.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H37\">",
"    <span class=\"h3\">",
"     Stress protocol",
"    </span>",
"    &nbsp;&mdash;&nbsp;The appropriate stress protocol varies with physician preferences, patient characteristics, and local laboratory expertise. Exercise ECG testing, which is most often performed, relies on both symptoms and objective changes on the ECG. The recommended protocol options are:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A predischarge submaximal test (modified Bruce or Naughton protocol) (",
"      <a class=\"graphic graphic_table graphicRef70044 \" href=\"mobipreview.htm?12/51/13118\">",
"       table 6",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?35/6/35945?source=see_link&amp;anchor=H26#H26\">",
"       \"Performance of exercise ECG testing\", section on 'Submaximal testing'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      A symptom-limited test before or after discharge. In selected low risk patients (ie, without heart failure, arrhythmias, or angina), an early full Bruce protocol has been safely completed as early as three days or before discharge [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/52/35658/abstract/82-85\">",
"       82-85",
"      </a>",
"      ]. It provides a greater exercise stress and is more likely than a submaximal test to detect residual ischemia [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/52/35658/abstract/84,85\">",
"       84,85",
"      </a>",
"      ]. However, the prognostic value of ST depression occurring at a higher work level is unproven and more data are needed to establish the safety and utility of this early protocol. Stress testing should",
"      <strong>",
"       not",
"      </strong>",
"      be performed within two to three days of STEMI",
"      <strong>",
"       in",
"      </strong>",
"      patients who have not undergone successful reperfusion.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Accurate stress ECG interpretation cannot be achieved in patients with baseline ECG abnormalities such as left bundle branch block, left ventricular hypertrophy with ST-T wave changes, ventricular preexcitation, or ventricular pacing. In such patients, either exercise radionuclide myocardial perfusion imaging (rMPI) or exercise echocardiography should be performed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/52/35658/abstract/86\">",
"     86",
"    </a>",
"    ]. Pharmacologic stress with either rMPI or echocardiography is required in patients who cannot exercise, although such modalities provide less information than exercise testing because they are not able to assess functional capacity (",
"    <a class=\"graphic graphic_algorithm graphicRef71324 \" href=\"mobipreview.htm?26/52/27470\">",
"     algorithm 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/30/44520?source=see_link\">",
"     \"Selecting the optimal cardiac stress test\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H38\">",
"    <span class=\"h3\">",
"     Predictive value",
"    </span>",
"    &nbsp;&mdash;&nbsp;An important limitation to the prognostic value of post-MI stress testing in the reperfusion era is that overall mortality is very low after fibrinolysis (even though only 50 to 60 percent achieve normal flow in the infarct-related artery) and is even lower in patients who have undergone primary PCI; as a result, the predictive value of a positive test for mortality is quite low [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/52/35658/abstract/87-92\">",
"     87-92",
"    </a>",
"    ]. In a review from the GISSI-2 database, 6296 patients with an STEMI who were treated with fibrinolytic therapy underwent a maximal symptom-limited exercise test and were followed for six months. 26 percent of the tests were positive, 36 percent nondiagnostic, and 38 percent negative [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/52/35658/abstract/89\">",
"     89",
"    </a>",
"    ]. The mortality rates in the three groups were 1.7, 1.3, and 0.9 percent. The positive predictive value of predischarge stress testing for cardiac death or reinfarction is less than seen with a reduced LVEF (",
"    <a class=\"graphic graphic_figure graphicRef69404 \" href=\"mobipreview.htm?23/60/24526\">",
"     figure 7",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/52/35658/abstract/93\">",
"     93",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The patients at highest risk are those who are deemed unable to exercise because of contraindications [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/52/35658/abstract/89-91\">",
"     89-91",
"    </a>",
"    ]. In the above report from GISSI-2, for example, mortality at six months was 7.1 percent in such patients compared to about 1.3 percent in those who could [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/52/35658/abstract/89\">",
"     89",
"    </a>",
"    ]. Patients who cannot exercise have increased comorbidities such as older age, more frequent history of MI, and more extensive coronary disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/52/35658/abstract/91\">",
"     91",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H39\">",
"    <span class=\"h2\">",
"     Contrast-enhanced magnetic resonance imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cardiac magnetic resonance (CMR) imaging offers excellent characterization of myocardial function and the extent of scar after an MI. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/3/34874?source=see_link&amp;anchor=H36992969#H36992969\">",
"     \"Clinical utility of cardiovascular magnetic resonance imaging\", section on 'Prediction of post-MI mortality'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H328427464\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The process of risk stratification in a patient who has had an acute ST elevation or Q wave myocardial infarction (STEMI) has two components: early in-hospital identification of patients at increased risk for recurrent ischemic events; and identification of patients after an MI who are at increased risk for arrhythmic or nonarrhythmic death. The following points summarize this process:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Risk scores which contain multiple individual risk factors have been developed. Some of these were derived from patients who received fibrinolytic therapy, while others were derived from patients who underwent primary percutaneous coronary intervention (PCI). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Risk scores'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients who receive fibrinolytic therapy, the most important risk factors are: age &gt;65 years; Killip class II-IV; blood pressure &lt;100 mmHg or hypotension; heart rate &gt;100 bpm; elevated serum creatinine; anterior myocardial infarction; and cardiac arrest during presentation. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Risk scores'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients who receive primary PCI, the most important risk factors are: reduced left ventricular ejection fraction; Killip class; elevated serum creatinine; anemia; reduced TIMI flow grade; triple vessel disease, and age &gt;65 years. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Primary PCI scores'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Numerous other risk factors have been identified, but have either not been tested in the development of a model or didn&rsquo;t add to the predictive ability of the model. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Risk predictors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Late risk stratification is performed before or sometimes after discharge. The main components are measurement of the left ventricular ejection fraction and, in many patients, stress testing to detect possible residual ischemia.",
"      <br/>",
"      <br/>",
"      Predischarge stress testing to detect residual ischemia is generally not performed in patients who have undergone PCI or CABG and have been fully revascularized (eg, single vessel disease and successful PCI). Such patients often undergo exercise testing a few weeks or more after discharge as part of a cardiac rehabilitation program or for activity counseling. (See",
"      <a class=\"local\" href=\"#H32\">",
"       'Late risk stratification'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Methods used for risk stratification for arrhythmic death are discussed separately. These include ventricular arrhythmias and late potentials on signal-averaged ECG. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?20/24/20874?source=see_link\">",
"       \"Incidence of and risk stratification for sudden cardiac death after acute myocardial infarction\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/52/35658/abstract/1\">",
"      Becker RC, Burns M, Gore JM, et al. Early assessment and in-hospital management of patients with acute myocardial infarction at increased risk for adverse outcomes: a nationwide perspective of current clinical practice. The National Registry of Myocardial Infarction (NRMI-2) Participants. Am Heart J 1998; 135:786.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/52/35658/abstract/2\">",
"      Califf RM, Pieper KS, Lee KL, et al. Prediction of 1-year survival after thrombolysis for acute myocardial infarction in the global utilization of streptokinase and TPA for occluded coronary arteries trial. Circulation 2000; 101:2231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/52/35658/abstract/3\">",
"      Rea TD, Heckbert SR, Kaplan RC, et al. Body mass index and the risk of recurrent coronary events following acute myocardial infarction. Am J Cardiol 2001; 88:467.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/52/35658/abstract/4\">",
"      Morrow DA, Antman EM, Charlesworth A, et al. TIMI risk score for ST-elevation myocardial infarction: A convenient, bedside, clinical score for risk assessment at presentation: An intravenous nPA for treatment of infarcting myocardium early II trial substudy. Circulation 2000; 102:2031.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/52/35658/abstract/5\">",
"      Granger CB, Goldberg RJ, Dabbous O, et al. Predictors of hospital mortality in the global registry of acute coronary events. Arch Intern Med 2003; 163:2345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/52/35658/abstract/6\">",
"      De Luca G, Suryapranata H, van 't Hof AW, et al. Prognostic assessment of patients with acute myocardial infarction treated with primary angioplasty: implications for early discharge. Circulation 2004; 109:2737.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/52/35658/abstract/7\">",
"      Halkin A, Singh M, Nikolsky E, et al. Prediction of mortality after primary percutaneous coronary intervention for acute myocardial infarction: the CADILLAC risk score. J Am Coll Cardiol 2005; 45:1397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/52/35658/abstract/8\">",
"      Morrow DA, Antman EM, Giugliano RP, et al. A simple risk index for rapid initial triage of patients with ST-elevation myocardial infarction: an InTIME II substudy. Lancet 2001; 358:1571.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/52/35658/abstract/9\">",
"      Marchioli R, Avanzini F, Barzi F, et al. Assessment of absolute risk of death after myocardial infarction by use of multiple-risk-factor assessment equations: GISSI-Prevenzione mortality risk chart. Eur Heart J 2001; 22:2085.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/52/35658/abstract/10\">",
"      Tu JV, Austin PC, Walld R, et al. Development and validation of the Ontario acute myocardial infarction mortality prediction rules. J Am Coll Cardiol 2001; 37:992.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/52/35658/abstract/11\">",
"      Morrow DA, Antman EM, Parsons L, et al. Application of the TIMI risk score for ST-elevation MI in the National Registry of Myocardial Infarction 3. JAMA 2001; 286:1356.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/52/35658/abstract/12\">",
"      Wiviott SD, Morrow DA, Frederick PD, et al. Performance of the thrombolysis in myocardial infarction risk index in the National Registry of Myocardial Infarction-3 and -4: a simple index that predicts mortality in ST-segment elevation myocardial infarction. J Am Coll Cardiol 2004; 44:783.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/52/35658/abstract/13\">",
"      Rathore SS, Weinfurt KP, Gross CP, Krumholz HM. Validity of a simple ST-elevation acute myocardial infarction risk index: are randomized trial prognostic estimates generalizable to elderly patients? Circulation 2003; 107:811.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/52/35658/abstract/14\">",
"      Wiviott SD, Morrow DA, Frederick PD, et al. Application of the Thrombolysis in Myocardial Infarction risk index in non-ST-segment elevation myocardial infarction: evaluation of patients in the National Registry of Myocardial Infarction. J Am Coll Cardiol 2006; 47:1553.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/52/35658/abstract/15\">",
"      Eagle KA, Lim MJ, Dabbous OH, et al. A validated prediction model for all forms of acute coronary syndrome: estimating the risk of 6-month postdischarge death in an international registry. JAMA 2004; 291:2727.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/52/35658/abstract/16\">",
"      Po&ccedil;i D, Hartford M, Karlsson T, et al. Role of the CHADS2 score in acute coronary syndromes: risk of subsequent death or stroke in patients with and without atrial fibrillation. Chest 2012; 141:1431.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/52/35658/abstract/17\">",
"      Lev EI, Kornowski R, Vaknin-Assa H, et al. Comparison of the predictive value of four different risk scores for outcomes of patients with ST-elevation acute myocardial infarction undergoing primary percutaneous coronary intervention. Am J Cardiol 2008; 102:6.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/52/35658/abstract/18\">",
"      Canto JG, Kiefe CI, Rogers WJ, et al. Number of coronary heart disease risk factors and mortality in patients with first myocardial infarction. JAMA 2011; 306:2120.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/52/35658/abstract/19\">",
"      Killip T 3rd, Kimball JT. Treatment of myocardial infarction in a coronary care unit. A two year experience with 250 patients. Am J Cardiol 1967; 20:457.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/52/35658/abstract/20\">",
"      Wu AH, Parsons L, Every NR, et al. Hospital outcomes in patients presenting with congestive heart failure complicating acute myocardial infarction: a report from the Second National Registry of Myocardial Infarction (NRMI-2). J Am Coll Cardiol 2002; 40:1389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/52/35658/abstract/21\">",
"      Steg PG, Dabbous OH, Feldman LJ, et al. Determinants and prognostic impact of heart failure complicating acute coronary syndromes: observations from the Global Registry of Acute Coronary Events (GRACE). Circulation 2004; 109:494.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/52/35658/abstract/22\">",
"      DeGeare VS, Boura JA, Grines LL, et al. Predictive value of the Killip classification in patients undergoing primary percutaneous coronary intervention for acute myocardial infarction. Am J Cardiol 2001; 87:1035.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/52/35658/abstract/23\">",
"      De Luca G, van 't Hof AW, de Boer MJ, et al. Impaired myocardial perfusion is a major explanation of the poor outcome observed in patients undergoing primary angioplasty for ST-segment-elevation myocardial infarction and signs of heart failure. Circulation 2004; 109:958.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/52/35658/abstract/24\">",
"      Crimm A, Severance HW Jr, Coffey K, et al. Prognostic significance of isolated sinus tachycardia during first three days of acute myocardial infarction. Am J Med 1984; 76:983.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/52/35658/abstract/25\">",
"      Pizzetti F, Turazza FM, Franzosi MG, et al. Incidence and prognostic significance of atrial fibrillation in acute myocardial infarction: the GISSI-3 data. Heart 2001; 86:527.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/52/35658/abstract/26\">",
"      Jabre P, Jouven X, Adnet F, et al. Atrial fibrillation and death after myocardial infarction: a community study. Circulation 2011; 123:2094.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/52/35658/abstract/27\">",
"      Betriu A, Califf RM, Bosch X, et al. Recurrent ischemia after thrombolysis: importance of associated clinical findings. GUSTO-I Investigators. Global Utilization of Streptokinase and t-PA [tissue-plasminogen activator] for Occluded Coronary Arteries. J Am Coll Cardiol 1998; 31:94.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/52/35658/abstract/28\">",
"      Armstrong PW, Fu Y, Chang WC, et al. Acute coronary syndromes in the GUSTO-IIb trial: prognostic insights and impact of recurrent ischemia. The GUSTO-IIb Investigators. Circulation 1998; 98:1860.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/52/35658/abstract/29\">",
"      Early and six-month outcome in patients with angina pectoris early after acute myocardial infarction (the GISSI-3 APPI [angina precoce post-infarto] study). The GISSI-3 APPI Study Group. Am J Cardiol 1996; 78:1191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/52/35658/abstract/30\">",
"      Gottlieb SO, Gottlieb SH, Achuff SC, et al. Silent ischemia on Holter monitoring predicts mortality in high-risk postinfarction patients. JAMA 1988; 259:1030.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/52/35658/abstract/31\">",
"      Deedwania PC. Asymptomatic ischemia during predischarge Holter monitoring predicts poor prognosis in the postinfarction period. Am J Cardiol 1993; 71:859.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/52/35658/abstract/32\">",
"      Savonitto S, Granger CB, Ardissino D, et al. The prognostic value of creatine kinase elevations extends across the whole spectrum of acute coronary syndromes. J Am Coll Cardiol 2002; 39:22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/52/35658/abstract/33\">",
"      Halkin A, Stone GW, Grines CL, et al. Prognostic implications of creatine kinase elevation after primary percutaneous coronary intervention for acute myocardial infarction. J Am Coll Cardiol 2006; 47:951.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/52/35658/abstract/34\">",
"      Ottani F, Galvani M, Nicolini FA, et al. Elevated cardiac troponin levels predict the risk of adverse outcome in patients with acute coronary syndromes. Am Heart J 2000; 140:917.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/52/35658/abstract/35\">",
"      Kanna M, Nonogi H, Sumida H, et al. Usefulness of serum troponin T levels on day three or four in predicting survival after acute myocardial infarction. Am J Cardiol 2001; 87:294.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/52/35658/abstract/36\">",
"      Giannitsis E, M&uuml;ller-Bardorff M, Lehrke S, et al. Admission troponin T level predicts clinical outcomes, TIMI flow, and myocardial tissue perfusion after primary percutaneous intervention for acute ST-segment elevation myocardial infarction. Circulation 2001; 104:630.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/52/35658/abstract/37\">",
"      Ohman EM, Armstrong PW, White HD, et al. Risk stratification with a point-of-care cardiac troponin T test in acute myocardial infarction. GUSTOIII Investigators. Global Use of Strategies To Open Occluded Coronary Arteries. Am J Cardiol 1999; 84:1281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/52/35658/abstract/38\">",
"      Ohman EM, Armstrong PW, Christenson RH, et al. Cardiac troponin T levels for risk stratification in acute myocardial ischemia. GUSTO IIA Investigators. N Engl J Med 1996; 335:1333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/52/35658/abstract/39\">",
"      Stubbs P, Collinson P, Moseley D, et al. Prognostic significance of admission troponin T concentrations in patients with myocardial infarction. Circulation 1996; 94:1291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/52/35658/abstract/40\">",
"      Omland T, Aakvaag A, Bonarjee VV, et al. Plasma brain natriuretic peptide as an indicator of left ventricular systolic function and long-term survival after acute myocardial infarction. Comparison with plasma atrial natriuretic peptide and N-terminal proatrial natriuretic peptide. Circulation 1996; 93:1963.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/52/35658/abstract/41\">",
"      Richards AM, Nicholls MG, Yandle TG, et al. Plasma N-terminal pro-brain natriuretic peptide and adrenomedullin: new neurohormonal predictors of left ventricular function and prognosis after myocardial infarction. Circulation 1998; 97:1921.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/52/35658/abstract/42\">",
"      Omland T, Persson A, Ng L, et al. N-terminal pro-B-type natriuretic peptide and long-term mortality in acute coronary syndromes. Circulation 2002; 106:2913.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/52/35658/abstract/43\">",
"      Richards AM, Nicholls MG, Espiner EA, et al. B-type natriuretic peptides and ejection fraction for prognosis after myocardial infarction. Circulation 2003; 107:2786.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/52/35658/abstract/44\">",
"      Tapanainen JM, Lindgren KS, M&auml;kikallio TH, et al. Natriuretic peptides as predictors of non-sudden and sudden cardiac death after acute myocardial infarction in the beta-blocking era. J Am Coll Cardiol 2004; 43:757.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/52/35658/abstract/45\">",
"      Mega JL, Morrow DA, De Lemos JA, et al. B-type natriuretic peptide at presentation and prognosis in patients with ST-segment elevation myocardial infarction: an ENTIRE-TIMI-23 substudy. J Am Coll Cardiol 2004; 44:335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/52/35658/abstract/46\">",
"      Khan SQ, Quinn P, Davies JE, Ng LL. N-terminal pro-B-type natriuretic peptide is better than TIMI risk score at predicting death after acute myocardial infarction. Heart 2008; 94:40.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/52/35658/abstract/47\">",
"      Beygui F, Collet JP, Benoliel JJ, et al. High plasma aldosterone levels on admission are associated with death in patients presenting with acute ST-elevation myocardial infarction. Circulation 2006; 114:2604.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/52/35658/abstract/48\">",
"      Goyal A, Spertus JA, Gosch K, et al. Serum potassium levels and mortality in acute myocardial infarction. JAMA 2012; 307:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/52/35658/abstract/49\">",
"      Narins CR, Zareba W, Moss AJ, et al. Relationship between intermittent claudication, inflammation, thrombosis, and recurrent cardiac events among survivors of myocardial infarction. Arch Intern Med 2004; 164:440.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/52/35658/abstract/50\">",
"      Shlipak MG, Heidenreich PA, Noguchi H, et al. Association of renal insufficiency with treatment and outcomes after myocardial infarction in elderly patients. Ann Intern Med 2002; 137:555.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/52/35658/abstract/51\">",
"      Anavekar NS, McMurray JJ, Velazquez EJ, et al. Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction. N Engl J Med 2004; 351:1285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/52/35658/abstract/52\">",
"      Wright RS, Reeder GS, Herzog CA, et al. Acute myocardial infarction and renal dysfunction: a high-risk combination. Ann Intern Med 2002; 137:563.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/52/35658/abstract/53\">",
"      McCullough PA, Nowak RM, Foreback C, et al. Emergency evaluation of chest pain in patients with advanced kidney disease. Arch Intern Med 2002; 162:2464.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/52/35658/abstract/54\">",
"      Kirtane AJ, Leder DM, Waikar SS, et al. Serum blood urea nitrogen as an independent marker of subsequent mortality among patients with acute coronary syndromes and normal to mildly reduced glomerular filtration rates. J Am Coll Cardiol 2005; 45:1781.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/52/35658/abstract/55\">",
"      Madjid M, Awan I, Willerson JT, Casscells SW. Leukocyte count and coronary heart disease: implications for risk assessment. J Am Coll Cardiol 2004; 44:1945.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/52/35658/abstract/56\">",
"      Barron HV, Cannon CP, Murphy SA, et al. Association between white blood cell count, epicardial blood flow, myocardial perfusion, and clinical outcomes in the setting of acute myocardial infarction: a thrombolysis in myocardial infarction 10 substudy. Circulation 2000; 102:2329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/52/35658/abstract/57\">",
"      Cannon CP, McCabe CH, Wilcox RG, et al. Association of white blood cell count with increased mortality in acute myocardial infarction and unstable angina pectoris. OPUS-TIMI 16 Investigators. Am J Cardiol 2001; 87:636.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/52/35658/abstract/58\">",
"      Barron HV, Harr SD, Radford MJ, et al. The association between white blood cell count and acute myocardial infarction mortality in patients &gt; or =65 years of age: findings from the cooperative cardiovascular project. J Am Coll Cardiol 2001; 38:1654.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/52/35658/abstract/59\">",
"      Grau AJ, Boddy AW, Dukovic DA, et al. Leukocyte count as an independent predictor of recurrent ischemic events. Stroke 2004; 35:1147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/52/35658/abstract/60\">",
"      Patel MR, Mahaffey KW, Armstrong PW, et al. Prognostic usefulness of white blood cell count and temperature in acute myocardial infarction (from the CARDINAL Trial). Am J Cardiol 2005; 95:614.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/52/35658/abstract/61\">",
"      Hajj-Ali R, Zareba W, Ezzeddine R, Moss AJ. Relation of the leukocyte count to recurrent cardiac events in stable patients after acute myocardial infarction. Am J Cardiol 2001; 88:1221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/52/35658/abstract/62\">",
"      Sabatine MS, Morrow DA, Giugliano RP, et al. Association of hemoglobin levels with clinical outcomes in acute coronary syndromes. Circulation 2005; 111:2042.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/52/35658/abstract/63\">",
"      Aronson D, Suleiman M, Agmon Y, et al. Changes in haemoglobin levels during hospital course and long-term outcome after acute myocardial infarction. Eur Heart J 2007; 28:1289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/52/35658/abstract/64\">",
"      O'Gara PT, Kushner FG, Ascheim DD, et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2013; 127:529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/52/35658/abstract/65\">",
"      O'Gara PT, Kushner FG, Ascheim DD, et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2013; 127:e362.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/52/35658/abstract/66\">",
"      Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (ESC), Steg PG, James SK, et al. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J 2012; 33:2569.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/52/35658/abstract/67\">",
"      Nicolosi GL, Latini R, Marino P, et al. The prognostic value of predischarge quantitative two-dimensional echocardiographic measurements and the effects of early lisinopril treatment on left ventricular structure and function after acute myocardial infarction in the GISSI-3 Trial. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico. Eur Heart J 1996; 17:1646.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/52/35658/abstract/68\">",
"      Burns RJ, Gibbons RJ, Yi Q, et al. The relationships of left ventricular ejection fraction, end-systolic volume index and infarct size to six-month mortality after hospital discharge following myocardial infarction treated by thrombolysis. J Am Coll Cardiol 2002; 39:30.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/52/35658/abstract/69\">",
"      Zaret BL, Wackers FJ, Terrin ML, et al. Value of radionuclide rest and exercise left ventricular ejection fraction in assessing survival of patients after thrombolytic therapy for acute myocardial infarction: results of Thrombolysis in Myocardial Infarction (TIMI) phase II study. The TIMI Study Group. J Am Coll Cardiol 1995; 26:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/52/35658/abstract/70\">",
"      Solomon SD, Glynn RJ, Greaves S, et al. Recovery of ventricular function after myocardial infarction in the reperfusion era: the healing and early afterload reducing therapy study. Ann Intern Med 2001; 134:451.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/52/35658/abstract/71\">",
"      Ndrepepa G, Mehilli J, Martinoff S, et al. Evolution of left ventricular ejection fraction and its relationship to infarct size after acute myocardial infarction. J Am Coll Cardiol 2007; 50:149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/52/35658/abstract/72\">",
"      Sheehan FH, Doerr R, Schmidt WG, et al. Early recovery of left ventricular function after thrombolytic therapy for acute myocardial infarction: an important determinant of survival. J Am Coll Cardiol 1988; 12:289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/52/35658/abstract/73\">",
"      Nijland F, Kamp O, Karreman AJ, et al. Prognostic implications of restrictive left ventricular filling in acute myocardial infarction: a serial Doppler echocardiographic study. J Am Coll Cardiol 1997; 30:1618.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/52/35658/abstract/74\">",
"      Somaratne JB, Whalley GA, Gamble GD, Doughty RN. Restrictive filling pattern is a powerful predictor of heart failure events postacute myocardial infarction and in established heart failure: a literature-based meta-analysis. J Card Fail 2007; 13:346.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/52/35658/abstract/75\">",
"      Whalley GA, Gamble GD, Doughty RN. Restrictive diastolic filling predicts death after acute myocardial infarction: systematic review and meta-analysis of prospective studies. Heart 2006; 92:1588.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/52/35658/abstract/76\">",
"      Zornoff LA, Skali H, Pfeffer MA, et al. Right ventricular dysfunction and risk of heart failure and mortality after myocardial infarction. J Am Coll Cardiol 2002; 39:1450.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/52/35658/abstract/77\">",
"      Moller JE, Hillis GS, Oh JK, et al. Left atrial volume: a powerful predictor of survival after acute myocardial infarction. Circulation 2003; 107:2207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/52/35658/abstract/78\">",
"      Grigioni F, Enriquez-Sarano M, Zehr KJ, et al. Ischemic mitral regurgitation: long-term outcome and prognostic implications with quantitative Doppler assessment. Circulation 2001; 103:1759.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/52/35658/abstract/79\">",
"      M&oslash;ller JE, Hillis GS, Oh JK, et al. Wall motion score index and ejection fraction for risk stratification after acute myocardial infarction. Am Heart J 2006; 151:419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/52/35658/abstract/80\">",
"      Silver MT, Rose GA, Paul SD, et al. A clinical rule to predict preserved left ventricular ejection fraction in patients after myocardial infarction. Ann Intern Med 1994; 121:750.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/52/35658/abstract/81\">",
"      Tobin K, Stomel R, Harber D, et al. Validation in a community hospital setting of a clinical rule to predict preserved left ventricular ejection fraction in patients after myocardial infarction. Arch Intern Med 1999; 159:353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/52/35658/abstract/82\">",
"      Topol EJ, Burek K, O'Neill WW, et al. A randomized controlled trial of hospital discharge three days after myocardial infarction in the era of reperfusion. N Engl J Med 1988; 318:1083.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/52/35658/abstract/83\">",
"      Senaratne MP, Smith G, Gulamhusein SS. Feasibility and safety of early exercise testing using the Bruce protocol after acute myocardial infarction. J Am Coll Cardiol 2000; 35:1212.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/52/35658/abstract/84\">",
"      Juneau M, Colles P, Th&eacute;roux P, et al. Symptom-limited versus low level exercise testing before hospital discharge after myocardial infarction. J Am Coll Cardiol 1992; 20:927.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/52/35658/abstract/85\">",
"      Jain A, Myers GH, Sapin PM, O'Rourke RA. Comparison of symptom-limited and low level exercise tolerance tests early after myocardial infarction. J Am Coll Cardiol 1993; 22:1816.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/52/35658/abstract/86\">",
"      Antman EM, Anbe DT, Armstrong PW, et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1999 Guidelines for the Management of Patients with Acute Myocardial Infarction). Circulation 2004; 110:e82.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/52/35658/abstract/87\">",
"      Miller TD, Gersh BJ, Christian TF, et al. Limited prognostic value of thallium-201 exercise treadmill testing early after myocardial infarction in patients treated with thrombolysis. Am Heart J 1995; 130:259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/52/35658/abstract/88\">",
"      Dakik HA, Mahmarian JJ, Kimball KT, et al. Prognostic value of exercise 201Tl tomography in patients treated with thrombolytic therapy during acute myocardial infarction. Circulation 1996; 94:2735.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/52/35658/abstract/89\">",
"      Villella A, Maggioni AP, Villella M, et al. Prognostic significance of maximal exercise testing after myocardial infarction treated with thrombolytic agents: the GISSI-2 data-base. Gruppo Italiano per lo Studio della Sopravvivenza Nell'Infarto. Lancet 1995; 346:523.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/52/35658/abstract/90\">",
"      Dom&iacute;nguez H, Torp-Pedersen C, Koeber L, Rask-Madsen C. Prognostic value of exercise testing in a cohort of patients followed for 15 years after acute myocardial infarction. Eur Heart J 2001; 22:300.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/52/35658/abstract/91\">",
"      Chaitman BR, McMahon RP, Terrin M, et al. Impact of treatment strategy on predischarge exercise test in the Thrombolysis in Myocardial Infarction (TIMI) II Trial. Am J Cardiol 1993; 71:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/52/35658/abstract/92\">",
"      Toft E, Nielsen G, Mortensen B, et al. The prognostic value of exercise testing early after myocardial infarction in patients treated with thrombolytics. Eur Heart J 1995; 16:1177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/52/35658/abstract/93\">",
"      Shaw LJ, Peterson ED, Kesler K, et al. A metaanalysis of predischarge risk stratification after acute myocardial infarction with stress electrocardiographic, myocardial perfusion, and ventricular function imaging. Am J Cardiol 1996; 78:1327.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 78 Version 15.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-122.72.80.101-C15F01F966-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_52_35658=[""].join("\n");
var outline_f34_52_35658=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H328427464\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      RISK SCORES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      TIMI risk score",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      TIMI risk index",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      GRACE risk model",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H183452799\">",
"      CHADS2 score",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Primary PCI scores",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Zwolle primary PCI index",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - CADILLAC risk score",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Comparison of risk scores",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      RISK PREDICTORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8885815\">",
"      Number of CHD risk factors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Heart failure",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Killip class",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Hypotension",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Tachycardia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Electrocardiogram",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Atrial fibrillation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H105894234\">",
"      Ventricular arrhythmias",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Recurrent ischemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Serum biomarkers",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Serum CK",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Serum troponins",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Brain natriuretic peptide",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Plasma aldosterone",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H458465082\">",
"      Serum potassium",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Glycemic control",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Claudication",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Decreased renal function",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      White blood cell count",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Anemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Bleeding",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Abnormal myocardial perfusion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      Age of aspirated thrombus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      LATE RISK STRATIFICATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      Left ventricular ejection fraction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      Right ventricular ejection fraction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      Stress testing",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H36\">",
"      - Candidates for testing",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H37\">",
"      - Stress protocol",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H38\">",
"      - Predictive value",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H39\">",
"      Contrast-enhanced magnetic resonance imaging",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H328427464\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/78\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/78|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"mobipreview.htm?26/52/27470\" title=\"algorithm 1\">",
"      Choice stress test modality",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/78|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?0/62/1007\" title=\"figure 1\">",
"      Postinfarction angina with EKG changes predicts reinfarction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?29/36/30287\" title=\"figure 2\">",
"      Post infarct ischemia outcome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?23/35/24125\" title=\"figure 3\">",
"      Troponin T in acute ischemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?34/1/34845\" title=\"figure 4\">",
"      Diabetes increases coronary mortality",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?29/2/29741\" title=\"figure 5\">",
"      LVEF predicts six-month mortality after STEMI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?37/50/38701\" title=\"figure 6\">",
"      LVEF predicts one-year mortality after STEMI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?23/60/24526\" title=\"figure 7\">",
"      Positve predictive of value stress test results",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/78|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?3/59/4027\" title=\"table 1\">",
"      Killip classification of acute MI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?22/39/23165\" title=\"table 2A\">",
"      GISSI risk index post MI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?43/13/44252\" title=\"table 2B\">",
"      GISSI risk index mortality",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?40/14/41195\" title=\"table 3\">",
"      TIMI risk index mortality MI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?1/49/1819\" title=\"table 4\">",
"      TIMI flow grades",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?2/61/3036\" title=\"table 5\">",
"      CADILLAC risk score",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?12/51/13118\" title=\"table 6\">",
"      Exercise testing protocols",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   CALCULATORS",
"  </h1>",
"  <div id=\"relatedCalculators\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"mobipreview.htm?27/53/28497?source=related_link\" title=\"calculator 1\">",
"      Calculator: Thrombolysis in Myocardial Infarction (TIMI) score for ST elevation acute myocardial infarction",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/45/36570?source=related_link\">",
"      Assessment of kidney function",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/31/34298?source=related_link\">",
"      Chronic kidney disease and coronary heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/10/30890?source=related_link\">",
"      Clinical features and treatment of ventricular arrhythmias during acute myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/1/37911?source=related_link\">",
"      Clinical features of primary aldosteronism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/60/16329?source=related_link\">",
"      Clinical manifestations and diagnosis of cardiogenic shock in acute myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/35/8759?source=related_link\">",
"      Clinical syndromes of stunned or hibernating myocardium",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/3/34874?source=related_link\">",
"      Clinical utility of cardiovascular magnetic resonance imaging",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/26/4521?source=related_link\">",
"      Electrocardiogram in the prognosis of myocardial infarction or unstable angina",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/38/7786?source=related_link\">",
"      Fibrinolytic (thrombolytic) agents in acute ST elevation myocardial infarction: Markers of efficacy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/43/1721?source=related_link\">",
"      Fibrinolytic therapy in acute ST elevation myocardial infarction: Initiation of therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/33/44567?source=related_link\">",
"      Glycemic control for acute myocardial infarction in patients with and without diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/35/30266?source=related_link\">",
"      Health hazards associated with obesity in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/24/20874?source=related_link\">",
"      Incidence of and risk stratification for sudden cardiac death after acute myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/35/43577?source=related_link\">",
"      Initial management of blood glucose in type 2 diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/55/18297?source=related_link\">",
"      Ischemic mitral regurgitation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/27/8634?source=related_link\">",
"      Management of failed fibrinolysis (thrombolysis) or threatened reocclusion in acute ST elevation myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/22/19818?source=related_link\">",
"      Natriuretic peptide measurement in heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/59/7098?source=related_link\">",
"      Overview of the non-acute management of ST elevation myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/33/44569?source=related_link\">",
"      Overview of the non-acute management of unstable angina and non-ST elevation myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/59/39866?source=related_link\">",
"      Overview of the risk equivalents and established risk factors for cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/6/35945?source=related_link\">",
"      Performance of exercise ECG testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/46/16106?source=related_link\">",
"      Primary percutaneous coronary intervention in acute ST elevation myocardial infarction: Determinants of outcome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/16/29961?source=related_link\">",
"      Primary percutaneous coronary intervention versus fibrinolysis in acute ST elevation myocardial infarction: Clinical trials",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/57/922?source=related_link\">",
"      Right ventricular myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/0/29703?source=related_link\">",
"      Risk factors and epidemiology of coronary artery disease in end-stage renal disease (dialysis)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/23/27001?source=related_link\">",
"      Risk of embolization in atrial fibrillation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/43/2746?source=related_link\">",
"      Risk stratification after unstable angina or non-ST elevation myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/6/11369?source=related_link\">",
"      Role of echocardiography in acute myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/30/44520?source=related_link\">",
"      Selecting the optimal cardiac stress test",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/35/4665?source=related_link\">",
"      Silent myocardial ischemia: Prognosis and therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/25/14742?source=related_link\">",
"      Sinus tachycardia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/48/9994?source=related_link\">",
"      Suboptimal reperfusion after primary percutaneous coronary intervention in acute ST elevation myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/14/16615?source=related_link\">",
"      Supraventricular arrhythmias after myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/38/39530?source=related_link\">",
"      Troponins and creatine kinase as biomarkers of cardiac injury",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/54/28521?source=related_link\">",
"      Use of aldosterone antagonists in heart failure",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f34_52_35659="Secretion clearance methods";
var content_f34_52_35659=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F78373&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F78373&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Secretion clearance/bronchial hygiene",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Technique",
"       </td>",
"       <td class=\"subtitle1\">",
"        Advantages",
"       </td>",
"       <td class=\"subtitle1\">",
"        Comment/disadvantage",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Directed cough",
"       </td>",
"       <td>",
"        Inexpensive, simple",
"       </td>",
"       <td>",
"        Chest pain may limit",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Regular exercise",
"       </td>",
"       <td>",
"        Inexpensive, strengthens respiratory and peripheral muscles",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Autogenic breathing",
"       </td>",
"       <td>",
"        Controls breathing",
"       </td>",
"       <td>",
"        Requires patient cooperation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Forced expiration",
"       </td>",
"       <td>",
"        Helps control breathing",
"       </td>",
"       <td>",
"        Requires patient learning",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Chest physical therapy (CPT) (postural drainage, hand, or mechanical chest clapping)",
"       </td>",
"       <td>",
"        Most tested in cystic fibrosis",
"       </td>",
"       <td>",
"        Needs assistant, hard to position, hypoxemia, sometimes worsens gastroesophageal reflux",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Positive expiratory pressure (PEP)",
"       </td>",
"       <td>",
"        Easy, inexpensive",
"       </td>",
"       <td>",
"        Device needs cleaning",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Oscillatory PEP (eg, flutter valve acapella device)",
"       </td>",
"       <td>",
"        Easy, inexpensive, adds vibration to airways",
"       </td>",
"       <td>",
"        Device needs cleaning",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        High frequency chest wall compression",
"       </td>",
"       <td>",
"        Better tolerated than chest PT",
"       </td>",
"       <td>",
"        Very expensive, pain may limit",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_52_35659=[""].join("\n");
var outline_f34_52_35659=null;
var title_f34_52_35660="Classification of primary esophageal motility abnormalities";
var content_f34_52_35660=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F64858&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F64858&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Classification of primary esophageal motility abnormalities",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Diagnosis",
"       </td>",
"       <td class=\"subtitle1\">",
"        Conventional manometry",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"3\">",
"        <strong>",
"         Achalasia (the true disorder)",
"        </strong>",
"       </td>",
"       <td>",
"        Absent distal peristalsis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Incomplete LES relaxation (residual pressure &gt;8 mmHg)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Elevated resting LES pressure (&gt;45 mmHg)",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Abnormal motility patterns (nonspecific esophageal dysmotility)*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle3_left\" colspan=\"2\">",
"        Discoordinated motility",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\" rowspan=\"4\">",
"        Diffuse (or distal) esophageal spasm",
"       </td>",
"       <td>",
"        Simultaneous contractions (&ge;20 percent wet swallows)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Intermittent peristalsis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Repetitive contractions (&ge;3 peaks)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Prolonged duration contractions (&gt;6 sec)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle3_left\" colspan=\"2\">",
"        Hypercontracting esophagus",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\" rowspan=\"2\">",
"        Hypertensive peristalsis (\"nutcracker esophagus\")",
"       </td>",
"       <td>",
"        Increased distal peristaltic amplitude (mean value &gt;220 mmHg)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Increased distal peristaltic duration (mean value &gt;6 sec)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\" rowspan=\"2\">",
"        Hypertensive LES",
"       </td>",
"       <td>",
"        Resting LES pressure &gt;45 mmHg",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        May be incomplete LES relaxation (residual pressure &gt;8 mmHg)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle3_left\" colspan=\"2\">",
"        Hypocontracting esophagus",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\" rowspan=\"2\">",
"        Ineffective esophageal motility (IEM)",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td>",
"        Increased low amplitude peristalsis (&ge;50 percent wet swallows)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Low distal peristaltic amplitude (&lt;30 mmHg)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Hypotensive LES",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td>",
"        Resting LES pressure &lt;10 mmHg",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle3_left\" rowspan=\"3\">",
"        Others",
"       </td>",
"       <td>",
"        Retrograde contractions",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Triple peaked contractions",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Isolated incomplete LES relaxation (&gt;8 mmHg)",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     LES: lower esophageal sphincter.",
"     <br>",
"      * Defined as exceeding two standard deviations from mean of normal values.",
"      <br>",
"       <span class=\"bullet\">",
"        &bull;",
"       </span>",
"       May be \"secondary\" to gastroesophageal reflux disease (GERD).",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_52_35660=[""].join("\n");
var outline_f34_52_35660=null;
var title_f34_52_35661="TNM stage salivary glands";
var content_f34_52_35661=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F61042&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F61042&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Tumor node metastases (TNM) staging system for cancer of the major salivary glands",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1_single\" colspan=\"4\">",
"       Primary tumor (T)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       TX",
"      </td>",
"      <td colspan=\"3\">",
"       Primary tumor cannot be assessed",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       T0",
"      </td>",
"      <td colspan=\"3\">",
"       No evidence of primary tumor",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       T1",
"      </td>",
"      <td colspan=\"3\">",
"       Tumor 2 cm or less in greatest dimension without extraparenchymal extension*",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       T2",
"      </td>",
"      <td colspan=\"3\">",
"       Tumor more than 2 cm but not more than 4 cm in greatest dimension without extraparenchymal extension*",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       T3",
"      </td>",
"      <td colspan=\"3\">",
"       Tumor more than 4 cm and/or tumor having extraparenchymal extension*",
"      </td>",
"     </tr>",
"     <tr>",
"      <td rowspan=\"2\">",
"       T4a",
"      </td>",
"      <td colspan=\"3\">",
"       Moderately advanced disease",
"      </td>",
"     </tr>",
"     <tr>",
"      <td colspan=\"3\">",
"       Tumor invades skin, mandible, ear canal, and/or facial nerve",
"      </td>",
"     </tr>",
"     <tr>",
"      <td rowspan=\"2\">",
"       T4b",
"      </td>",
"      <td colspan=\"3\">",
"       Very advanced disease",
"      </td>",
"     </tr>",
"     <tr>",
"      <td colspan=\"3\">",
"       Tumor invades skull base and/or pterygoid plates and/or encases carotid artery",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\" colspan=\"4\">",
"       Regional lymph nodes (N)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       NX",
"      </td>",
"      <td colspan=\"3\">",
"       Regional lymph nodes cannot be assessed",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       N0",
"      </td>",
"      <td colspan=\"3\">",
"       No regional lymph node metastasis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       N1",
"      </td>",
"      <td colspan=\"3\">",
"       Metastasis in a single ipsilateral lymph node, 3 cm or less in greatest dimension",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1_start\">",
"       N2",
"      </td>",
"      <td class=\"sublist_other_start\" colspan=\"3\">",
"       Metastasis in a single ipsilateral lymph node, more than 3 cm but not more than 6 cm in greatest dimension, or in multiple ipsilateral lymph nodes, none more than 6 cm in greatest dimension, or in bilateral or contralateral lymph nodes, none more than 6 cm in greatest dimension",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       N2a",
"      </td>",
"      <td class=\"sublist_other\" colspan=\"3\">",
"       Metastasis in a single ipsilateral lymph node, more than 3 cm but not more than 6 cm in greatest dimension",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       N2b",
"      </td>",
"      <td class=\"sublist_other\" colspan=\"3\">",
"       Metastasis in multiple ipsilateral lymph nodes, none more than 6 cm in greatest dimension",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       N2c",
"      </td>",
"      <td class=\"sublist_other\" colspan=\"3\">",
"       Metastasis in bilateral or contralateral lymph nodes, none more than 6 cm in greatest dimension",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       N3",
"      </td>",
"      <td colspan=\"3\">",
"       Metastasis in a lymph node, more than 6 cm in greatest dimension",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\" colspan=\"4\">",
"       Distant metastasis (M)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       M0",
"      </td>",
"      <td colspan=\"3\">",
"       No distant metastasis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       M1",
"      </td>",
"      <td colspan=\"3\">",
"       Distant metastasis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\" colspan=\"4\">",
"       Anatomic stage/prognostic groups",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Stage I",
"      </td>",
"      <td>",
"       T1",
"      </td>",
"      <td>",
"       N0",
"      </td>",
"      <td>",
"       M0",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Stage II",
"      </td>",
"      <td>",
"       T2",
"      </td>",
"      <td>",
"       N0",
"      </td>",
"      <td>",
"       M0",
"      </td>",
"     </tr>",
"     <tr>",
"      <td rowspan=\"4\">",
"       Stage III",
"      </td>",
"      <td>",
"       T3",
"      </td>",
"      <td>",
"       N0",
"      </td>",
"      <td>",
"       M0",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       T1",
"      </td>",
"      <td>",
"       N1",
"      </td>",
"      <td>",
"       M0",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       T2",
"      </td>",
"      <td>",
"       N1",
"      </td>",
"      <td>",
"       M0",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       T3",
"      </td>",
"      <td>",
"       N1",
"      </td>",
"      <td>",
"       M0",
"      </td>",
"     </tr>",
"     <tr>",
"      <td rowspan=\"6\">",
"       Stage IVA",
"      </td>",
"      <td>",
"       T4a",
"      </td>",
"      <td>",
"       N0",
"      </td>",
"      <td>",
"       M0",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       T4a",
"      </td>",
"      <td>",
"       N1",
"      </td>",
"      <td>",
"       M0",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       T1",
"      </td>",
"      <td>",
"       N2",
"      </td>",
"      <td>",
"       M0",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       T2",
"      </td>",
"      <td>",
"       N2",
"      </td>",
"      <td>",
"       M0",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       T3",
"      </td>",
"      <td>",
"       N2",
"      </td>",
"      <td>",
"       M0",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       T4a",
"      </td>",
"      <td>",
"       N2",
"      </td>",
"      <td>",
"       M0",
"      </td>",
"     </tr>",
"     <tr>",
"      <td rowspan=\"2\">",
"       Stage IVB",
"      </td>",
"      <td>",
"       T4b",
"      </td>",
"      <td>",
"       Any N",
"      </td>",
"      <td>",
"       M0",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Any T",
"      </td>",
"      <td>",
"       N3",
"      </td>",
"      <td>",
"       M0",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Stage IVC",
"      </td>",
"      <td>",
"       Any T",
"      </td>",
"      <td>",
"       Any N",
"      </td>",
"      <td>",
"       M1",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    The major salivary glands include the parotid, submandibular, and sublingual glands. Tumors arising in minor salivary glands (mucus-secreting glands in the lining membrane of the upper aerodigestive tract) are staged according to the anatomic site of origin (eg, oral cavity, sinuses, etc).",
"    <br>",
"     Note: cTNM is the clinical classification, pTNM is the pathologic classification.",
"     <div class=\"footnotes\">",
"      * Extraparenchymal extension is clinical or macroscopic evidence of invasion of soft tissues. Microscopic evidence alone does not constitute extraparenchymal extension for classification purposes.",
"     </div>",
"     <div class=\"reference\">",
"      Used with the permission of the American Joint Committee on Cancer (AJCC), Chicago, Illinois. The original source for this material is the AJCC Cancer Staging Manual, Seventh Edition (2010) published by Springer New York, Inc.",
"     </div>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_52_35661=[""].join("\n");
var outline_f34_52_35661=null;
var title_f34_52_35662="Abnormal adult behavior management algorithm";
var content_f34_52_35662=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F57512&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F57512&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Management approach to the patient with confusion",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 364px; height: 524px; background-image: url(data:image/gif;base64,R0lGODlhbAEMAsQAAP///wAAAMDAwEBAQICAgIiIiERERLu7uyIiIt3d3ZmZmWZmZjMzM8zMzBEREe7u7lVVVXd3d6qqquDg4JCQkCAgIKCgoGBgYNDQ0HBwcDAwMPDw8FBQULCwsBAQEAAAACH5BAAAAAAALAAAAABsAQwCAAX/ICCOZGmeaKqubOu+cCzPdG3feK7vfO//wKBwSCwaj8ikcslsOp/QqHRKrVqv2Kx2y+16v+CweEwum8/otHrNbrvf8Lh8Tq/b7/i8fs/v+/+AgYJNGQOGh4iJiouMjY6Og5GDAxQClpeYmZqbnJ2enAGSon8DAl+ho6l6paeqrnesXqivtHGxXbO1umy3OAYBBkG5u8RnvSMPEAHLES0SDg8sBcEzw8XXYsciDAzRBwwt00PW2OVd2g0B0SQFywwNAAEMywoJywEKAQcACggAEfcaiDvgIIADBQAMzAuwAAU5cxCxaDvgj0Q6eAuCBSgAoIA/cfb29YsnYYQ4BxwV/0AzEOxAgAQnHkacOQXdSxIjAVCMJ/JjsJD8PiJg+GCaPZjxEhjgeDQmzadXtAHgBvPbRQAQNPbsSA1fwooiDp7kWGAl05smZEJdq0Sq0mUOmrWTB09fUK4i5jJA8KCgvKItCx5MeBZpCbVsExeRigWx4sdAGF9xDLnyDslWKFvebANzFc2cQ8fwTAW06NMsKH1azbo1a9OoY58o9Kj2ogoVbOtOJLv3FAIEfAt/A3y48TXFjys3k3y58zDNn0vnEn269SvVr2uXkn279yXADQHf8L1823sBPJhff4QCeg7s4w/BgJ6C/PtAPNybgL8/Dw7LVODfgDlYsMwFBCZYw/8Ey1ig4IMyVBAAeRBW2EIGGlio4QodZLDhhydsgAGIJJZICwa7pajiiiy26OKLjDho4g0CaODajTjmqOOOPPaoyQXBzWiDAANo152QLxBpZJBIzqDkdUc2ycKT1kUppQpUwrBUE1vWYeWVKGRpggQMmdDlDeLEcKYZQ/2FwpdgmiBmCSxBQydHOKSpJZ5pPIAAnyXAGScJc45gTwMIIITVPWQtgwA8cwEDwJ8AHJXPMgvYg2kCCzXEzj3BLAXUSBQtUwCnzPDjF0fKuHmCXg24VBIDC2QkggHNtLpRR47GKo9B8IyQ6JtMDjplkSgUAI44HsG0VAMOwBMBBOnsIw7/pU2JkA9gIkDQUALRjpBOSeKIatdIKI0AAQQAQHsAriZ1MxWg4gaAUTDPZFXpS0eV5WwB0EoLgUv7GOCpArSmIKixABQqQpvLJFDrrQVc6mhO1xaG8D0JpAmxV9pWVO6p5yKQ7aSKGqDAN8A0sAB6npaQ004AvLzOUhE0NDFhFgeAgEsi7LwzsQy34LBLN0fg0QN+AhyuCFfpazCvCSDQDJkdg4NVzBbZi1WoHHllgD/pdstuteouoOw63VIDtdf6SoAASyJQFO7STQc8AtA1c63CwsY6vAC72kIzjwOURqqzoy2589JcQyUALUOoRkzCyz6Dzas8/hBkauXN/OIz/zy6IuTAPp/S5VIDfnrKADUPLJT4PQvwLbTfgRZbdJjI9qDnDt4CIYHbL/SFOjLD5gD4oA6jSfwNojNgWBQRaC0CqDssH2fzx2kPJvfGeX8l+MOJLyX5wpnfpADote/++/DHL//89Ndv//345x+/7rvToX7/3eMfAM3zvwGmT4AG9E4BEyibBTIQNQ58oGgiKEHOULCCEtGfBjfIwQ568IPtMwUGSUCa2JQQgCc8TQorVL23BSs1InROL1zCl5o9D0JNm0ozXLDC0MzQZzq7IYQIEgG+VK4hKjEVCWO4nB/m4wC28txgIPSyfQQPXA2Alwl6yJkfKgUBtkqXStiWIP++fWxl8zDACwHAxc14MR3AyBZaFMS34JnAjiJoo2W8WDNJpassZCQQ3yr3EtE9aonS4aM9AmMQRQ1Kj5WBJJgk+RhKSsmSicGkiTZgCQ1UYkTG4WSNKsFEBjIIPQg6TvsyhEEJ3UNGxhkAehA4wAughz/Hcc89SsnADtxDQMqhzz1GCIAN3MNDy9FPAOBDTA0sowPOsWUA7EPMDCyDQsoxUABAOUL29U45DAImMeNBS99UIJXj5AAvjZMBWBLTncsRAC7HSU9RWAA4+MynPvfJz376858ADahABwqceSbhngRNqEIXytCGGjQSAwBSQydK0YoqtALrXIxELcrRjnr/FKOp0KQbRDqajAKCpLwwKSlUKgSUrsGlaoBpGmQKw5CytA80NcZNI7PTPeTUDD8tQ1BRMNQxFDUbPV1FUntw1DA0FQxP9QHfmLpUHkQ1Cb8zwVQROYoVugR7TODbVi9TVbKeoAGyo1cNsloEtpJgrHksqx28OscmiBU2PJRrDrQBLk8VgHB5EuIQ3Lo3clz1HEt1iWFKhY9D6UQdkKtLP7gmOgM8gGAgu9UyLNumn/3qbr2Kx2RhcFhtKMtMm72sPvCxlLEdUSdtUhwJOss60TngrZ+FVGgjuzlJMRYhjDWsXulA13sQBCHPSEhDvKW3acUDsHnhS+wK4BJ64Y0B/9RFBcGU21x2BQC6eWWCaf123eziSSEwuWK0yoYXFFgNaVq1i8G6S1+7nAS5t00XXNk43DnQFSma4hhBLIUef9jlcn6tnTV2VgAF1w0VteqZgY/3gtLy0iMlYLCDKfYw9OTDMFl9AObKBBD2PjZoC5CwikVmgABH7Cb7PSwX/juCKQprbu162vUo3BHp/gmuePuxOk7cN72N4MCk7W9neAkuwv01yNkdQZfwCAD2nhYnQ07Y2xYL4QUYOccvjFowbFzlRp1Axlugcd06q60DyxbJUk7tfivLtHl4FsW9bQicw7sEqbBMHhyh81S7RMgEeG4jk4tZ5cD41TIVFs+ylf8t5l4HW0fxw3FnVrItNA0HC9v0013l9AzQrAVSZ8HUEhG1DFAdFVW3gdVW8HSoQZ2EXwiWTpJKgqxFAesqkGZNOHgGGd0qbBZ0CdjudUcg4ypeJqNnhyYgrAuQTYVeV9vVLpB2CbQtZbW2IIdbxHaFnV0VBoA3L7eeqbhjuk6ALCOLjdpsQjrVroVAF3QBdmS5OpVv3kYqUgrYEqzisRBHoizTzTZBttLxgCMGOFP0bq1nh+KAVoUubAWvFL1TZy/ajsofSdxVq+RV01mnpSQUGxde6KbYK5dgXTk+QFbL1biOBaO+xzs2wLxmq11hmB9aDnfCS3AyfahXINQ4Onr/H7sPHOeDMPEgiz+OXi8eTyoCH08ItNc2rxZYuybr9AhRloIxzR0lAcpggMGTp7KZm/1xwVgxCXQ+swnfpW8p2LWh0MLwM3rMw13i25aAtqWSTcrDI8gJAERMu6yzTI0jdvQKvi4FzBzkWXB7O4jBgpWz6cPtUO/XzXWMtlvtEPOk08rdJ79ur5NbJwmj8pWpHHhUDD4Uhd8Klave5mgkTGyc9xbXx01rZPilG1vCHI631K97GBx07TWJ5tMU6YBcKuDxfgdP7j40offZ2YwSQaETXejac5jwYdtKoTmOVkc1RC/+MCTpnO/64rtg92/QO0Rbj4YURm96ncZ/rGd//5MggEBlgHmHgGRAeVHAgFCgfwVIgIIAgROogEZlgUg1dLyGgU7FgVDlgSPggE8ggk5Agk1AgYFgguK1UR7Vgi54USCYRyz4gjRYg/wEUqOAUDZ4UTO4gwL1UEeggz44hDUIhNOhgvXkUzGYhLSAhEyIB074hHO1hFIogVXYG1F4hXKQhVoYgF3YBiAUhmI4hmToPuXEhHhFExdUNGk4E2v4IC3ULl7TAm0YEdXxbpcWJznEANDGAnUIEXeIACD3h4IUF0ZEbyEHKIRYDndYFhUTCtCHJFW0NZUSLVp0GA2kO/jQDu3QeTGHJGbkYY+3RouIDXeoAH6yDAeXEAZXIv91hDuUeGSZeBgIcSmeWHozMkgLUUihJYuxcYodpnGpUkGleA1vaCzFWAzHOCjJSAzLKCUTYAkBYAlGqBiWcAEXYAla6EuzFBrOdA/qcYXGhB7cZBnWdA/MdIWytAzhyBnscw/UdIUEgI6nQY5d+I7TpEIB8oUAoEzV+Bi6hE5aCCDiFBrCBE9V6B4CGRr68Y9JyCDQhBocwEr8WAHYJBoWgEz8iJCcEY38+JF/QIQi2VHKM5ImeZL+5JCBEAAo2ZIDVYos6ZIyKZI4qArNeAYwWUlUKAuDkJOKwYVJcJNm4JOZtJO40JM5IJQV+ApKSQZEyRZAiQRNOQZPCT3eFgX/3CYD+xWCRskFUwl1J1A1uyIFVVkCEAMBAGgmgAJXWykEWfloK9CW/MWUJhByamQD1PYP6bYEZTlbCPFFyzZ3V4lbSvCWMCCXUXkEw/AAAVASydCKanKVEDCYTNCXwuJIDlASdDZ39AY0idhZ0IdZY9QR1qMTgoEQ09AOhqEQmNJjQ9ENtqJ1iQg0lYOW99ANiNmVW7CYY2kSvRJguLlaChApWbRxbRYxgiacibcqCZFaT4d3Elebr4WJOKAWyUMY5TV3NUd40FZHZ3M61fUwCHGdZaYqRfEzdOJ5AmEyfVEP/FJI3RkK+kJ0jZmbdCkzorMAD9BdeycB4YmLLFdX/wInXdgVnnO3dQT6iHi2dPNJiVhEnTdgnZgpARommPtiaKEwimaUMiszC9MgNyQgRzanltcznNQwLDjTEBoaCteZRc5nn64gE7ETARLmovTAN4oXegLKERrGlmnkMgn2nBPTJdd5RhBqAxJaKWPTY0xDKd12oVvlLfAFc9UyVX2BXSXwR9DAVluCNR4DXAigY1sDNA26AODAmB2qAolpBMPwLvAwXV9mpouHD3wDoIVhoVDWlsLnY9mVAJzSEFPmNvjnixGqAmd5M6lloUdBeL0SOz4TmrkQAXbyVqcZfXGmRF+6DdQgf7Rpb54zFGmagPdpKLriZLTzqXTqoQHBfP87qlnAoFqoNTrN+arN6QAJQ2j2tn4kYJlRkJfGRpmLdzpBsKZF8JVhwKtPQCaB2QK+KgJxyFOjCgjIChHESgTGCgbTag7VOg5IWZ06Ga1/kK080KxPCpZkaXUIF6Nm2T7Ayg57uZtJeQXk2gR7RlS6qQXkIJfJ8q74Gq8r8FoKAQDP0AAW835twg3LoJkYRw99RA8Wg32bo32/klmLZ1tZR0hWFH6R1X7fNWJpWQLbKgT5anvTYDKI2Hi045T+qgJUZ27CmniQZTL2wKOa43OcJ6c6dxU9J3W4tQ5ZBwFa83kO8C/d5XLbV3I2eQKCJz0OqmPbYpiNsbIpYKT2sEP/GxMxaWJfNbsVZWFpdFcRO2F4JFBiJLMVyaMPO0N2BYZ28oAQ9ZquSRtfHHZ4zne1cDeUUosCu2dudmE1Anu32zcy29cP9lASRaR1KZd5g8t59WIPCLGkVPp5fPplJmFgKDeA6iq3YEllfuulpSkG2Vp+7FIWAuEogKu1UGd4hjSIrJV9dbEVhdWa8NcuQzEUB+CoPhNvDAFwDfuxXBW3JSB4eFJokPMSiaay3roH6WAYfgKZNRCywtCthYoHjYYnYKUD0AsE19oKyVuU4OoH4ooN2fsD28uT3au5c4sC81oEtpYC+uoCb8tsmbuSeUuYgpsC6zsExea+oQC1MYGu//ILvNJav3CZvieQv265l0Djv2kBwHM5vwN8vsHbv5pjpobWJo/bYJvah4z1iK0Zm4nCsaPbi+K3EFhHf+J3m6r1cL9FGK5FbxgrqhAcrgT8YCunwWGBX4RxdnVlYr0HwsNpPfypLt8pc4JVuAtMDYORXAz6LdEyn/H7wDY5k1S8T7yaxAnhAEO7L+ihFIFWADkTonNktxJzovWQdgogYX55KyZaAjaaqnjhYoWEJ2d0tg48vj5QxXqcTzV8YuWSMyZTZQY3eGG6RuX5MFfzOJ1jYx5BuUQsh0acYWcKx1dGZlPGNZF7x/c6IzKBxcn3KIwVf3hCacG7KsXrp68pFv/0J1uGYsKWapo+A8eJFspgOX6vGcV4vB1CaTwrBZIrIJTPilObbCLlq1S+rALFnAe5rB3J3KwMfGrDXCLNTJn+q68PiwTLfB3TrALPnG23dQTZbB3NDMP05hGv2XAqPDim16mpkppokaNEEM7T0czqeXTN0p79qVjLS6ZF7BGoI2KHBM7RTCLbLFp+Z8ZvnMFhDDRs18Yp7LvDOtAgss1YI3tmLKdoqirCys+Q3M1WJdEf0szhR7xmjKqKgmMnBn16cjJGIM/SkcxQCNIbAtOwINMaQtNTeMwpgNN14NLPwdPEZdMWAtT+JdQVMo0+ktRKvdRM3UlGDSEwEtUqghv/Ul3VtlGOOk0Gz5jVo7DVXC0JXv3VgxDWYh0IZF3WIXmGaO2Gar3WgNjWbs2IcB3XxjjXdC0E+FiGer3XfF0/7aiF6PMYRF0hga0Yg30dfBhdy1oChZ0Yw9AOhOOkTXIR4HK5K9DYbPHYWjye7bohygJzv/UAtkUo34Qaj/0n0DA7dCEkYRoNS3w6Q8bYpV2P28YXDrAAf6Kz/KogINE+CUC2pO0bp705FQO2jAsiaUJmWzYCmL0Ww314O5d6QpImodxoXNPcUPHc+eC6D4TdT3HYD+LdNAHeCiLeM0HeA4IBAkABNiIAF2kZ0cg+loDV9SRN90DfkMGN92DXBqRN//soGuO4S1V4SgeCGuuoilfoSgHAkZUxj8uQjlJ4jgGgkomBj/EohdxIkaehTPhdT+OokacBIH9dhc4UkaihkF84j+9tkAv+heYdERVA4eN04Sd+1zaOBRZg1Tq+41btAzz+40DeIrVAANnY1EZ+5DwilEiN5Eze5K8x5PzNB0q+C+itBWeNkz5Q5fBKC1eOtz2g5f3K5VG+B1OuC2COHWOeA1vVrFFsrVlO5VAeE47iwDfgyZTZ5tz65SdwljDh0SuAwDawle8bD3GeFqj5zVKVC2xO53nOA+QwLICJBoOOzIVOi3KYde4swo6HwfZbwdLDW2i7wW8VWyPG2Rcqwv+bE9BHqgOPPqHiUOqVporm7CawItpwQRi2bhBYhmcTC6afU85LsbYqvMCC6Cq7Wum7ihC4jeno6XJZ99qdThi2wp/6wMPT48M1Aw7Y8jhCHC7OlRZvbgLXuRS/I6dx4cfseRC6DV8Uw+67jnc2e8hNu577MFZI3L/pDplnbgXdcQ+PgunUwLZq93FyzGUrp8UwocbyBcZcczJd6zOTUhgCn8YF5hR6Lu6uHgwPbzIwRsHiWXf/YBBfHPImJqR61hMnc9A23C6iQ8lmDO5iHhMGB3yvjGE0r9w2/MfLTrl2YTeGXDaF+w/x935z1MhiCvOOvud/uaRG0ZhCX56d+KX/Yta4Z7K8heWnv7cV7GXRDxYNGO3y4on0rtDvBje71LfK7tA5bPZogovbpduaB0bKlGoqq/tYv9IxaN+aYs/qe34PEBAN5eIorDsU7TUssGLdhIH4c2cQWX8Xh3Yquziii2dnJo3Fq3jsMQ8GvCyV4Z4nxw2GyN4FwcymnU8Dc/GycbDvVdDlZVDmtaD6VMD6yJv0Zh76qeD6tAD7v1HkTt77vi+NWf77OUIAwo8jui8FOR7kyr/8jODjzM8iAfD8LHLjrU/9zm392Y39363948395+39EXH84B/m408M+r0MIF7+rhDgz6T+uvCNCO7+tCDhsy3/o2Dh9v/6y9Dh//kPAoA4kqV5oqm6sm06BJ4707V947m+873/A4M1SoAjPCKTyiWz6XzSMAELtGq9YrParcsz4YLD4jG5XCKY0+o1u+1+w+NyESFgv+Pz+j2/7/8DBgoO9g3MHSIiEaAlqgkYNkZK3ixOlj1aZmqiVG6CYXqGZnaKZoGWoiKSpladsr66rcI2uc7alsneJtXq9m7l+gbxBhNDAdsYFMxFMDwcDRdHLwEn4CEAINxBJJQkzxwEqAQctHgDmM8kOHADKGQHMBwU3CGQA8zbbatAS/cLUQdgJwKBAgAJDCBwNgIdj3HllOFYEEGEhAAFASwoUODaOQgAIiBoYNCAPRT8/P+h7AFQILaLABxIIGGAgZ0F7e7YVODATgFwBmkG8ChiwZ0E+EI+MGDHgYI7CrzBs1PwwLtwJBDEBABhIomNIhgogznjZMqyOADSa7kQoggDHhsEECmiaVKuAHxCMHDCYQMHIiNAAKfwHESoyrw6mOiTRMC2LkXgC4BAWWMXZM1inrHyqkuxa0VYVAA04AGaBhr4JLiXXNO0EQI4UGYOKmsE1bgtHlEZgs2uHOFKYDoWUubiZxmVuM15JMfPFRMgmPh8BG+8ek0EiNlXLgm4B7nSbnct9j2rI7BSDAAxo1cAcA+AJHfwwPsTl43jN4HWzrWqEAa3dcdh/AWklGSohZP/AFBCDWWHUTiBU9NNFoXnzoTZlCDRCAXsFABJkanXYE1GXWfCffmhCMAxm7Q3gjos2RCPScSlWOMJK06CjwMljcAMgD+caGNxOAo5QpBFmkUkkkcimZKSuvGog0OlMNmkP0+CFqUJuYmjJZc1TGkhAA9ItkJkEDQw2VDN4MHWPjRamSKWAEyZwpco1DnCnTOEyVEBDOyYAkgizQdXA8FxYxEAFf1oH5xx5rfiUSI5BIEdzSiYzzv1jGMRPgxQesAC1xkAEn9aXfpAAwviaY+Yky3Q2wmedcUAenQWxGELVUJazDHbfeTROH86A1ZeeloFjjKGYqTXOLfdthixAID1/+cKfd4VwAMHONAoaDCCxoBul2rpaK81HtPaqeMQhZNqIiy2mJhU0UlOMhHYtFi7I1rKwGOM2WPtvorO+u9HtkJkUV9ZrcDrub786hfA04pwLLzaZisCs8c6RJXEgt3TjAleWTwCA3o9wMACD3hmLYcAxjfSAc9Np2hwIr0848MoSopTvahKlWlQKUuW26ehfnUd0ddYKlVkBQXaHVAGPKCTi3FB4KaIASwA3XpsXrRRAlmn4PDOt8x5BMvlqiBBiTSw7K0NcZf96NllpS0EM6GYfTcseaPYt9+sAJ6f4IOjUjgZ3IKrxeGIi6L4Eepy7R5QajZgINfOFPA2F49D7v+J5EKIKYI6vRXwnwNClcYNmY1jAXromoweROkhl9BiCWCJIfvsltQOBOUZyTrUdUUNpbXjdv8eTPA/3K77Pc0ph5HypjDffC/P+3C7OkKlrg7V7lXGexi+a98I9z0MfxdQvGeOkzOv9559+rasr0XnY6B//yH5Y4Fx/LOf/14BwH70r4BxOKA0EqjANzAwGg58YBsiWIwJUnANFiQGBjOYhg0Go4MexMUFBGDCE6IwhSpcIQtb6MIXwjCGMpzhCilAwBFuwgID2CEPe+jDHwIxiEIcohADQMQjIjGJScwADptYAvM4MYpwgKIUq7gGKloxi2TAoha7yAUuejGMVwD/oxjL6AQymjGNSUCjGtvYgwmYMAAmxIAb6wiEDuSBiXbc4w42kAcB8DGQOdAAHgRpSBvUwQ5GOCQjd3UHCjQykteyAx0laUkTcCAGl9wkCYhwAU6CUgpUACUnK/AFUm4SOahcJSsjgQEawjKWspwlLWtpy1vSspJlHIAGlOjLXwIzmMIcJjGLacwe9jKNAwBkK1kgwrMts5nOvGEUoynNNymTmdfUmRmtuU1zdVObSdjTDxhSCnPugppO9KYJqpEW/8BuS2zcAUP2xwJ72nMN4VlNxnLwzJ2xMzmVGUhBDpKQFpDTB/X0HAry6YZ9YodtNfjnwwJKguoRdAS0wohT/+5SFWwog2US2FdBZiIhoXmkaSJrWohMB6F3FOQ1doBLTfZn0soJLU/cgk1JO9ec8sx0p8K5qU1WlY9q1IYw+4IOfxpA0gQBRTFRkRg3dylOgb7TJejEiLjI4xOv6G4B4jKAXsAxthJNq1q2IUxXriOc4NCJYfjUC1mzNTZx/UyjytBJUhjAkvqIgDx8ratZreXSpEJ0IBPpWDgg8JYdgcNexSsBRc9l0aux5F0vYdg9OmSbxvhkbf7q7Km8cRvNDixWvVmoQfJglGysbK5sPe1F6lS9AmmtdLc9iDKg1S8FIFU8bHXIA/ZlE8aq5RwK0NdkSVDZXl3WpZktKEIumv+dj4xnQENBQLeqEROQzDYgJaPY9B7wADVtCK/CMQFTDGvT3or3LXkiz8vMCdiXHKZbph2oVxRVXajEhC7UOm5M8CLfAzC3btlMgTtP5Z8fGQgB12gNTVxaGP5cY78JQCnQLEI0B6BXYztZAFX4w7JU9YVr721tAtIkGZ3uZKjKiwxqYtxTFj8NqLZia7uEhgCbtKspP7GDVIfSXCOps4nRTYl3ZvFcSC1ZGhFqKSyeHKcoX9PKVsKyNLXcJC4/IU8mMKc6DKaErQLMBQk1E0OBlGQcgvmMEmUrCTTkAzGfAM1QUvM8G+o5o0oGRHaYM2XfPMI4NwHPMnFTNeSWBD3/Z4nPOHDo6SADvjY3zNAejLO6ctIhNxF1yDgFik1ySg6VOoOlbhKNbt7RLnE1uBmjaotd6gUOmnzsHZ0rQHAtZGqgiWweJbg1bHDWVGwcOzJvM2zuMI3NcNaALqXKc1nFW2q/8MYg2D6ePESmVm7UU1YhWoBtgutSCUBroLZ2iAFsQp628NohFrLYsLytXRJE9hwLABZgrhKB+ji0AEd2qGU0nUFOjyYBpfEQd8LLVKdUxSLvYhceVAvvroibHPYcR/ykQhh8PRHBVokVRpPR6/7UVlQVRwFzKZcQ44op4D/dkLMVDO0WRGdRA832Z27D84oVz7Hk6/ZgNmLeELcD/68/27ioxEWmqXC34es2Mn4/41+mHZi85Rn2yPdN1ZsUa99x0crbvmdpyLj1euC0qguOUqBj9zwgOd1wwl1Mk1M75cNIb3Skmb7TbFzkZBFN8E7V441PXcPuleqosPHddaByzcdAvpTnFg4PiOyvL44u9IITYWe4RW0WEVD72sWIaDOUuQZ7K46XkXR6VLa+SK8nZeyFNHtdQHqNhE5n53NApubgQSgd39wJGlymiHNDNPxRe+4/s4Lm0/nOu1f0Dmpvo9vXKmqKAkcDWMY6vxZf3ZrNFuYxDf0ZnD8I1GeC9WuE/fMIvDc2S4j0UIDR5AKdBeparo2hMxEfHd4dNP/A0bAVASpbAQrg1aQKsUnMpoTKrJ3Dv7EKx7EKD7RfirxftmxLt9CJNjjV8ThI+L0THnhNtpRJnkGEYHXX6qxVMgAWs8yaC47dqADHPdBVAdxXO2VHvrWbv9VLuhmF0tULs/XABaJIBg5MQRAMBIAF9agbZi0HdcjK7Swai33LTWRFMpTOvGRYAXBhzN0gFWqM5ixX1xWXz7BbAYDc2MCDEh4AG46WBRocBb2fSEGGuCyhAYiPMzTZu0lXFKYHV3hFDk5b1b3M97QgDk7JxtwgIzIiYeTgmoyJRbQcxqjMz3hMw/VXSZBMzU1T79mA1bgUTV2KSAzfymiedY0g8ij/X6DZYAm0Bv/xVAkyYVIMyEwRYADCg0i0CwLcIORxx99RYtdJXl4JHuS5YY6F3g0YYX5kYA6Mng/IiBb8nNos4wq4TfXN4QM9IzEYCPglweo9QTPiRzdGEjkahzk2EjoWhzo6wZrVAMHZADzWyhuwY2a44zglS5+hAGulwPpdzCuyQPotDyimQbzwYwvIY5qpAD2SgATMXBrcI2bkIxJsCgM2AF+FTGRRoo0hoB28DaDxhlM8XonZwSuapAIkxVKIAJlInRlMpFlU5BEgpGSpBUEoS2DtlX4posYtmxDK2+N5VTjsz1vtCMZcxe59zjYq0EwKAUJSXedAZD/tlhb6/0nZ/dbPCBlGdA1oEaUeutZr+GE9tEFMloVTBgHIJBjL8E5u0BdPPuLIXMN1mZWCuJt2FaXBNJlLliVTFhBaAsHSJNhHcGBuCNWNvdqydVSPKYUDXCKFfaVH8ceU9cZU9qVBHgJBaoFmxo5f+g9gOgGjuAERroFZpgRo1pFpogRqupFq+gNrtpFr9gNsqpFsSsMAUAAu6eZu8mZv+uZvnpANpVEGHFNxGicxGdFxKudyHpEefVMiJORzelF0SqcWUWd1WtF1YqcUaed2OlF3eicOgWd4etB4kmcBdcAOJScknacXSQEejFJ7dlEF4MEpyacWXcAdVMB9epEF3IFz8v+nFU3AHXRAgHYRIQXABhioFmWAES2oFuGRKj1oFPnRVU2oEy3ShVaRfWpohxooIYBoiIroiJJoiZroif4BI5mnHa1oFLWoG71oE8WoGs3oCNWoGd1oBuWoGO3oA/XodKroNf1oAbXoQoIBQO6AkXJmFQyp/0Tn742MJyLpkl6LUk6a+VGGldKAbN1Ak95PdP7JNRrpF2mpDSgp6fHAmPJJkM4ArKDOHdDVOyAEbCQKfSzISsLGR4IKnQCFmU3IqN2BqAhFqXTa9GTDSrHkpECe56jaD94BovIEn3rcYX6EAOLE/pgkmjIGmyKUtnCLqjiETelFU5CDmtQbsgyGDPL/orMcRkTCorbQm8i12EDRhdiwjAKIjYj9BZqE6rIlYl61lgRwCLhRRqtWHV9dF9opqx+6gJemT0ImIRiy1WLQBhzGFGzIhhdyBL3Im6smXVFMnL2oYU4knD0RRKyMgMtJ6wig63DRBxm2a4V8FjsExEZszlzdXws4q/bwox2GzCN6A7Vm6YY0h3eoKtlpZeLlSc49h9DVh04ECsPW63UQRK66x9fFJWQkxHllqVhNIq5urKkm1VsORnvhVVFqKnZw6gqIYms5FeVNq1XQxtNQpp4ijYUQnNu12KFOiS9CBoGQSEYZiANA3uTBw9voXZYKo0pezsBayGGeGDyoyohh/+qnNevKvsE0SsJ5+SkT7GvzfC1KwGkWhO3slK2MYu0qnS3krG2XlmkNUGkYAKQ5te3gUJGaIktAeu3b0kBiMSSSWsHcak3d+s3deqLehhnfot/A8lMaCO4TrWyDdQ2ptcOnXSRRSpjUdpjaOaCkKsqv6YmuCc1EbMShqsqCnJxSgWtTLRW7geS2TFXDxdrp5oNMUC6wpVqq/BqqbS7kHpLh5p86ZI5dQKWtttc6RB8K5FyIdGKk6RV1PJY82MatMlvq+u3y2sOwbCxY8OCReRdptkW1BWGxaIS9xWpaacSvburvNttA4MFymQaCBKS5KkC8Xs8ZSki3JpdtDdS7GP8ArlIscP2W9Q4s/lbOlLAL6pDY443A8AlwG1bhbaRWaoXrBK/W4GKtYVWjFKplZLaE0XFsZw2GgF2i/jrsfLHFCctDABMsrpxDF8YV2A1YDA9hyPYEA0vi07Vw3I1veg2GCpMXCCMdnWBtik1uUURY99EEpwgkQRCNK5KNi1zOcSWV4vFI4fFaVDUxrjLepcBwj00xRwWE63oI7FKdnuwE4OUYD3dYQbCUAlhxGyet7xpSk3It3Yhn2gLB2HKnHpMS4d4NIPuoH4OSIO+MIRMpIXMSIp8LI3+pijJnJEvyJFOyMTkypABnJmvyJnMyLXnoJ4NyKIvyKJNyKZvyKaMVciqr8iqzciu78ivDcizL8ixLUwgAADs=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     ABG: arterial blood gas; CBC: complete blood count; CT: computed tomography; CXR: chest x-ray; ECG: electrocardiogram; ED: emergency department; EEG: electroencephalogram; UA: urinalysis.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_52_35662=[""].join("\n");
var outline_f34_52_35662=null;
var title_f34_52_35663="Growth precocious puberty";
var content_f34_52_35663=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F60956&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F60956&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Growth patterns relevant to the assessment of precocious puberty in girls",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 331px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Height (upper curves) and weight (lower curves) plotted versus age against the backdrop of normal expectations for growth. The triangles reflect height versus bone age, and the shaded box on right hand y axis represents the 95 percent confidence limits for adult height based on parents' heights (M = mother's height centile; F = father's height centile). In the left panel, a child with premature adrenarche has had a modest acceleration of linear growth and skeletal maturation consistent with the impact of relatively weak adrenal androgens. Her \"height age\" and bone age are equal (both approximately a year in advance of chronological age). In the right panel, the more dramatic impact of gonadal steroid production is evident in a girl with gonadotropin dependent (central) precocious puberty. The linear growth rate is more accelerated and the skeletal maturation dramatically advanced (bone age &gt;&gt; height age &gt; chronological age).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_52_35663=[""].join("\n");
var outline_f34_52_35663=null;
